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ABSTRACT 
 
Pharmacological intervention is an essential step in health promotion. 
However, the process of setting a diagnosis and choosing appropriate drug 
treatment is complex and lots of drugs are often prescribed and used in 
inappropriate ways, especially in elderly patients. The direct consequence 
is an increase of adverse drug events, hospitalization and mortality rates, 
along with healthcare resource wastage, and additional healthcare costs. 
Therefore, the main objectives of the present thesis were to: (1) deeply 
investigate the prescribing practice among general practitioners (GPs) in 
two Italian regions, (2) evaluate the appropriate drug use by their patients, 
(3) develop and administer tailored educational and/or informative 
intervention addressed to GPs and their patients, in order to promote 
appropriate drug prescribing and use. 
The present thesis was based on baseline data from the EDU.RE.DRUG 
project (funded by the Italian Medicines Agency), including all GPs and 
their adult patients (≥40 years) from eight local health units (LHUs) in 
Campania and Lombardy (respectively, 4.8 million and 4.7 million of adult 
subjects included, of which 1.6 million and 1.7 million were 65 years or 
older). We defined a set of explicit indicators for potential inappropriate 
prescription (polypharmacy, drug consumption, potential drug-drug 
interactions, therapeutic duplication , drug to be avoided in the elderly 
according to the ERD-list [EDU.RE.DRUG-list], anticholinergic and sedative 
load in the elderly) and drug use (adherence to chronic therapies) and we 
adapted them to the Italian drug formulary. Using administrative health-
care databases from the involved LHUs, we retrospectively assessed the 
annual prevalence rates of the selected indicators during the period 2014-
2016. 
Despite some remarkable geographical differences and time trend 
variability, overall we observed high rates of polypharmacy and drug 
consumption, and a high prevalence of inappropriate drug prescription in 
primary care setting in Italy. In particular, among older people (≥65 years) 
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about 40-50% and 10-20% received 5-9 drugs and at least 10 drugs, 
respectively; around 25-35% in Lombardy and 50-65% in Campania were 
prescribed at least one inappropriate drug included in the ERD-list; nearly 
5-9% had a high anticholinergic load; and less than 2% showed a high 
sedative load. Furthermore, 10-25% of adult patients were exposed to at 
least one potential drug-drug interaction, and 3-7% to at least one 
therapeutic duplicate. In addition, a suboptimal level of adherence to 
chronic therapies was observed: for all the long-term therapies analysed, 
the mean adherence level was far lower than 80%, which is the threshold 
above which the medication has a reasonable likelihood of achieving the 
most clinical benefit. 
These results highlight a widespread need for intervention to improve the 
quality of prescribing and drug use. In this regard, the strategies we 
implemented will contribute to define the optimal way to address this 
critical issue. 
  
 VI 
RIASSUNTO 
 
L'intervento farmacologico è un elemento essenziale nella promozione della 
salute. Tuttavia, il processo che prevede la formulazione di una diagnosi e 
la scelta di un trattamento appropriato è complesso e, spesso, molti 
farmaci vengono prescritti e/o assunti in modo inappropriato, specialmente 
nei pazienti anziani. La conseguenza più frequente è un incremento degli 
eventi avversi da farmaco, del tasso di ospedalizzazione e della mortalità, 
in parallelo a un utilizzo non razionale delle risorse assistenziali e una spesa 
sanitaria onerosa. 
Gli obiettivi primari della presente tesi sono stati: (1) indagare la pratica 
prescrittiva tra i medici di medicina generale (MMG) di due regioni italiane, 
(2) valutare l'uso appropriato del farmaco da parte dei loro pazienti, (3) 
sviluppare e implementare un intervento educativo e/o informativo su 
misura rivolto ai MMG e ai loro pazienti, al fine di promuovere 
l’appropriatezza prescrittiva e l’uso adeguato del farmaco. 
Nella presente tesi è stata descritta l’analisi al basale del progetto 
EDU.RE.DRUG (finanziato dall’Agenzia Italiana del Farmaco), che ha 
incluso tutti i MMG e i loro pazienti adulti (≥40 anni) di otto ASL/ATS in 
Campania e Lombardia (rispettivamente, 4.8 milioni e 4.7 milioni di 
soggetti adulti inclusi, di cui 1.6 milioni e 1.7 milioni avevano un’età ≥65 
anni). 
Sono stati individuati una serie di indicatori espliciti di prescrizione 
(politerapia, consumo di alcune classi di farmaci, potenziali interazioni 
farmaco-farmaco, duplicati terapeutici, farmaci da evitare negli anziani 
secondo la lista ERD [lista EDU.RE.DRUG], carico anticolinergico e carico 
sedativo negli anziani) e d’uso del farmaco (aderenza alle terapie croniche) 
potenzialmente inappropriati, che sono stati, quando necessario, adattati 
al formulario farmaceutico italiano. Sono stati determinati in modo 
retrospettivo i tassi di prevalenza annui degli indicatori selezionati, 
utilizzando i database amministrativi sanitari delle ASL/ATS coinvolte, 
relativi agli anni 2014-2016. 
Nonostante alcune differenze a livello geografico e nei trend temporali, nel 
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complesso sono stati osservati alti tassi di politerapia e consumo dei 
farmaci e un'elevata prevalenza di prescrizione inappropriata nel setting 
della medicina generale italiana. In dettaglio, dei soggetti anziani (over 65 
anni) circa il 40-50% e il 10-20% ha ricevuto 5-9 farmaci e almeno 10 
farmaci, rispettivamente; circa il 25-35% in Lombardia e il 50-65% in 
Campania aveva almeno una prescrizione inappropriata dei farmaci inclusi 
nella lista ERD; circa il 5-9% presentava un elevato carico anticolinergico; 
e meno del 2% mostrava un elevato carico sedativo. Inoltre, il 10-25% dei 
pazienti adulti era esposto ad almeno una potenziale interazione farmaco-
farmaco, mentre il 3-7% ad almeno un duplicato terapeutico. Infine, è 
stato osservato un livello non ottimale di aderenza alle terapie croniche: 
per tutti i trattamenti a lungo termine analizzati, il livello medio di aderenza 
era di gran lunga inferiore all'80%, soglia sopra la quale il farmaco ha una 
ragionevole probabilità di raggiungere il massimo beneficio clinico. 
Questi risultati evidenziano una diffusa e profonda necessità di intervento 
per migliorare la qualità della prescrizione e dell’utilizzo dei farmaci. In 
questo contesto, le strategie implementate nell’ambito della presente tesi 
contribuiranno a definire il metodo più efficace per affrontare in maniera 
ottimale questa grave problematica. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
APPROPRIATENESS 
OF PRESCRIBING  
- 2 - 
Health assessment and medical care quality improvement are important 
issues in several countries. Political managers, health professionals and 
customers continuously require information on health care, in order to 
describe current levels of quality care, to identify critical areas, and to 
design and plan appropriate interventions. Since the general practitioner-
patient interaction leads in most cases to a drug prescription, the 
prescribing quality in general practice is a crucial issue, having a significant 
impact on the well-being of patients and representing a substantial part of 
healthcare expenditure. 
 
 
 
1.1 CONCEPTUALIZATION OF APPROPRIATENESS 
 
Several and sophisticated definitions of appropriateness have been 
suggested for health care in general, but none provides a solidly 
unequivocal conceptualisation [Buetow et al, 1997]. 
Harvey [Harvey, 1991] defined appropriate care as “that strategy of action 
which maximises the potential health benefits valued by informed 
individuals or populations after considering the likely outcomes, their 
probabilities and their costs, for each of the separate components of the 
strategy, and that health care professionals are willing to provide”. He 
considered the appropriate care as an evaluation of available choices about 
alternative uses of resources. By contrast, the Health Services Utilization 
Study (HSUS) of the RAND Corporation and University of California defined 
appropriateness by making a more explicit comparison of the health 
benefits and costs, and support for this conceptualisation can be inferred 
from Donabedian's pivotal definition of quality of care [Donabedian, 1980]. 
In the HSUS study, health care is supposed to be appropriate “when for an 
average group of patients presenting to an average U.S. physician, the 
expected health benefit exceeds the expected negative consequences by a 
sufficiently wide margin that the procedure is worth doing, excluding 
considerations of monetary cost” [Kahn et al, 1988]. Briefly, if the risks 
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outweigh the benefits, the procedure is stated to be inappropriate. 
Although it was one of the most widely used definition, it was criticized 
because of the lack of explicitly respect of the patient’s choice and because 
it did not take in account the healthcare resources available. In response 
to such deficiencies, five years later, a Working Group for the National 
Health Service (NHS) Executive defined appropriate health care as the 
selection of "the intervention that is most likely to produce the outcomes 
desired by the individual patient" and specified certain criteria that must 
be met for an intervention to be appropriate [Working Group for the 
Director of Research and Development of the NHS Management Executive, 
1993]. Again, it was pointed out a lack of mentions of cost-effectiveness 
concern. 
The chance to define appropriateness is facilitated, with reference to 
prescribing, by comparing this construct with that of rationality. Is 
(ir)rational prescribing necessarily the same as (in)appropriate 
prescribing? These terms are at the same time related but different, and 
an understanding of these differences will help to define appropriateness 
in prescribing. 
 
 
1.1.1 Rationality and Appropriateness in Prescribing 
 
The World Health Organization (WHO) defined the rational use of medicines 
as a situation where "patients receive medications appropriate to their 
clinical needs, in doses that meet their own individual requirements, for an 
adequate period of time, and at the lowest cost to them and their 
community" [WHO, 1985]. Rational prescribing refers to a process, and it 
emphasises how prescribing decisions are to be made. Accordingly, 
prescribing is rational when prescribers logically process the information 
available to them, whereas erroneous reasoning defines irrational 
prescribing. 
Although (in)appropriate prescribing and its dimensions are true or 
proximal outcomes of the process of (ir)rational prescribing, it is not always 
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the case. Thus, for example, prescribing may be rational yet inappropriate 
when correct reasoning leads to a poor outcome because of informational 
deficits or major differences in the perceptions or cognitive styles of the 
doctor and patient. Conversely, prescribing may also be irrational yet 
fortuitously appropriate. In addition, (in)appropriate prescribing may be 
influenced by factors that transcend logic, including feelings, values and 
intuition, and prior outcomes. 
In operational terms, the rationality of prescribing tends to be viewed 
solely from a medical perspective, making it inherently more limited than 
prescribing appropriateness. The latter construct extends the address on 
"rational drug use" and summarises the complex rationales that underlie 
prescribing [Nichter et al, 1994]. What is deemed rational from a medical 
perspective may be considered irrational by the patient, and vice versa 
[Brahma et al, 2012]. It is therefore essential that both medical and 
consumer/patient perspectives are considered in order to gain a full 
understanding of the appropriate use of medicines. Accordingly, 
appropriateness can be defined as the outcome of a process of decision-
making that maximises net individual health gains within society's 
available resources [Buetow et al, 1997]. This definition implies that 
appropriateness depends on equity in resource allocation as defined by 
care that meets the needs of individual patients within population-centred 
constraints. And, also, it suggests that net individual health gains depend 
on achieving a balance between maximising patient welfare and 
distributing resources according to needs. To prescribe appropriately, 
therefore, is a science and an art; the challenge is to get the right balance 
between pharmacological rationality, the need of individual patients, and 
an economic issue. 
As previously discussed, appropriate prescribing can be achieved through 
a continuous process of shared decision making with the patient, which 
consists of six steps [WHO, 1994]. Ideally the process of appropriate 
prescribing is a continuous cycle (Figure 1.1): 
1) Definition of the patient’s problem  
A patient usually presents a complaint or a problem. Making the correct 
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diagnosis is important to start the appropriate treatment. 
2) Specification of the therapeutic goal(s) 
Before choosing a treatment, the therapeutic aims must be specified. For 
example, when a patient has been diagnosed with colon cancer and an 
operation would be the best treatment, but the patient will probably suffer 
greatly from the operation, the physician and patient may decide against 
the operation and choose for symptomatic treatment instead, in order to 
maintain functionality of the patient as long as possible. 
3) Suitability of the selected intervention(s) 
The next step is to investigate whether and which non-pharmacological 
interventions are appropriate, and if a pharmacological intervention is 
necessary. If that is the case, a physician needs to make an evidence-
based selection of a medication, for example based on treatment 
guidelines. However, guidelines offer medication advice appropriate for the 
general population. Therefore, the physician subsequently needs to check 
if this medication advice is suitable for the individual patient. Suitability 
can be determined based on patient and drug factors. Patient factors 
include physiological status (e.g., pregnancy, kidney failure) and 
susceptibility to adverse effects, as well as on-going drug therapy, as there 
may be potential for drug–drug interactions. Drug factors that could 
influence selection include evidence of safety and efficacy (a review of the 
drug indication and convenience of the dosage form), as well as 
pharmacokinetic and pharmacodynamic properties. For instance, a 
medicine with a once-daily dosing regimen may be preferred over one with 
multiple dosing for reasons of compliance [Ofori-Asenso et al, 2016]. 
4) Writing of prescriptions and updating the medication list 
It is important to document all changes to the medication regimen and 
adjust the patient’s medication list, to make it readily available for the 
patient and other involved health care providers. 
5) Informing the patient 
Patients need information, instructions, and warnings to provide them with 
knowledge to accept and follow the treatment and to acquire the skills to 
take the medication appropriately. For most patients, in fact, transitioning 
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into the role of someone who has to take medicines is often a difficult 
process, and the presentation of a diagnosis by medical personnel only as 
a basis to take medicine may not be a sufficient motivator [Britten et al, 
2000]. For this reason, this stage is very crucial and essential: effective 
communication with patients is a skill that any prescriber should aspire to 
achieve, as this is the instrument through which medical information is 
communicated, as well as addressing patient’s needs, expectations, and 
even emotions [Ha et al, 2010]. 
6) Monitoring (stopping) the treatment 
Monitoring the treatment outcome enables the physician to determine 
whether the initiated treatment really was appropriate, or whether 
additional action is required. If the problem has been solved, the treatment 
can be stopped. If not, re-examination of all the steps is needed. 
Monitoring can be performed passively, by explaining the patient what to 
do if the treatment is not effective, inconvenient, or if side effects occur. 
Monitoring can also be performed actively by making an appointment with 
the patient to determine whether the treatment has been appropriate. 
 
 
Figure1.1 – Appropriate prescribing process 
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In summary, there are four aims that a good prescriber should try to 
achieve, both on first prescribing a drug and on subsequently monitoring 
it [Barber, 1995]: 
• MAXIMIZING EFFECTIVENESS 
There is little doubt that maximizing effectiveness should be an aim of good 
prescribing. During a therapy we try to re-establish, modify or improve 
certain physiological functions and we can verify if it works by testing and 
measuring the relative parameters. The aim is to achieve the standard 
values as quickly and completely as possible. 
• MINIMIZING RISKS 
It is not possible to achieve an absolute level of safety, but it is considered 
as an "acceptable level of risk" to a culture, a context, or an individual. 
Thus, the aim would be to reduce the frequency and severity of the adverse 
drug reaction, taking into consideration all unexpected reactions, even the 
minor side effects. 
• MINIMIZING COSTS 
The economic assessment of drug treatment has undergone sudden, rapid 
growth to the extent that it has produced the neologism 
“pharmacoeconomics”. Health expenditure has a strong impact on the 
economy of several countries; hence, the main aim is the reduction of 
costs: it can be achieved quickly by identifying and reducing money and 
resources wastage and, more slowly, by paying more attention during the 
prescription of a therapy. In fact, a correct prescription often leads to more 
rapid healing, while an inappropriate prescription can lead to the 
prolongation and worsening of the disease; the lower incidence of adverse 
effects, moreover, would avoid having to take further drugs, favouring 
adherence to therapy by the patient. Costs should be taken from the 
perspective of the NHS. This is funded by public money, and reducing costs 
frees money for more health care -both facts providing ethic justification 
for including cost minimization. 
Assessing the benefits of drug treatment in financial terms is more difficult 
and questionable, best avoided by most prescribers until methodological 
issues are better refined. 
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• RESPECTING PATIENT CHOICES 
There are many ethical and practical reasons why the patient's choices, 
particularly informed choices, should be taken into consideration during 
prescribing. It is important to listen to the patients and to inform him/her 
about everything related to therapy: he/she is the one who practically has 
to take the drugs and to follow the dosing and timing schedule or the 
clinician’s instructions. The doctor must also understand, based on any 
objections raised by the patient, whether it is necessary and possible to 
prescribe alternative and more suitable therapies, such as a cheaper drug. 
Being listened to and involved in the choice of therapy makes the patient 
more satisfied and predisposed to treatment, leading to the establishment 
of a trust relationship between patient and doctor, which is often lacking 
and is, instead, fundamental. Obviously, it does not mean that it is always 
possible to make the patient's needs coincide with the therapy he/she will 
be prescribed. 
 
Box 1.1 – Definition of good prescribing [Duerden et al, 2011] 
 
 
  
“…Whereas consensus may be gained within medicine on how to 
balance effectiveness, risk, and cost of drug treatment for a condition, 
including the patient makes judgement on the quality of prescribing 
difficult to conduct at a distance. In contrast, drug and therapeutics 
committees, pharmacists, medical advisers, and commissioning 
agencies are increasingly making judgements on the acceptability of 
prescribing. These approaches need not be mutually exclusive. The 
model of good prescribing proposed can be integrated with the 
proscriptive, protocol driven approach currently gaining favour – for 
example, by setting a standard that 80 per cent of prescribing meets 
the protocol. The level at which the standard is set must come from 
debate among prescribers, patients, and commissioning agencies.” 
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1.1.2 Types of Inappropriate Prescribing 
 
The failure to prescribe appropriate drug therapy is named ‘inappropriate 
prescribing’. In some cases, inappropriate prescribing simply results in the 
absence of any clinical effect. In other, more serious cases, the 
consequences may include aggravation of the illness, additional diagnostic 
testing, increased hospitalizations and mortality, especially in older people, 
or in co-morbid individuals who may have compromised physiologic 
functions [Hamilton et al, 2009]. 
Other possible adverse outcomes related to inappropriate prescribing are 
the decreased quality of life, adding discomfort to the patient, and the 
deterioration of clinician-patient relationship. Furthermore, the 
inappropriate use of medicines can lead to increasing costs for the patient 
and health care system and to wastage of scarce health resources, which 
can further reduce the availability of other vital medicines or increase 
treatment cost [Ofori-Asenso et al, 2016]. 
For its association with all these negative outcomes inappropriate 
prescribing has become a global healthcare concern. 
There are different types of inappropriate prescribing. The most common 
are the following: 
• PRESCRIPTION CASCADE 
It refers to the process in which an adverse drug reaction (ADR) is not 
recognized as such, but is interpreted as manifestation of a new pathology. 
Consequently, for the treatment of this new clinical manifestation, new 
unnecessary therapies are prescribed, which expose the patient to the risk 
of develop other ADRs. This phenomenon can be easily prevented by 
knowing and promptly identifying the side effects of drugs. 
• DRUG INTERACTIONS 
Drug interaction is the phenomenon that occurs when a drug (drug-drug 
interaction, DDI), a food (drug-food interaction) or a pathological condition 
(drug-pathology interaction) interacts with a drug taken by the patient, 
with consequent alteration of the profile risk/benefit. 
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• UNDER-PRESCRIBING 
It indicates the instance where the drugs required are not prescribed, or 
an insufficient treatment duration or dosage is issued. Under-prescribing 
can contribute to significant morbidity and mortality, although it remains 
an area of medicine use that has attracted less attention. 
• OVER-PRESCRIBING 
It refers to instances where a drug that is not indicated is prescribed, or if 
indicated, the duration of treatment is too long, or the quantity of medicine 
given to patients exceeds the amount required for the current course of 
therapy. 
• DUPLICATE OR MULTIPLE PRESCRIBING 
It refers to the simultaneous prescription of two molecules of the same 
therapeutic class to treat a certain pathology or different pathologies, 
causing a substantial increase in iatrogenic risk. 
• INCORRECT PRESCRIBING 
This category refers to drugs for which risks, under conditions specific, 
exceed the potential benefits and their use would be avoided. It occurs 
when a medicine is given for the wrong diagnosis, the prescription is 
prepared improperly, or adjustments are not made to incorporate the 
patient’s co-existing medical, genetic, or environmental conditions. 
• EXTRAVAGANT PRESCRIBING 
It occurs when the GP prescribes the most expensive drug, when a less 
expensive one of comparable safety and efficacy and suitable for the 
patient and his pathology exists. This prescription is driven by no 
therapeutic rationale and does not provide any additional therapeutic 
advantage compared to cheaper drugs. Similarly, extravagant prescribing 
is said to have occurred when a patented product in a class is prescribed 
when low costs generics are available in the same class, which could have 
been used without compromising care. 
 
 
  
- 11 - 
1.2 EVALUATION OF MEDICATION PRESCRIPTIONS 
 
Drug prescribing is one of the most important processes in health care and 
an essential step in health promotion. However, the process of setting a 
diagnosis and choosing appropriate drug treatment is complex. It is a 
medical act characterized not only by clinical, but also administrative and 
ethical aspects. It involves not only the choice, but also the decision of 
optimal dosing and scheduling, informing and educating the patient, and 
doing the follow-up of the effectiveness of the medications. Bell and 
colleagues [Bell et al, 2004] proposed a framework, consisting of five main 
domains, for the evaluation of medication prescriptions (Figure 1.2). 
1) The first main domain is the act of prescribing by clinicians. As 
previously described, clinicians need to assess and fill in the needs for a 
medication therapy, and the patient’s preferences. The combined data 
input of medication data, patient data and possible drug formulary 
restrictions yield the output (a prescription). The prescriber may lack 
adequate training, or there may be inadequate continuing education, 
resulting in the reliance on out-dated prescribing practices which may have 
been learnt while under training. Potential threats for errors during 
electronic prescribing are mistakes during the selection of patients (wrong 
patient), clinical problems (wrong diagnosis, or not reporting a diagnosis), 
or medication selection (wrong dosages). 
2) The second domain is the transmission of the prescription. In primary 
care, patients usually perform this domain themselves, although 
telephoning or secure emailing of prescriptions by clinicians to pharmacists 
are possible. Potential threats include transcribing errors. 
3) The dispense activity can be done by clinicians (when medications are 
available on hand), or by pharmacists. In clinical practice, the separation 
of prescribing and dispensing activities is considered to be a safety 
mechanism to ensure an additional independent assessment of the 
proposed therapy before patient begins treatment [Chou et al, 2003]. 
Therapeutic knowledge by the dispenser is essential to cross-check any 
loopholes in the prescription made and make appropriate 
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recommendations/interventions to the prescriber, if necessary [Ofori-
Asenso et al, 2016]. Pharmacists more and more employ electronic 
systems to store and to access the same information as in the prescribing 
phase. Potential threats include errors in the drug choice, meaning 
dispensing other medications. 
4) The administration of the medication involves the patient, and 
sometimes a wide range of other allied health personnel (e.g. nurses in the 
home or hospital setting). Potential beneficial aspects include the 
generation of medication administration aids, reminders for renewals, or 
the consultation of educational material. Potential threats mainly refer to 
adherence. 
5) Finally, the monitoring involves the patient and a clinician, but can also 
involve other allied health personnel. Feedback during this step could yield 
changes in the prescriptions of a patient. Potential beneficial aspects 
include the generation of alerts when a renewal of a medication was not 
done, the automated generation of questionnaires to detect adverse 
effects, or corollary orders (e.g. monitoring tests). Potential threats include 
the negligence to report adverse effects by the patient or health care 
professionals or non-adherence to medications. 
 
Electronic systems can aid medication prescribers and dispensers during 
the whole process. Potential beneficial aspects of electronic systems 
include safety alerts (based on known allergies, interactions, laboratory 
tests), formulary alerts (e.g. to improve medication adherence), or the 
automatic possibility of dosage calculations. 
 
 
 
- 13 - 
 
Figure1.2 – The functional model of medication management proposed by Bell 
and colleagues 
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1.2.1 Measurement of Appropriateness of Prescribing 
 
In the last decades there has been an increased focus on the measurement 
of the appropriateness of prescribing, which means finding reliable 
indicators, systematically developed, that allow to identify the appropriate, 
effective, safe, and cost-effective use of medicines, based on continuously 
updated and valid knowledge, in a health protection perspective. According 
to the Organisation for Economic Co-operation and Development (OECD), 
an indicator is “a quantitative or qualitative factor or variable that provides 
a simple and reliable means to measure achievement, to reflect changes 
connected to an intervention, or to help assess the performance of a 
development actor.” [DAC Working Party on Aid Evaluation, 2002]. A 
prescribing indicator is therefore a measurable element of prescribing 
performance in clinical practice, for which there is evidence or consensus 
that it can be used to assess quality, and hence change in the quality, of 
care provided [Lawrence et al, 1997]. In these terms, indicators provide a 
quantitative basis for clinicians, planners, and organizations aiming to 
achieve improvement in health care and the processes by which patient 
care is provided [Mainz, 2003]. 
Indicators measurement and monitoring serve many purposes, but the 
objectives of their evaluation are essentially two. Firstly, to raise the 
standard of care and achieve the best practice in terms of health outcomes. 
Data from the WHO show that more than 50% of all drugs are prescribed 
or dispensed inappropriately, while 50% of patients do not use them in a 
correct way [WHO 2012]. This alters the balance between risk and benefit, 
leading to ineffective and useless therapy but also increasing the risk of 
occurrence of unnecessary and avoidable side effects. Secondly, to 
rationalize the healthcare pharmaceutical expenditure. According to the 
WHO, the economic burden of futile services (those that do not provide 
benefit to patients) represents between 20 and 40% of all health 
expenditure [WHO 2010]. In such a condition in which resources are 
limited, the economic budget must be placed in first line among the criteria 
of choice between alternative solutions, also at health level. A correct use 
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of resources would lead to an expenditure control that, in turn, may allow 
reinvesting resources in areas of highest need. 
 
 
1.2.2 Characteristics and Classification of Indicators of Appropriate 
Drug Prescription 
 
An ideal indicator would have the following key characteristics: (i) valid 
and reliable; (ii) highly or optimally specific and sensitive, i.e. it detects 
few false positives and false negatives; (iii) based on agreed definitions, 
and described exhaustively and exclusively; (iv) able to discriminates well; 
(v) be related to clearly identifiable events for the user (e.g. if meant for 
clinical providers, it is relevant to clinical practice); (vi) suitable for 
comparisons; and (vii) evidence-based [Mainz, 2003]. Each indicator 
should be defined in detail, with explicit data specifications in order to be 
specific and sensitive (Table 1.1). 
 
Table 1.1- Attributes of indicators 
Attribute Description 
Valid 
-Meeting the indicator is considered a better quality (content/face 
validity) 
-Measure is a good translation of actual clinical situation or problem 
(concurrent or construct validity) 
Reliable Data should be complete, accurate, consistent and reproducible 
Credible/ 
Communicable 
Indicator must be considered acceptable by both assessors and those 
being assessed and therefore be developed with the help of 
prescribers. Outcome must be understandable and relevant for clinical 
practice 
Objective Data should be independent as possible 
Available Data required should be collected for routine clinical or organizational 
reasons or be available quickly with minimum of extra effort and cost 
Contextual 
Indicator should be context free or important context effects (i.e. 
population size, distribution of age and sex, case-mix) should be 
adjusted for 
Comparable Indicator should refer to a golden standard, or to other data in similar 
circumstances 
Repeatable Indicators should be sensitive to improvements over time 
Remediable Intervention is possible when improvements are needed 
Interpretation Indicator should be used appropriately in its presentation and 
interpretation 
Suitable Indicator should be useful for more than one organization 
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There are different types of prescribing quality indicators, which reflect the 
three areas of the medical care quality, namely structure, process and 
outcomes [Donabedian, 1988]: 
• Structural indicators that assess the quality of organizational 
factors in health care. Structural indicators are aspects of the health 
system, organization of care and available resources. They describe 
the type and amount of resources used by a health system or 
organization to deliver programs and services, and they relate to the 
presence or number of staffs, clients, money, beds, supplies, and 
buildings. In the area of prescribing, it may be access to necessary 
drugs, availability of industry-independent drug information, an 
updated formulary or prescribing guidelines. 
• Process indicators that measure the quality of processes in health 
care. Process indicators assess what the provider did for the patient 
and how well it was done. Processes are a series of inter-related 
activities undertaken to achieve objectives. They cover the actual 
performance, the decisions and actions of the clinicians, for example 
prescribing the appropriate treatment or choosing a drug according 
to recommendations. Notably, prescribing quality indicators are 
most often process-oriented. 
• Outcome indicators that measure results achieved in health care 
(Box 1.2). An ideal outcome indicator would capture the effect of 
care processes on the health and well-being of patients and 
populations. In the area of prescribing, they are related to the 
benefit or harm to the patient, equivalent to what is measured in 
clinical trials, but assessed as consequences of prescribing in a non-
experimental setting. Thus, outcome indicators cover all types of 
drug effects: risk of death or hospitalisation, measures of disease 
severity or activity, functional impairment, and impact on patients’ 
well-being and quality of life. Outcome may be influenced by both 
structures and processes (e.g. a patient may die if there are no 
physicians with appropriate skills available (structure) or if the 
patient was prescribed an inappropriate drug (process)). Outcome 
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indicators are important, as improvement in patient health 
(outcome) is the aim of drug prescribing [Campbell et al, 2016]. 
 
Box 1.2 – Definition of outcomes in health care [Mainz, 2003] 
 
 
The taxonomy grid proposed to categorize prescribing quality indicators 
subdivided them not only on structure, process and outcome indicators 
axis, but also on a second drug-, disease-, and patient- axis [Hoven et al, 
2005]. Examples of indicators for each category is reported in Table 1.2. 
The latter classification is based on the amount of clinical information they 
incorporate (Figure 1.3): 
• Drug-oriented indicators include information solely on drugs. are 
based on drug prescribing/dispensing data alone and can be used 
irrespective of the indication for which the drug is prescribed. Access 
to patient‐level data enables construction of more clinically relevant 
drug‐oriented indicators linking different drugs to one another or 
over time [Campbell et al, 2016]. 
• Disease-oriented indicators include information on drugs linked 
to diagnosis, where prescribing quality is seen as a part of the 
treatment quality. They may indicate either to what extent patients 
are being treated with the recommended drugs for a certain 
condition or to what extent drugs are avoided in patients with 
conditions for which they should not be used. 
Outcomes can be articulated as ‘The Five Ds’: 
1) death: a bad outcome if untimely 
2) disease: symptoms, physical signs, and laboratory abnormalities 
3) discomfort: symptoms such as pain, nausea, or dyspnea 
4) disability: impaired ability connected to usual activities at home, 
work, or in recreation 
5) dissatisfaction: emotional reactions to disease and its care, such 
as sadness and anger 
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• Patient-oriented indicators include information on individual 
clinical characteristics of the patient, e.g. severity of the disease. 
For such an indicator, very detailed information at the individual 
patient level is necessary. It may involve access to clinical data from 
patient records, maybe even individual patient assessments, using 
interview and clinical examination [Hanlon et al, 1992; Pont et al, 
2004]. 
 
Table 1.2 – Examples of process and outcome prescribing quality indicators 
Indicator Drug oriented Disease oriented Patient oriented 
PROCESS 
Co-prescribing gastro 
protective drugs and 
NSAID’s in elderly 
patients 
 
Off label drug use in 
children 
 
Avoidance of drugs 
with strong 
anticholinergic 
properties in elderly 
patient 
 
Ratio prescribing lipid-
lowering drugs for 
primary/secondary 
prevention in 
hypercholesterolemia 
Algorithm for 
benzodiazepine 
prescribing in 
individual patient in 
nursing home 
OUTCOME 
Drug induced 
hospitalization 
% of patient with 
hypertension under 
control 
 
% diabetics with 
complications 
Morbidity/mortality in 
relation to adherence 
to guidelines, taking 
into account clinical 
characteristic of the 
patient 
 
Readmission to 
hospital 
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Figure 1.3 – Representation of theoretical model to describe different types of 
quality assessment and quality indicators of drug prescribing [adapted from 
Campbell et al, 2016] 
 
 
1.2.3 Selection of Indicators of Appropriate Drug Prescription 
 
The selection of indicators should be done on a clinical basis, as the 
indicators are functional to the improvement of the clinical outcome, and 
on an economic basis, as the indicators are functional to the reduction of 
patient management cost, apart from the price of the drug. 
In fact, a prescribing behaviour conforming to the therapeutic 
recommendations decreases the likelihood of using other services, such as 
diagnostic tests, treatment of side effects, hospital admissions; in 
addiction, it obviously increases the probability of achieving a favourable 
therapeutic outcome. The indicators play a central role in improvement 
programs of healthcare performances and are commonly used for 
monitoring of interventions aimed at improving diagnostic-therapeutic 
prescribing behaviour among prescribers. 
The indicators of appropriateness that can be used as essential tools in the 
process of driving pharmaceutical expenditure and clinical outcomes 
Higher steps indicate an increasing level 
of complexity in the clinical information 
but may also indicate increasing 
credibility to health care professionals or 
an increasing feasibility of demonstrating 
that the indicator is a quality indicator 
and not simply a performance indicator 
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include: 
• Prescribing indicators, which describe the prescribing variability 
of the clinicians in different clinical or pathological conditions in 
terms of prevalence of patients. 
• Consumption indicators, which describe the variability in the use 
of medicines in terms of volume or cost. The variability of prescribing 
is usually expressed in terms of volumes (Defined Daily Dose per 
1,000 inhabitants/die) or expenditure (per capita expenditure) and 
shows the deviation of the units being evaluated from the average 
of the evaluation context: the regions in the national context, the 
Local Health Units (LHU) in the regional context, individual Medical 
Specialists or General Practitioners (GP) in the local context. 
• Adherence indicators, which describe the adherence of 
prescribing behaviour to predefined standards. They include 
indicators of both adherence to drug use (e.g. the continued use of 
drugs in chronic treatment) and adherence to the therapeutic 
indications (e.g. prescription of drugs with a specific indication for 
the type of patient considered). 
Adherence indicators are characterized by a change of perspective 
in the measurement and assessment of the appropriateness of 
prescribing with respect to the more traditional consumption 
indicators. Instead of a method that identifies as inappropriate the 
use of drugs that induces an excess (or lack) of consumption 
compared to an average reference, without providing an explanation 
of such variability, they are based on a method that classifies as 
inappropriate the use of drugs under recommendations different 
from those for which its effectiveness has been tested or will be 
reimbursed. In order to explain the prescribing variability, the 
indicators of adherence are a necessary tool in the interpretation of 
the results described through consumption indicators. However, it 
must be kept in mind that if, on one hand, the unexplained 
prescribing variability (in excess or in defect compared to the 
average reference) indicates potential appropriateness problems, on 
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the other greater homogeneity with respect to the average level 
does not mean a high prescribing appropriateness. 
 
 
1.2.4 Prescribing Indicators 
 
Medication appropriateness can be measured by evaluating the content or 
quality of a prescribing decision (i.e. a process measure) or its outcome 
(i.e. an outcome measure) [O’Connor et al, 2012]. Different tools to assess 
appropriate prescribing have been developed and published (Figure 1.4); 
they can be grouped roughly into implicit and explicit tools, and tools 
showing a combination of both approaches [Kaufmann et al, 2014]. 
 
 
1.2.5 Implicit tools 
 
Implicit tools rely on expert professional judgement, relating to the 
appropriateness or inappropriateness of a specific treatment option, based 
on all the available clinical evidence. One of their advantages is focusing 
on the patient and decisions with regard to prescribing appropriateness at 
an individual level. However, implicit criteria often are time‐consuming to 
apply and, as they depend on clinicians’ knowledge and attitudes, can be 
subject to differences in opinions and therefore generally exhibit a poor 
level of inter‐rater reliability. Implicit criteria are also often difficult to apply 
to administrative databases and national registers, as they are less easily 
standardized. 
An example of implicit criteria is MAI (Medication Appropriateness Index), 
developed in USA [Hanlon et al, 1992], which is based on the evaluation 
of 10 questions (concerning indications, efficacy, patient's condition, 
possibility of using the drug in the individual patient, drug-drug and drug-
disease interactions, unnecessary therapeutic duplicates, duration of 
therapy, cost) aimed at assisting the clinician in assessing the quality of 
the patient's pharmacological prescriptions. 
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Figure 1.4 - Categories of measures of appropriateness of prescribing and their 
main characteristics 
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Another example is the AOU (Assessment Of Underutilization of 
Medication) tool [Jeffry et al, 1999] which is based on an instrument 
reported by Lipton and colleagues [Lipton et al, 1992]. It requires the 
clinician to have a detailed list of the medical conditions and current drugs 
used by the patient in order to determine prescription omissions based on 
existing evidence in the medical literature. 
 
 
1.2.6 Explicit tools 
 
Explicit tools are criterion-based indicators and are often developed from 
literature reviews, evidence-based guidelines, expert opinions, and 
consensus techniques. Explicit criteria are generally drug- or disease- 
oriented (rather than patient-oriented) and usually include lists of drugs or 
drug classes, dosages, drug–drug combinations and drug–disease 
combinations that are known to cause harmful effects and should be 
avoided. The advantage of explicit criteria is that they can be applied to 
prescriptions even in the absence of clinical interpretation and judgment. 
Therefore, these criteria are quick and easy to apply and generally exhibit 
a good level of inter‐rater reliability. However, they usually do not take into 
account the presence of comorbidities, nor do they consider previously 
unsuccessful therapeutic approaches or patient preferences [O’Connor et 
al, 2012]. Furthermore, they need regular updates and country-specific 
adaptation, failing to address international comparisons of prescribing 
patterns. 
 
There is no ideal approach to assessing appropriateness of prescribing, and 
both types have advantages and disadvantages which should be taken into 
consideration when developing or choosing a suitable screening tool. 
However, due to the time‐consuming nature, poor inter-rater reliability and 
limited application to administrative databases of implicit criteria, the 
majority of studies that have examined potentially inappropriate 
prescribing (PIP) to date have used explicit criteria, even though implicit 
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criteria are considered more sensitive [Taxis et al, 2016]. The term 
“potentially” is used because a drug prescription doesn’t necessarily mean 
that the patient will take the medication (even if it is often the case), or 
that the use of the drug will cause a negative health outcome. 
 
1.2.6.1 BEERS CRITERIA 
Beers and collaborators first published a list of potentially inappropriate 
medications (PIMs) in 1991, developed by the Delphi method for nursing 
home residents [Beers et al, 1991] and then expanded to other geriatric 
settings in 1997 [Beers et al, 1997] and 2003 [Fick et al, 2003]. Since 
2011, the American Geriatric Society (AGS) has been the steward of the 
criteria and has produced updates on a 3-year cycle that began in 2012 
[AGS Beers Criteria Update Expert Panel, 2012]. The following update have 
occurred in 2015 [AGS Beers Criteria Update Expert Panel, 2015] and at 
the beginning of 2019. The 2019 Beers criteria [AGS Beers Criteria Update 
Expert Panel, 2019] consist of a list of medications or medication classes 
that must be avoided as they are deemed potentially inappropriate in all 
older individuals, a list of medications that are considered potentially 
inappropriate in older individuals who have one of the specified health 
problems, and a list of medications/medication classes that should be used 
with caution in all older individuals. For each criterion, the quality of the 
evidence is graded and the clinical significance (severity) is rated. Since 
the 2015 update, these criteria also include a list of drug-drug interactions 
with a high risk of harmful outcome in older people as well as a list of drugs 
to be avoided/adjusted in individuals with kidney impairment [Taxis et al, 
2016]. The AGS Beers Criteria continue to be useful and necessary as a 
clinical tool, as an educational tool at the bedside, and as a public health 
tool to improve medication safety in older adults. The AGS Beers Criteria 
can increase awareness of polypharmacy and aid decision making when 
choosing drugs to avoid in older adults. The main limitation to the Beers 
criteria is their limited transferability to markets other than United States, 
where they were developed [Fialováe et al, 2005]. 
 
- 25 - 
1.2.6.2 STOPP/START CRITERIA 
The Irish tool was first developed using the Delphi consensus method in 
2008 [Gallagher et al, 2008], and an update was published in 2014 
[O'Mahony et al, 2015]. It consists of two complementary parts: a list of 
34 evidence-based prescribing indicators for commonly encountered 
diseases in older people – the Screening Tool to Alert Doctors to Right 
Treatment (START; with ‘right’ meaning appropriate, indicated) – and a list 
of 80 clinically significant criteria for potentially inappropriate prescribing 
– the Screening Tool of Older Persons’ Prescriptions (STOPP). The criteria 
are organized according to the physiological systems to which each relate, 
thereby enhancing their usability. In addition, each criterion is 
accompanied by a brief explanation, outlining the reason why each PIM is 
considered potentially inappropriate or why a particular condition is under-
prescribed. The STOPP/START criteria have been validated and shown a 
higher sensitivity at detecting PIP in different settings. However, the 
number of criteria involved and the length of the lists make the manual 
application time-consuming. 
 
1.2.6.3 EU(7)-PIM LIST 
The EU(7)-PIM list [Renom-Guiteras et al, 2015] was the first attempt to 
unify other lists of explicit criteria on potentially inappropriate medications. 
The general basis of the EU(7)-PIM list derives from the earlier developed 
German PRISCUS list [Holt et al, 2010], but has now integrated criteria 
from the Laroche list (France) [Laroche et al, 2007], McLeod’s list (Canada) 
[McLeod et al, 1997] and Beers criteria (United States) [Beers et al, 1997; 
Fick et al, 2003]. It is developed with participation of experts from seven 
European countries (Estonia, Finland, France, Germany, the Netherlands, 
Spain, Sweden), that allows identification and comparison of PIM 
prescribing patterns for older people across European countries. The 
EU(7)-PIM lists 282 drugs (including seven medication classes), of which 
some are accompanied with dosage information. An additional strength of 
this method is the proposed dosage adjustment for each medication, as 
well as the option of an alternative medication or therapy. 
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1.2.6.4 ANTICHOLINERGIC LOAD 
Another approach to the evaluation of medication use in older adults is to 
determine a patient’s anticholinergic load. Drugs with anticholinergic 
properties are frequently used in older people despite their high potential 
risk of central and peripheral side effects. These effects can include 
constipation, heat intolerance, dry eyes, dry mouth, tachycardia, urinary 
retention, forgetfulness, agitation, paranoia, and delirium, among others. 
A number of different scales/methodologies have been developed to assist 
in the calculation of an individual’s anticholinergic load, including the 
Anticholinergic Cognitive Burden (ACB) [Boustani et al, 2008]. The ACB 
scale was generated through a combination of laboratory data, literature 
review, and expert opinion. This scale has been shown to be associated 
with an increased risk in mortality and worsening cognitive function in 
multiple populations, including 13,000 older adults in the United Kingdom 
[Fox et al, 2011]. The ACB scale was updated in 2012 [Campbell et al, 
2013] and include drugs that are rated in an ordinal fashion from 0 to 3, 
with 0 signifying no known anticholinergic activity and 3 signifying marked 
activity (Box 1.3). 
 
Box 1.3 – Criteria for drug categorization in the ACB scale 
 
 
1.2.6.5 SEDATIVE LOAD 
Besides anticholinergic drugs, also medication with sedative properties can 
worsen cognitive impairment and physical functioning, increase the risk of 
falls and negatively impact activities of daily living, hospitalization and 
mortality. Despite that, sedatives are more frequent among older people 
1) ACB score of 1: evidence from in vitro data that the medication 
has antagonist activity at muscarinic receptors 
2) ACB score of 2: evidence from literature, prescriber’s information, 
or expert opinion of clinical anti-cholinergic effect 
3) ACB score of 3: evidence from literature, prescriber’s information, 
or expert opinion of the medication causing delirium  
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than among the general population. Cumulative exposure to and use of 
multiple drugs with sedative properties can be assessed using the Sedative 
Load (SL) Model [Linjakumpu et al, 2003]. The SL Model classified drugs 
into 4 groups based on their sedative potential. Group 1 included only 
psychotropics (primary sedatives, 40 drugs). Group 2 included many drugs 
for somatic disorders (drugs with sedation as a prominent side effect or 
preparations with a sedating component, 80 drugs). Psychotropics were 
included in almost all pharmaceutical classes in group 2. Group 3 included 
the major medicinal categories, and only drugs for somatic disorders 
(drugs with sedation as a potential adverse effect, 220 drugs). Group 4 
included all the other medicines (drugs with no known sedation). 
 
1.2.6.6 POTENTIAL DDIs 
Another indicator of potentially inappropriate prescription is the concurrent 
use of interactive drugs as prescribed by one or more different prescribers. 
Drug–drug interactions (DDIs) are defined as ‘‘two or more drugs 
interacting in such a manner that the effectiveness or toxicity of one or 
more drugs is altered” [Gagne et al, 2008]. Although combination 
therapies are generally used to achieve better therapeutic results, DDIs 
can lead to life-threatening adverse reactions or therapeutic failure by 
changing the therapeutic efficacy of drugs [Gören Z et al, 2017]. Not all 
adverse events can be avoided, but DDIs may be among the most 
preventable and manageable because of their potential predictability. 
Recently, several web-based tools have been developed in the attempt to 
identify potential DDIs and to prevent medication errors associated with 
them, such as Intercheck, Micromedex, MediRisk and Lexi-Interact 
software programs. Note that, when the interactions present in the 
prescription are theoretically evaluated through databases and not by their 
actual occurrence as a negative clinical outcome, they are considered 
“potential” [Rodrigues et al, 2017]. All drug interactions are classified 
according to two parameters (Figure 1.5): 
• clinical relevance that takes into account potential clinical 
outcomes, and the type, quality and relevance of supporting clinical 
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data [Tragni et al, 2013];  
• pharmacological documentation that refers to how deeply the 
interaction has been studied and investigated, and reported in 
literature 
 
 
Figure 1.5 - Classification of severity of DDIs based on Micromedex software. 
 
1.2.6.7 THERAPEUTIC DUPLICATION 
In addition to DDIs, also therapeutic duplication (TD) can increase the risk 
of adverse drug reactions, without additional therapeutic benefits for the 
patient, and reduce individual safety and excess healthcare costs. 
TD is the practice of prescribing two or more drugs from the same 
therapeutic category simultaneously, such that the combined daily dose 
puts the patient at increased risk of adverse drug reactions without 
additional therapeutic benefits. The risk of TD increases as patients receive 
more drugs from multiple health care institutions or from different 
prescribers. The elderly, for instance, are at increased risk of TD as they 
use many medications [Kim et al, 2015]. 
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1.3 STRATEGIES TO TACKLE INAPPROPRIATE PRESCRIBING 
 
As pharmacotherapeutic developments have taken place and use of 
medicines have increased, there has consequently been a growing 
recognition of the significant burden associated with the harm caused by 
drugs to individual patients and their cost to society [Søndergaard J et al, 
2016]. 
One important approach is to identify potentially inappropriate prescribing 
and correct and optimize it where necessary, with the expectation that this 
will avoid serious harm [Avery AJ et al, 2018]. A wide range of 
interventions can be implemented to change patients’ and prescribers’ 
behaviour to improve drug prescribing. Interventions can occur at the 
individual clinician/health professional level (micro‐level), at group or team 
level (meso‐level) or at an organization/policy/regulatory level (macro‐
level) [Søndergaard J et al, 2016]. 
These strategies can be grouped broadly as targeted or system-oriented 
approaches [Ofori-Asenso et al, 2016]. In details, targeted approaches 
comprise educational/professional and managerial/organizational 
interventions, while system-oriented strategies include regulatory and 
economic/financial interventions [Hogerzeil, 1995]. 
• Educational/professional strategies are often aimed at 
persuading or informing, and this usually involves the use of printed 
materials, seminars, bulletins and face-to-face interventions. 
Continuing medical education (CME) was the most common 
educational intervention and utilized various methods, including 
interactive teaching complemented by a decision algorithm, mailed 
educational material combined with individualized feedback, and 
face-to-face visits to physicians [Kaur et al, 2009]. 
• Managerial/organizational interventions are mainly aimed at 
guiding practice and supporting decision-making. They refer to 
various restrictions on prescribing, e.g. restrictive lists, a maximum 
number of drugs per prescription, budgetary or cost restrictions, 
endorsement by higher qualified consultants, patient co-payment 
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strategies, price measures, structured prescription forms or a 
maximum duration for inpatient prescriptions (automatic stop-
orders). 
• Regulatory measures utilize laws and regulations to influence 
prescribers’ practices through restrictions and requirements. 
Examples include procedures to critically evaluate drugs and product 
information (e.g. datasheet, patient information leaflet) before 
market approval is granted, scheduling drugs for different sales 
levels (over the counter, pharmacy only, prescription only) and 
specifying for each drug a minimum level of prescriber or health 
facility (for example, no injectable antibiotics at health centres). 
• Economic/financial strategies are aimed at promoting positive 
financial incentives while at the same time eliminating perverse 
incentives for prescribers [Gurbani, 2011]. Economic interventions 
that may be employed include the implementation of significant 
changes in service providers’ reimbursement schemes or disallowing 
prescribers to sell medicines themselves, which can remove the 
financial motivation for over-prescribing [Hogerzeil, 1995]. 
 
 
1.3.1 Educational/professional interventions 
 
Educational interventions are designed and implemented to influence 
prescribing clinicians in order to encourage a modification of their practice 
performance using clinical information strategies. It is important to keep 
in mind that there is not a single strategy to suit all circumstances and that 
there is not a precise guidance on which combinations of strategies are 
more effective when a multiple-component intervention is implemented. 
With respect to influencing prescribing patterns, several systematic 
reviews that have examined interventions targeting individual 
professionals showed academic detailing, audit and feedback, use of local 
opinion leaders and reminders (for drug dosing) to be generally effective 
[Grimshaw et al, 2001; Ostini et al, 2004; Ross et al, 2009; Brennan et al, 
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2013; Davey et al, 2017]. 
 
1.3.1.1 PRINTED EDUCATIONAL MATERIAL  
Passive distribution of printed educational material is widely used to 
influence prescribing patterns. However, there is evidence of only a 
marginal beneficial impact on professional practice when it is used as a 
standalone intervention and compared to no intervention. The 
effectiveness of printed educational materials compared to other 
interventions, or of printed educational materials as part of a multifaceted 
intervention, is still uncertain [Giguère et al, 2012]. 
 
1.3.1.2 AUDIT AND FEEDBACK 
Audit and feedback continue to be widely used as a strategy to improve 
professional practice. In an audit and feedback process, an individual’s 
professional practice or performance is measured and then compared to 
professional standards (e.g. clinical guidelines) or targets or with other 
practices. Feedback can be given in a written, electronic or verbal format, 
and may include recommendations on clinical action. 
Audit and feedback can be effective in improving professional practice to a 
small or moderate degree, even more when feedback is intense and when 
baseline adherence to recommended practice is low. A Cochrane 
systematic review including 140 trials of audit and feedback showed a 
4.3% increase in healthcare professionals' compliance with desired practice 
[Ivers et al, 2012]. Feedback was most effective when delivered by a 
supervisor or respected colleague, and presented frequently, and if 
featuring both specific goals and action plans, aiming to decrease a 
targeted behaviour, targeting lower baseline performance, and being 
delivered to non‐physicians [Ivers et al, 2014]. 
 
1.3.1.3 ACADEMIC DETAILING  
Also referred to as ‘educational outreach’ and ‘educational visiting’, 
academic detailing (a trained educator visits a prescriber or group of 
prescribers in their practice setting to deliver key messages) has been 
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found to be effective in influencing prescribing and changing behaviour 
[Bloom, 2005]. Results from a Cochrane systematic review involving 69 
studies and more than 15,000 health professionals reported an increase 
(+5.6%) in compliance with desired practice [O’Brien et al, 2007]. 
Despite these findings, educational outreach is an expensive strategy and 
thus may not be cost effective in all circumstances. One of the key features 
of successful academic detailing is a sound understanding of the clinical 
content of the programme to be implemented. 
 
1.3.1.4 REMINDERS, ALERTS AND COMPUTERIZED DECISION SUPPORT 
SYSTEMS 
Reminders are potentially effective and are likely to result in moderate 
improvements in process of health care. Reminder systems have been used 
for many years. Manual paper reminders (involving no computers) range 
from simple notes attached to the front of every chart to more 
sophisticated reminders given under specific conditions for specific types 
of patient. Computer‐generated reminders using physicians’ patient record 
systems are generally delivered to health professionals when they are 
making decisions regarding treatment. In this regard, a meta-analysis of 
16 randomized controlled trials showed that computer-based reminders 
improved preventive care performance by 77% when compared to control 
condition [Shea et al, 1996]. Furthermore, different systematic reviews 
showed that reminders to health care professionals could be effective in 
promoting change in practice across a variety of clinical settings and areas, 
including test ordering, vaccination, drug selection, dosing, prescribing and 
general disease management [Buntinx et al, 1996; Balas et al, 2000; 
Kawamoto et al, 2005] 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
THE ITALIAN SCENARIO  
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2.1 THE ITALIAN NATIONAL HEALTH SYSTEM 
 
The Italian National Healthcare System (NHS) was founded in 1978, based 
on the principles of universal coverage, social financing through the use of 
general taxation and non-discriminatory access to the health care services 
[Ministero della salute website]. It is designed on the Beveridge model, 
providing uniform and comprehensive care, free of charge, to the entire 
population [Folino-Gallo et al, 2009]. The Italian NHS is organised into 
three levels: national (the Central Government), regional (Regions’ 
Governments), and local (Local Health Units, LHU) level, and it is regionally 
based (Figure 2.1). 
Regions, in fact, enjoy significant autonomy in determining the macro 
structure of their health systems and have power to legislate within the 
framework established by the Central Government. At local level, 
geographically based LHUs are managed by a general manager appointed 
by the governor of the Region, and deliver public health care, community 
health services and primary care directly, and secondary and specialist 
care directly or through public hospitals or accredited private providers 
[Cicchetti et al, 2016]. 
The NHS provides all citizens and legal foreign residents with economic 
coverage of drugs with documented clinical efficacy and used for treating 
serious and chronic diseases [Onder et al, 2014]. The amount of public 
money to be spent on health care is annually established by the Central 
Government and assigned to the regions in order to provide the ‘‘essential 
levels of care’’ (LEA), which must be assured homogenously to citizens 
throughout the country. Each region allocates the funds to its LHUs mainly 
on an age-adjusted capitation basis. Assigned funds are used by LHUs for 
the direct provision of both in-patient and out-patient care, for GPs 
remuneration, and for the costs reimbursement of healthcare services 
afforded by independent and university hospitals and/or accredited private 
providers [Folino-Gallo et al, 2009]. 
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Figure 2.1 – Detailed overview of the Italian health care system  
[Ferré F et al, 2014] 
 
It is clear that the Italian health system is highly decentralized, with most 
organizational powers governed by regions and rather limited powers at 
national level. Although the state has full control over the definition of the 
benefit package (LEA), there is evidence that the actual provision and 
quality of these services varies greatly across regions, as shown by the 
significant flows of patients moving from the south-central regions to 
central-northern ones in order to obtain care. The decentralization of the 
health system has allowed the stronger northern and central regions to 
design their own models and to fully exploit higher degrees of autonomy 
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obtained over the last 20 years. Interestingly, these regions have followed 
rather different pathways, without contradicting the basic principles of the 
NHS, and thus they have designed rather different regional NHS models. 
This diversification suggests that there may be different ways to shape a 
universal tax-funded national health system and that important variants 
may be generated by different environmental factors, even within a single 
nation. The most salient issue with the Italian decentralization process is 
that it benefitted much less (if not even harmed) the southern regions of 
the country. This gap between the southern and the northern parts of the 
country is mainly attributable to the lower quality of the political, 
managerial and professional capacities available in the southern regions 
[Ferré F et al, 2014]. 
 
 
2.1.1 The Italian Pharmaceutical System 
 
The Italian NHS is responsible for providing pharmaceutical care and 
accounts for the majority of total pharmaceutical spending. The main 
national authority responsible for the pharmaceutical regulations in Italy is 
the Italian Medicines Agency (Agenzia Italiana del Farmaco or AIFA), which 
was established on July 2004 and replaced the Department of Drugs at the 
Ministry of Health in the responsibility of medicines for human use: 
marketing authorisation, pricing and reimbursement, governance of 
pharmaceutical expenditure, pharmacovigilance, and information to health 
professionals and patients. The Ministry of Health and the Ministry of 
Economics have a function of control on AIFA activities and cooperation for 
the elaboration of pharmaceutical policies, regulation and control of 
pharmaceutical expenditure.  
One of AIFA’s main missions is indeed to promote and guarantee a safe 
and appropriate use of medicines, thus contributing to enhance the 
standards of public health care. 
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2.1.1.1 THE PHARMACEUTICAL REIMBURSEMENT SYSTEM 
The Italian pharmaceutical reimbursement system covers all relevant 
diseases and the whole country providing universal pharmaceutical 
coverage to the whole population, including legal residents. The general 
conditions of the reimbursement system are established on a national 
level. The current reimbursement classification categorises medicines into 
two reimbursement classes, according to a combination of criteria in terms 
of effectiveness and cost: 
• Class A comprises essential medicines and medicines for serious and 
chronic diseases (i.e. antihypertensive drugs, antibiotics, 
hypoglycaemics agents, antibiotics, antidepressants, 
antiaggregants, anticoagulants, anti-Parkinson drugs, etc.). 
Medications of this class are partially (involve a modest co-payment 
that varies across Regions) or fully reimbursed by NHS and are 
available only through a medical prescription. The class also includes 
the subgroup H, consisting of medicines requiring specialist 
supervision and eligible for reimbursement only when used for in-
patient care (hospital use only). 
• Class C includes pharmaceutical products that are not reimbursed 
by the NHS and can be acquired with or without prescription. They 
usually are medicines for disease of slight importance and for minor 
ailments (i.e. benzodiazepines, antispasmodics, topical treatments, 
etc.). 
AIFA applies a price regulation only to reimbursed pharmaceuticals. By 
contrast, for non-reimbursed medicines price is freely determined (with 
some limitations) by manufacturers and monitored by the Agency and the 
Ministry of Health. 
 
 
2.1.2 The Primary Care 
 
The health care system consists of the structures and human resources 
assigned to primary care, both medical and diagnostic services, and other 
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services such as assistance provided in residential or semi-residential 
facilities. The primary care is provided by self-employed and independent 
physicians, general practitioners, and paediatricians, under contract and 
paid a capitation fee based on the number of people on their list. This form 
of care, capillary widespread on the territory, rotates around the figure of 
the general practitioner (GP), who represents the benchmark for the 
citizen's general care and the main actor in drug management for the 
benefit of patients. 
In 2016, the GP number was about 44 000 in Italy, with a mean value of 
7.3 GPs per 10 000 inhabitants. At regional level, the number ranged from 
6.7 GPs per 10 000 inhabitants in the North-West and North-East to 8.0 
GPs per 10 000 inhabitants in the Islands [ISTAT data, 2016].  
As first-level care providers, GPs are directly involved in the appropriate 
selection and efficient use of the majority of drugs. Furthermore, taking 
the overall health care of the patients who rely on them, they are also 
required to manage the drug therapies prescribed by hospital or 
ambulatory specialists. In support of the GP, the pharmacist plays a very 
important role, since he is an expert on the drug and its related problems 
and often represents a guide for the patient, helping him through 
communication and listening. 
Over the last 15 years, there have been attempts to reorganize the primary 
care providing, with the objective of moving from the traditional model of 
GPs and other health professionals working in single practices to an 
integrated care model that connects different health care professionals and 
bridges the gap between front-line staff and patients [Ferré F et al, 2014]. 
Again, different institutional and managerial capacities may result in very 
heterogeneous solutions across regions. 
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2.2 DEMOGRAPHIC AND EPIDEMIOLOGIC DATA OF ITALIAN 
POPULATION 
The knowledge of the demographic structure of the population by age and 
gender represents the starting point for understanding the main health 
needs of a country, needs that differ depending on people's life stages. 
 
 
2.2.1 Demographic projections 
 
It is estimated a slight decrease in the resident Italian population in a few 
years: from 60.6 million at January 1st, 2017 (index date) to 60.5 million 
in 2025. It is also estimated that in Italy the resident population will 
decrease to 59 million in 2045 and 54.1 million in 2065 (Figure 2.2). 
Compared to 2017 (60.6 million), the decline would be equal to 1.6 million 
residents in 2045 and 6.5 million in 2065. Taking into account the 
variability associated with demographic events, the estimate of population 
at 2065 fluctuates from a minimum of 46.4 million to a maximum of 62. 
The probability of increasing the population between 2017 and 2065 is 9% 
[ISTAT Annual Report, 2018]. 
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Figure 2.2 – Projection of resident population in Italy (median value and 90% 
confidence intervals) 
 
In this instance also, there are differences between North and South of 
Italy. In details, the southern regions would lose population for the whole 
projection period, while the centre-northern area would see a progressive 
decline of the population only from 2045 onward, after a positive 
demographic balance in the first thirty years. The empirical probability that 
the population of the Centre-North will be larger in 2065 than today is 
about 30% while in the South it is nearly zero. A shift in the weight of the 
population from the South to the Centre-North of the country is expected 
in the coming years. In 2065 the Centre-North would hold 71% of Italian 
residents against the current 66%; on the contrary, the South would reach 
29% against the current 34%. In almost all demographic and health 
indicators, there are marked regional differences for both men and women, 
reflecting the economic and social imbalance between the north and south 
of the country. 
Demographic projections also provide a picture of how the age structure 
of the population may change in the future (Figure 2.3). These variations 
are determined by several factors, including birth and death rates, 
migration and aging. 
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Figure 2.3 – Projections for age classes (median value and 90% confidence 
intervals) and mean age (90% confidence intervals) of resident population in 
Italy 
 
Based on projections, the population aged 15-64 years would reach its 
minimum percentage level in 2050 (54.1%) and then get weight up to 
54.8% by 2065 in the median scenario, with uncertainty margins between 
52.5 and 56.7%. The elderly population (people aged at least 65), in turn, 
would reach its maximum around 2051 (33.9%) and then start a decline 
phase of such as to fall back to 33.3% by 2065. The portion of young 
people (up to 14 years of age) would tend to stabilize around a median 
value of 12% in the long term, actually hiding a great range of likelihoods 
ranging from a minimum of 9.7% to a maximum of 14.2% in 2065. 
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2.2.2 Aging and health status 
 
Italy is one of the most long-lived countries in the world: life expectancy 
is nearly 81 years for males and 85,6 years for females. Even with respect 
to life expectancy at 65 years, in Italy men and women live longer than 
the European average (19.4 years vs 18.2 years and 22.9 years vs 21.6 
years, respectively). In the presence of a falling birth rate, the 
demographic imbalance increases: with almost 170 elderly (over 65 years) 
for every 100 young people (between 0 and 14 years), Italy is the second 
oldest country in the world after the Japan (Table 2.1) [ISTAT data, 2018]. 
 
Table 2.1 – Percent of older population in Italy from 2008 to 2018 
Variable 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 
0-14 years 
(%) 
14.1 14.1 14.1 14.1 14.0 14.0 13.9 13.8 13.7 13.5 13.4 
15-65 
years (%) 
65.7 65.6 65.5 65.4 65.2 64.8 64.7 64.5 64.3 64.2 64.1 
15-39 
years (%) 
31.5 31.0 30.5 29.9 29.6 29.0 28.6 28.1 27.7 27.3 27.0 
40-64 
years (%) 
34.2 34.6 35.0 35.5 35.6 35.8 36.1 36.3 36.6 36.9 37.1 
Over 65 
years (%) 
20.2 20.3 20.4 20.5 20.8 21.2 21.4 21.7 22.0 22.3 22.6 
65-84 
years (%) 
17.8 17.8 17.8 17.8 17.9 18.2 18.3 18.6 18.8 18.9 19.1 
Over 85 
years (%) 
2.4 2.5 2.6 2.7 2.9 3.0 3.1 3.2 3.3 3.4 3.5 
Mean age 
(years) 
43.1 43.2 43.4 43.6 43.8 44.0 44.2 44.4 44.7 44.9 45.2 
Population 
(millions) 
58.7 59.0 59.2 59.4 59.4 59.7 60.8 60.8 60.7 60.6 60.5 
 
However, among elderly aged 75 years and over, health conditions in Italy 
appear to be worse than in other European countries. As regards chronic 
diseases, in comparison with the European Union, Italian people report 
better health conditions among younger elderly people (aged 65-74 years) 
with lower rates for almost all chronic diseases. On the contrary, elderly 
people aged 75 years and over have worse health conditions. In Italy, 
about half of the elderly is affected by at least one severe chronic disease 
or has more than three chronic diseases. Among the elderly aged 80 years 
and over, the estimates are even higher, 59.0% and 64.0% respectively. 
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There are not only differences in disease prevalence related to age, but 
also related to sex and geography. Women report severe chronic 
pathologies less frequently than men, but more often comorbidity and 
physical and sensory functional limitations. In Southern Italy, comorbidity 
is estimated to be higher (56.4%) than in Northern Italy (42.7%), also 
taking into account the age distribution. Also, the percentage of elderly 
with at least one severe chronic disease is higher in the South (49.4% vs 
39.4%), as is the percentage of elderly with severe mobility limitations 
(27.7% vs 17.0%) or severe sensorial limitations (16.5% vs 12.8%) or 
severe difficulties in personal care activities. In general, the most common 
chronic diseases are: hypertension (17.8%), arthrosis/arthritis (16.1%), 
allergic diseases (10.7%), osteoporosis (7,9%), chronic bronchitis and 
bronchial asthma (5.9 percent), diabetes (5.7%). With the exception of 
allergic diseases, all other chronic diseases increase with age [ISTAT 
Report, 2017]. 
 
 
2.2.3 Patient complexity 
 
Although the constant increase in life expectancy has led to reaching old 
age in conditions of discrete well-being and independence, it has 
determined the exponential growth of a new category of patients, 
characterized by a particular vulnerability due to the presence of different 
chronic diseases at the same time (multimorbidity), fragility, and physic 
and cognitive disability. 
This patient presents a complexity that poses new challenges to the 
“traditional” medicine focused on the treatment of individual diseases. In 
particular, the pharmacological treatment of chronic diseases, based on 
the systematic application of the guidelines is currently criticized and for 
many reasons it is often considered inappropriate in the complex patient. 
Thus, from a health care model based on the identification, elimination or 
control of the etiologic agent, in a few decades a “chronic disease setting” 
started to take precedence. In this scenario, it is clear that the 
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pharmacological treatment in the elderly represents a remarkable issue. 
Polypathology, non-periodic revision of therapy (i.e. lack of medication 
review and reconciliation), excess of self-medications, and prescribing 
errors contribute to determine the use of a high number of drugs and the 
risk of possible drug-drug interactions as well as adverse drug reactions. 
Almost 8% of medical visits in older patients end up with a potentially 
inappropriate prescription [WHO, 2002]. Findings from an Italian study 
showed even higher percentage: 18% of elderly outpatients aged 65 years 
and over had one or more occurrences of potentially inappropriate 
medication prescribing [Maio et al, 2006]. 
The appropriate use of drugs is therefore one of the major challenges of 
clinical geriatrics. The scientific literature has been devoting considerable 
attention to identifying explicit criteria to evaluate the appropriateness of 
drug therapy in the elderly, starting from data on pharmaceutical 
consumption. 
 
2.2.3.1 POLYTHERAPY AND COMORBIDITY IN THE ELDERLY 
Data on the drug utilization from six Italian regions (Lombardy, Veneto, 
Lazio, Tuscany, Campania and Puglia), which represent more than 55% of 
the whole Italian population, shows that drug consumption and 
pharmaceutical expenditure are highly concentrated in some age classes 
of the population [OsMed Report 2017]. 
Overall, in 2017 there was a prevalence of drug use of 66.1%, with a 
significant difference between men (61.8%) and women (70.2%). The 
prevalence of drug use increased from about 50% in children and up-to-
54-years adults, to over 95% in the elderly population (over 74 years) 
(Figure 2.4). Simultaneously, there has been an increase of average drug 
consumption, estimated as defined daily dose (DDD) per 1000 inhabitants 
per day: from about 400 doses for adults between 40 and 50 years to 3000 
for elderly over 74 years. Individually, a subject between the ages of 65 
and 74 consumes an average of 2.6 doses of drug every day, while it rises 
to 3.5 for over 74 years (Figure 2.5). 
The combination of increasing prevalence of drug use and growing average 
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pharmaceutical consumption results in an increment in expenditure for 
drugs reimbursed by the NHS in older people. In details, subjects over 64 
years of age show a per capita expenditure up to three times higher than 
the national average; furthermore, for every individual over 64 years, 
pharmaceutical expenditure is about 6 times higher compared to the 
average expenditure incurred for an individual belonging to lower age 
classes. 
 
Figure 2.4 – Trend in drug use by sex and age classes in Italy in 2017 
 
 
 
Figure 2.5 – Trend in drug consumption by sex and age classes in Italy in 2017 
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In both sexes and in all age classes under study, an average of 9.7 different 
drugs per user is recorded, with a difference between classes, ranging from 
the lowest average value of 7.7 medications in the 65-69 age class to the 
highest value of 11.8 in subjects aged 85 or over (Table 2.2). In particular, 
in both sexes, an increase in the number of drugs taken was observed with 
the progression of the decades of age: in men, from the average value of 
7.6 drugs in the 65-69 age class to 12.1 in subjects aged 85 years or older; 
a similar trend was also found in women with 7.8 different pharmaceuticals 
taken in the 65-69 age class and 11.6 different active substances in women 
aged 85 years or older. The distribution of users by number of different 
drugs showed that over 64% of elderly users were prescribed at least 5 
substances during the year 2017 and that 21.6% of subjects over 65 years 
took at least 10 medications, thus suggesting a frequent use of 
polypharmacy in the elderly. The most prescribed therapeutic categories 
in the geriatric population were the drugs for cardiovascular system, 
antimicrobial drugs for systemic use, and drugs for gastrointestinal system 
and metabolism. 
 
Table 2.2 – Number of drugs prescribed in Italian older people in 2017 
 
Considering these data, together with the estimates on population aging, 
it is clear how important the prescribing appropriateness in the elderly is, 
as regard both to correct allocation of the NHS resources and to greater 
safety in drug use. Everybody who prescribes for older people needs to be 
aware of the important physiological changes that occur with aging that 
Age Classes 
(years) 
Average number of medications 
MEN WOMEN TOTAL 
65-69 7.6 7.8 7.7 
70-74 9.1 9.3 9.2 
75-79 10.1 10.3 10.2 
80-84 11.4 11.4 11.4 
≥ 85 12.1 11.6 11.8 
Total 9.6 9.9 9.7 
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affect drug pharmacokinetics (absorption, distribution, metabolism, and 
excretion) and pharmacodynamics (the effect a drug has on the body). The 
elderly patient appears to be a subject who, due to the presence of 
comorbidity and the physiological changes that different systems undergo 
with age, is treated on average with a high number of drugs. However, the 
simultaneous intake of more drugs predisposes older people to adverse 
outcomes arising from prescribing errors. Moreover, this type of patient 
often presents neurosensory, cognitive and motor limitations that make 
the diagnostic procedures -indispensable for a correct clinical diagnosis- 
even more difficult. Finally, the increased risk of adverse events with 
polytherapy is exacerbate by a lower compliance to the treatment. Indeed, 
latest data from the National Report on Medicines use in Italy [OsMed 
Report 2018] shows that, for treatment with chronic therapies (including 
statins, antihypertensives, antiosteoporotic, and antidepressant drugs), 
both medication adherence and persistence decrease with age. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
AIM OF THE PROJECT  
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Prescription of medicines is a fundamental component of the healthcare of 
people. However, the process of setting a diagnosis and choosing 
appropriate drug treatment is complex. Appropriateness of prescribing 
occurs when patients receive medications appropriate to their clinical 
needs, in doses that meet their own individual requirement, for adequate 
length of time and at the lowest cost for them and their community [WHO, 
1985]. The failure to prescribe appropriate drug therapy, which is called 
inappropriate prescribing, has become an important public-health issue 
worldwide because of its association with negative health outcomes, 
including adverse drug events (ADEs), increase of hospitalization and 
mortality, but also healthcare resource utilization and wastage. Therefore, 
inappropriate prescribing represents a clinical and economic burden to 
patients and society [Gurwitz et al, 1990; Hanlon et al, 2001; Simonson et 
al, 2005]. 
This issue is particularly relevant in older people, which are characterized 
by chronic conditions and multimorbidity, leading to an increased use of 
drugs or polypharmacy. These features of ageing, together with others of 
geriatric medicine, affect drug prescribing in this age group, making the 
selection of appropriate pharmacotherapy even more challenging and 
complex. 
Notably, appropriate prescribing does not guarantee a proper drug use. 
Evidence suggests that non‐compliance to physicians’ prescriptions is very 
common [Casula et al, 2012], partly because of the complexities of daily 
therapy regimen as well as other patient-related factors, or poor patient- 
physician communication. 
Thus, it is necessary to implement strategies aiming at assessing and 
reducing the number of inappropriate medications and at optimizing 
appropriate drug use, including education and information for healthcare 
professionals and the public, from independent sources and with the 
support of well‐trained staff. 
In this context, the Epidemiology and Preventive Pharmacology Centre 
(SEFAP) of the Department of Pharmacological and Biomolecular Sciences 
(University of Milan) have designed and conducted a project 
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(EDU.RE.DRUG project) aiming to deeply investigate the prescribing 
practice among general practitioners (GPs) and the appropriate drug use 
by their patients in two Italian regions. 
In details, the project consisted of three phases, with the objectives of: 
• characterizing inappropriate prescription and drug use profiles and 
highlighting the most frequent events of inappropriateness (phase 
1); 
• implementing tailored interventions for GPs and their patients 
focused on this critical issue (phase 2); 
• comparing the prescriptive behaviour of GPs pre- and post-
interventions, in order to define whether an effective change in 
prescribing has occurred (phase 3). 
 
The present thesis describes the first two phases of the EDU.RE.DRUG 
project, which is currently in progress. 
Accordingly, the main objectives of the thesis project were: 
(i) to develop indicators of inappropriate prescribing suitable to Italian 
context; 
(ii) to retrospectively assess the rates of the selected indicators of 
inappropriate prescribing and drug use during the period 2014-
2016, with a particular focus on older patients; 
(iii) to compare two different geographical areas in Italy; 
(iv) to develop and administer informative and/or educational 
interventions addressed to GPs and their patients, aimed at 
improving prescribing quality and promoting proper drug use. 
 
The results obtained will represent the basis for assessing the effectiveness 
of implemented interventions for GPs and their patients in a real-life 
setting. Moreover, analysis of baseline data will be used to identify factors 
to be studied as predictors of inappropriate prescribing, and therapeutic 
areas most affected by inappropriate prescribing, in order to establish 
priorities for action, to focus efforts and optimize the scarce available 
resources. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
METHODS  
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4.1 DATA MANAGEMENT 
 
The EDU.RE.DRUG project is a prospective, pragmatic, multicentre and 
open‐label trial, which started in April 2017 (registration details on 
clinicaltrial.gov: NCT04030468; EudraCT number: 2017-002622-21). 
The EDU.RE.DRUG project was supported by project grants from the Italian 
Medicines Agency (Bando 2012 per la Ricerca Indipendente) and funded in 
2016 (funding code: FARM12KSBT). The study was then approved by the 
Ethics Committee of the University of Milan on 07 June 2017 (code 15/17). 
 
 
4.1.1 Study population 
 
For the EDU.RE.DRUG project, eight Local Healthcare Units (LHUs) were 
enrolled: four in Campania region, in the southern part of Italy, and four 
in Lombardy region, in the north of Italy (Table 4.1 and Figure 4.1). Each 
LHU informed their own GPs through a letter about the participation to the 
EDU.RE.DRUG project, coordinated by the Epidemiology and Preventive 
Pharmacology Service (SEFAP) of the department of Pharmacological and 
Biomolecular Sciences at the University of Milan. 
 
Table 4.1 – Local Healthcare Units involved in the EDU.RE.DRUG project. Data 
from DEMO-ISTAT website updated to 1 January 2017 
Region LHU 
Municipa
lities 
Population Population 
over 40 yy 
Lombardy 
Bergamo 242 1,109,933 639,481 
Brianza (Lecco area*) 88 339,238 203,847 
Brianza (Monza 
Brianza area*) 
55 868,859 517,916 
Val Padana (Mantova 
area*) 
69 412,610 249,647 
Campania 
Avellino 118 432,506 244,287 
Caserta 104 924,166 483,167 
Napoli 1 Centro 31 979,381 542,098 
Napoli 2 Nord 32 1,052,947 522,778 
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*The term ‘area’ refers to a subdivision of the Local Health Units, instituted at the end of 
2015 in Lombardy.
 
 
Figure 4.1 – Geographical maps showing LHUs involved in the EDU.RE.DRUG 
project 
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The EDU.RE.DRUG population was selected among all citizens (Table 4.2) 
assisted by those GPs from the enrolled LHUs who were active at the end 
of 2016 (physicians retired in 2016 were excluded from the study). Eligible 
subjects were all the patients referring to the selected GP cohorts, aged 
≥40 years in 2016 and with at least one drug prescription in the same 
year. 
 
Table 4.2 – Number of total assisted citizens in 2014-2016  
Region LHU 2014 2015 2016 
Lombardy 
Bergamo 945,052 943,147 930,147 
Brianza (Lecco 
area) 
299,098 299,298 349,104 
Brianza (Monza 
Brianza area) 
758,365 759,795 893,112 
Val Padana 
(Mantova area) 
414,745 413,793 414,304 
Campania 
Avellino 362,766 383,886 399,166 
Caserta 763,993 817,095 886,809 
Napoli 1  811,784 873,881 949,594 
Napoli 2  850,009 913,070 1,043,959 
 
 
4.1.2 Data source 
 
The study data were retrieved from administrative databases containing 
healthcare data of all beneficiaries of the NHS in the LHUs involved. In fact, 
since 1997, NHS has managed healthcare delivery through a system based 
on electronically linkable databases containing information on NHS-
reimbursable health services [Corrao et al, 2008]. These databases, which 
are set up and constantly updated by regional or local health authorities, 
include: 
• Demographic Databases: this is an inhabitant registry where the GP 
chosen by each subject is recorded. It stores information on 
residents who receive NHS assistance, including birth date, sex, 
district of residence, and GP code and information on GPs, such as 
birth date, sex, and number of patients. 
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• Pharmacy Databases: information based on dispensing records of 
prescribed drugs reimbursable by the NHS, including prescription 
date, dispensing date, the name of each drug dispensed, WHO 
Anatomical Therapeutic Classification (ATC) code (Box 4.1), 
marketing authorization code (AIC), dose(s), number of items per 
prescription, number of boxes, and cost for NHS. 
• Hospital Databases: information on all hospitalizations at public or 
private hospitals of the LHUs, including admission date, primary and 
secondary diagnoses, that are expressed as codes of the 
International Classification of Diseases ICD-9 or ICD-10, and date 
of discharge. This kind of information was not used in the present 
thesis, but it will be examined in the third phase of the 
EDU.RE.DRUG project. 
 
Box 4.1 – WHO Anatomical Therapeutic Classification (ATC) classification system 
 
 
Reimbursement data are deemed highly accurate for information on the 
utilization of reimbursed drugs dispensed to patients and capture drugs 
In the ATC classification system, the active substances are classified in 
a hierarchy with five different levels. The system has fourteen main 
anatomical/pharmacological groups or 1st levels. Each ATC main group 
is divided into 2nd levels which could be either pharmacological or 
therapeutic groups. The 3rd and 4th levels are chemical, pharmacological 
or therapeutic subgroups and the 5th level is the chemical substance. 
The 2nd, 3rd and 4th levels are often used to identify pharmacological 
subgroups when that is considered more appropriate than therapeutic 
or chemical subgroups [WHOCC website]. 
Example: 
A  Alimentary tract and metabolism (1st level, anatomical main  
  group) 
A10  Drugs used in diabetes (2nd level, therapeutic subgroup) 
A10B  Blood glucose lowering drugs, excl. insulins (3rd level,  
  pharmacological subgroup) 
A10BA  Biguanides (4th level, chemical subgroup) 
A10BA02 Metformin (5th level, chemical substance) 
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prescribed by multiple prescribers; however, drugs documented in the 
database are limited to those that are reimbursed by NHS. 
Individual‐level pharmacy dispensing and reimbursement data also contain 
unique identifiers per patient (fiscal code), prescriber (ID code) and 
pharmacy dispensing the drug. 
By translating the fiscal code of each patient and the ID code of each GP 
into unequivocal alphanumeric codes, the LHUs provided anonymized data, 
for which they locally stored the conversion tables, providing guarantees 
in respect of the privacy of every citizen (according to art. 110 on medical 
and biomedical and epidemiological research, Legislation Decree 
101/2018). The presence of unique patient and prescriber identifiers allows 
to link pharmaceutical data to information on patients and GPs (e.g. age, 
sex, number of patients) stored in separate databases. These more 
extensive data on patients and prescribers are necessary to analyze drug 
utilization patterns and assessing the appropriateness of drug use and 
prescribing. 
 
 
4.1.3 Data collection and preparation 
 
For each LHUs involved, drug dispensing data regarding patients included 
in the study population were collected for a three-year period, between 
01/01/2014 and 12/31/2016. In the Box 4.2 the query for data extraction 
is reported in Italian language, as reported in the original agreement; the 
query was defined and shared with the LHUs’ coordinators. Once the data 
were collected, they entered the “pre-processing” stage, at which raw data 
were cleaned up and organized for the following stage of data processing. 
During preparation, raw data were diligently checked for any errors. In 
details, the data management comprised missing values identification, 
duplicate records removal, errors detection and correction, unused or 
irrelevant information discarding. Additionally, for each drug prescription 
record, the number of days covered by prescribed therapy was estimated 
merging with a database specifically developed starting from the Tunnel 
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software by Farmadati. It includes the Defined Daily Dose (DDD) (Box 4.3) 
for every ATC code of single and in combination drugs available on the 
Italian market and reimbursed by Italian NHS; therefore, the number of 
days’ supply was calculated as the active substance quantity dispensed 
divided by the DDD. 
 
Box 4.2 – Query for extracting data for the EDU.RE.DRUG project 
 
 
Box 4.3 – Defined Daily Dose (DDD) definition [WHOCC website] 
 
- Dall'anagrafe medici dicembre 2016 si selezionano i medici attivi. Si crea così la coorte 
dei medici che verrà anonimizzata nel campo codice regionale. 
 
Variabili estratte: codice medico anonimizzato, età, sesso, distretto di 
appartenenza, carico assistiti. 
 
- Dall’anagrafe assistiti dicembre 2016, si crea la coorte dei pazienti attivi (con almeno 
una prescrizione) con data di nascita ≤ 31/12/1976 che hanno come medico uno di 
quelli della coorte precedentemente selezionata. 
 
Variabili estratte: codice anonimizzato paziente, sesso, data di nascita, 
codice medico anonimizzato. 
 
- Dal Data Warehouse della regione, si estraggono le prescrizioni della coorte dei pazienti 
relative alla farmaceutica. 
 
Variabili estratte: codice anonimizzato paziente, data di prescrizione, 
data di spedizione (quella su cui si farà il filtro delle date 2014-2016), 
ATC, AIC, descrizione specialità, pezzi, codice medico prescrittore 
anonimizzato (sarà presente quello dei medici della coorte, di altri medici 
oppure nullo quando non valorizzato). 
The DDD is the assumed average maintenance dose per day for a drug used 
for its main indication in adults. The DDD is a unit of measurement and does 
not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic 
doses for individual patients and patient groups will often differ from the DDD 
as they will be based on individual characteristics (such as age, weight, ethnic 
differences, type and severity of disease) and pharmacokinetic considerations. 
Only one DDD is assigned per ATC code and route of administration (e.g. oral 
formulation). The DDD is nearly always a compromise based on a review of 
available information including doses used in various countries when this 
information is available. The DDD is sometimes a “dose” that is rarely if ever 
prescribed, because it might be an average of two or more commonly used 
doses. Drug utilization data presented in DDDs only give a rough estimate of 
consumption and not an exact picture of actual use. DDDs provide a fixed unit 
of measurement independent of price, currencies, package size and strength 
enabling the researcher to assess trends in drug consumption and to perform 
comparisons between population groups. 
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Furthermore, each pharmacy dataset was organized with the same 
structure and the same variables. Finally, pharmaceutical databases were 
matched with demographic data of each patient and relative GP through 
record linkage procedures. Data linkage used in this project was 
deterministic, as it combined different datasets by single and stable 
identifiers (ID code of each patient and GP), achieving exact matches and 
perfect linking (Figure 4.2). 
 
Figure 4.2 – Record linkage procedure 
 
Importantly, record linkage facilitates more elaborate studies, which can 
generate knowledge about explanatory factors underlying observed drug 
use patterns, identify patient and prescriber characteristics that determine 
drug use and evaluate the benefits and adverse effects of drug use in 
clinical practice, as well as related economic consequences.  
The number of records for each dataset, arranged and ready for the 
analyses, are reported in Table 4.3. 
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Table 4.3 – Number of prescriptions per year for the LHUs involved in the 
EDU.RE.DRUG project 
Region LHU 
N. of 
prescriptions 
in 2014 
N. of 
prescriptions 
in 2015 
N. of 
prescriptions 
in 2016 
Lombardy 
Bergamo 7,151,126 6,973,259 7,023,774 
Brianza (Lecco 
area) 
1,939,096 2,005,800 2,168,987 
Brianza (Monza 
Brianza area) 
4,961,097 5,051,594 5,395,832 
Val Padana 
(Mantova area) 
3,346,692 3,245,871 3,213,563 
Campania 
Avellino 4,262,365 4,541,996 4,528,166 
Caserta 9,487,371 9,699,224 10,030,833 
Napoli 1 Centro 9,287,737 10,554,317 11,697,540 
Napoli 2 Nord 7,985,602 9,969,854 10,791,272 
 
All analyses were performed using SPSS (version 24.0; IBM Corp., Armonk, 
NY, USA) and SAS software (version 9.4; SAS Institute, Cary, NC, USA). 
 
 
 
4.2 DATA ANALYSIS 
 
4.2.1 Selection of Drug Consumption Indicators 
 
For the evaluation of prescribing practice, prevalence of polytherapy was 
evaluated as percentage of patients with 1-4 drugs, 5-9 drugs, and ≥10 
drugs during 1-year period, for each year considered (2014-2016). In 
details, the number of drugs in each quarter was calculated, and the 
highest number of drugs dispensed in a single quarter was used to define 
polytherapy over the 1-year period [Onder et al, 2014]. 
Moreover, we selected some of the most commonly used drug classes 
(ACE-inhibitors [C09AA, C09B], angiotensin receptor blockers [C09CA, 
C09D], anti-asthmatics [R03], antibiotics [J01], proton pump inhibitors 
[A02BC, A02BD], selective serotonin reuptake inhibitors [N06AB], 
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serotonin-norepinephrine reuptake inhibitor [N06AX], and statins 
[C10AA]) to be described as percentage of patients on each treatment and 
as amount of DDD prescribed per 1000 inhabitants/die (DID). 
 
 
4.2.2 Selection of Appropriateness Prescribing Indicators 
 
An intensive searching and screening activity in literature was performed 
regarding indicators of appropriate prescribing in adult and older 
population which could be applied to the EDU.RE.DRUG population and 
evaluated using available data. 
After reviewing the scientific literature on the topic, a set of indicators was 
identified, that had to: 
- be explicit indicators, that require each prescription to be compared with 
a set of pre-defined standards, within the context of the individual 
patient; 
- be applicable and valid regardless of the patient's clinical characteristics; 
- refer only to drugs available on Italian market and reimbursed by Italian 
NHS (which are therefore traced into administrative databases). 
 
Afterwards, the following indicators were identified: 
• Potential drug‐drug interactions (pDDIs). We analysed 
dispensing data to assess the annual prevalence of prescriptions of 
pDDI through MediRisk software, developed by Medilogy group, 
based on INXBASE by Medbase, a Finnish company formed by 
experts in pharmacotherapy, which produces medical decision 
support databases to safeguard effective and safe use of drugs. 
INXBASE is a drug-drug interaction database containing short, and 
concise evidence-based information concerning consequences of 
and recommendations for over 20.000 drug interactions [Inxbase 
website]. DDIs are classified according to clinical significance (A-D, 
from minor [A] to contraindicated or very serious drug-drug 
interaction [D]) and documentation level (0-4, where 0 
- 61 - 
corresponding to evidence from in vitro studies and 4 
documentations from randomized clinical trial, systematic review, or 
meta-analysis). 
In this project, two drugs included in the DDI database were 
considered potentially interacting if their coverage periods 
(calculated since dispensation date and based on DDDs) overlapped 
of at least 1 day. Only pDDIs with clinical significance C, excluded 
those with a level of documentation of 0, and D were considered for 
this analysis. 
 
• Therapeutic Duplicates (TD). We assessed the annual prevalence 
of TD, that occurs when two or more drugs from the same chemical 
subgroup (same ATC code at the fourth level but different ATC code 
at the fifth level) are prescribed with at most 3 days between their 
dispensation dates. 
 
The prevalence of TD, as well as of pDDI, was calculated for each 
LHU as the proportion of patients over 40 years with any occurrence 
of TD (or pDDI) relative to the total number of citizens aged 40 years 
or over. 
 
• Inappropriate prescriptions in the elderly. Only for the elderly 
population (aged ≥65 years), we defined the ERD-list 
(EDU.RE.DRUG list) developed based on the updated Beers 
criteria, the STOPP&START criteria and the EU(7)-PIM list. The 
three lists were merged and adapted to Italian NHS. We considered 
only the list of drugs that should generally be avoided in the elderly 
because drugs considered inappropriate in older people with 
specific medical conditions cannot be assessed using the LHU 
outpatient pharmacy data because the data do not include 
information regarding indications for use. Several drugs were 
excluded because they have never been marketed in Italy (such as 
desiccated thyroid) or they are no longer available (such as 
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barbiturates except phenobarbital). In addition, drugs not 
reimbursed by the 2016 Italian National Formulary were not 
included in the list, because they could not be assessed by the 
analysis of the LHU outpatient pharmacy data. 
A total of 80 potentially inappropriate medications in subjects aged 
65 years or older were included in the ERD-list (Table 4.4). We 
defined prescription of potentially inappropriate medication (PIM) 
as having a prescription claim for at least one of the drugs in the 
ERD-list and we estimated annual rates of prevalence of the overall 
PIM prescription rate in the elderly for each LHU. 
 
• Anticholinergic Cognitive Burden (ACB) Score. The indicators 
of appropriate prescribing in elderly comprised also high score (≥3) 
of the Anticholinergic Cognitive Burden scale (see paragraph 
1.2.6.4). Drugs available on the Italian market and reimbursed by 
Italian NHS, which are included in the list, are reported in Table 
4.5. A total ACB score for each participant was calculated by adding 
the individual scores of different medications in a patient’s 
regimen. Patients with ACB score equal or greater than 3 have 
increased risk of cognitive impairment compared with non-users of 
anticholinergics [Boustani et al, 2008]. 
 
• Sedative Load (SL) Score. We also evaluated the Sedative Load 
in the elderly (see paragraph 1.2.6.5), applying the published lists 
[Linjakumpu et al, 2003], again selecting only drugs available on 
the Italian market and reimbursed by Italian NHS (Table 4.6). For 
each patient, scores of all the medications received are summed to 
determine a total patient score (SL score). Patients with SL score 
equal or greater than 3 are recorded as inappropriate occurrence. 
 
The annual prevalence of ACB and SL occurrence was calculated in 
the elderly for each LHU.   
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Table 4.4 – The ERD-list 
ATC code Drug Name Reason for PIM 
A02BC01 Omeprazole (PPI>8 weeks) Long-term high dose PPI therapy is 
associated with an increased risk of C. 
difficile infection and hip fracture. 
Inappropriate if used >8 weeks in 
maximal dose without clear indication 
A02BC02 Pantoprazole (PPI>8 weeks) Long-term high dose PPI therapy is 
associated with an increased risk of C. 
difficile infection and hip fracture. 
Inappropriate if used >8 weeks in 
maximal dose without clear indication 
A02BC03 Lansoprazole (PPI>8 weeks) Long-term high dose PPI therapy is 
associated with an increased risk of C. 
difficile infection and hip fracture. 
Inappropriate if used >8 weeks in 
maximal dose without clear indication 
A02BC04 Rabeprazole (PPI>8 weeks) Long-term high dose PPI therapy is 
associated with an increased risk of C. 
difficile infection and hip fracture. 
Inappropriate if used >8 weeks in 
maximal dose without clear indication 
A02BC05 Esomeprazole (PPI>8 weeks) Long-term high dose PPI therapy is 
associated with an increased risk of C. 
difficile infection and hip fracture. 
Inappropriate if used >8 weeks in 
maximal dose without clear indication 
A10AB01 Insulin, sliding scale (without 
concomitant treatment with 
basal insulin) 
No benefits demonstrated in using 
sliding-scale insulin. Might facilitate 
fluctuations in glycemic levels 
A10AB04 Insulin, sliding scale (without 
concomitant treatment with 
basal insulin) 
No benefits demonstrated in using 
sliding-scale insulin. Might facilitate 
fluctuations in glycemic levels 
A10AB05 Insulin, sliding scale (without 
concomitant treatment with 
basal insulin) 
No benefits demonstrated in using 
sliding-scale insulin. Might facilitate 
fluctuations in glycemic levels 
A10AB06 Insulin, sliding scale (without 
concomitant treatment with 
basal insulin) 
No benefits demonstrated in using 
sliding-scale insulin. Might facilitate 
fluctuations in glycemic levels 
A10BB01 Glibenclamide Risk of protracted hypoglycemia 
A10BB07 Glipizide Risk of protracted hypoglycemia 
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A10BB12 Glimepiride Risk of protracted hypoglycemia 
A10BD02 Glibenclamide Risk of protracted hypoglycemia 
A10BD05 Pioglitazone Age-related risks include bladder 
cancer, fractures and heart failure. Use 
for more than one year has been 
associated with an increased risk of 
bladder cancer. May increase the 
incidence of fractures of the upper 
arms, hands and feet in female 
diabetics (compared to other oral 
antidiabetic agents). Can cause fluid 
retention in older adults, which may 
exacerbate or precipitate heart failure 
A10BD06 Glimepiride/pioglitazone Risk of protracted hypoglycemia/see 
pioglitazone 
A10BD09 Pioglitazone Age-related risks include bladder 
cancer, fractures and heart failure. Use 
for more than one year has been 
associated with an increased risk of 
bladder cancer. May increase the 
incidence of fractures of the upper 
arms, hands and feet in female 
diabetics (compared to other oral 
antidiabetic agents). Can cause fluid 
retention in older adults, which may 
exacerbate or precipitate heart failure 
A10BF01 Acarbose No proven efficacy 
A10BG03 Pioglitazone Age-related risks include bladder 
cancer, fractures and heart failure. Use 
for more than one year has been 
associated with an increased risk of 
bladder cancer. May increase the 
incidence of fractures of the upper 
arms, hands and feet in female 
diabetics (compared to other oral 
antidiabetic agents). Can cause fluid 
retention in older adults, which may 
exacerbate or precipitate heart failure 
B01AA07 Acenocoumarol Risk of bleeding, especially in people 
with difficult control of INR value 
B01AC05 Ticlopidine Risk of altered blood counts 
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B01AC56 Esomeprazole (PPI>8 weeks) Long-term high dose PPI therapy is 
associated with an increased risk of C. 
difficile infection and hip fracture. 
Inappropriate if used >8 weeks in 
maximal dose without clear indication 
C01AA08 Metildigoxin Elevated glycoside sensitivity in older 
adults (women>men); risk of 
intoxication 
C01BA03 Disopyramide Potent negative inotrope; 
anticholinergic side effects; may 
induce heart failure; may cause 
sudden cardiac death. Data suggest 
that for most older adults’ rate control 
yields better balance of benefits and 
harms than rhythm control 
C01BC03 Propafenone High risk of drug interactions. Data 
suggest that for most older adults’ rate 
control yields better balance of 
benefits and harms than rhythm 
control 
C01BC04 Flecainide Higher rate of adverse effects, 
especially in older adults. Data suggest 
that for most older adults’ rate control 
yields better balance of benefits and 
harms than rhythm control 
C02AB01 Methyldopa Risk of orthostatic hypotension, 
bradycardia, syncope, CNS side effects 
(sedation, depression, cognitive 
impairment) 
C02AC05 Moxonidine Risk of orthostatic hypotension, 
bradycardia, syncope, CNS side effects 
(sedation, depression, cognitive 
impairment) 
C08CA05 Nifedipine Increased risk of hypotension; 
myocardial infarction; increased 
mortality 
G02CB03 Cabergoline CNS side effects 
G03AA09 Ethinylestradiol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
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G03AA10 Ethinylestradiol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
G03AB06 Ethinylestradiol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
G03BA03 Testosterone Potential for cardiac problems  
G03CA01 Ethinylestradiol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
G03CA03 Estradiol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
G03CA04 Estriol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
G03CA09 Promestriene Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
G03CX01 Tibolone Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
G03FA01 Estradiol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
G03FA11 Estradiol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
G03FA14 Estradiol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
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G03FA17 Estradiol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
G03FB05 Estradiol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
G03FB08 Estradiol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
G03FB09 Estradiol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
G03FB12 Estradiol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
H01BA02 Desmopressin High risk of hyponatremia 
L02AB01 Megestrol Evidence for carcinogenic potential 
(breast and endometrial cancer) and 
lack of cardioprotective effect in older 
women 
M01AB01 Indometacin Very high risk of GI bleeding, 
ulceration, or perforation, which may 
be fatal; risk of CNS disturbances 
M01AB05 Diclofenac Very high risk of GI bleeding, 
ulceration, or perforation, which may 
be fatal; cardiovascular 
contraindications 
M01AB15 Ketorolac Very high risk of GI bleeding, 
ulceration, or perforation, which may 
be fatal 
M01AB16 Aceclofenac Very high risk of GI bleeding, 
ulceration, or perforation, which may 
be fatal; cardiovascular 
contraindications 
M01AC01 Piroxicam Very high risk of GI bleeding, 
ulceration, or perforation, which may 
be fatal 
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M01AC05 Lornoxicam Very high risk of GI bleeding, 
ulceration, or perforation, which may 
be fatal; cardiovascular 
contraindications 
M01AC06 Meloxicam Very high risk of GI bleeding, 
ulceration, or perforation, which may 
be fatal 
M01AE03 Ketoprofen Very high risk of GI bleeding, 
ulceration, or perforation, which may 
be fatal 
M01AE09 Flurbiprofen Very high risk of GI bleeding, 
ulceration, or perforation, which may 
be fatal; cardiovascular 
contraindications 
M01AX01 Nabumetone Very high risk of GI bleeding, 
ulceration, or perforation, which may 
be fatal; cardiovascular 
contraindications 
N02AD01 Pentazocine Risk of delirium and agitation 
N02AX02 Tramadol More adverse effects in older adults; 
CNS side effects such as confusion, 
vertigo and nausea 
N03AA02 Phenobarbital Risk of sedation, paradoxical excitation 
High rate of physical dependence, 
tolerance to sleep benefits, greater 
risk of overdose at low dosages 
N03AB02 Phenytoin Narrow therapeutic window; increased 
risk of toxicity in older adults (e.g. CNS 
and hematologic toxicity) 
N03AE01 Clonazepam Risk of falls, paradoxical reactions 
N03AX11 Topiramate Risk of cognitive-related dysfunction 
(e.g., confusion, psychomotor slowing) 
N04AA01 Trihexyphenidyl Risk of anticholinergic and CNS side 
effects including orthostatic 
hypotension, falls, sedation, weakness, 
confusion, amnesia 
N04AA02 Biperiden Risk of anticholinergic and CNS side 
effects including orthostatic 
hypotension, falls, sedation, weakness, 
confusion, amnesia 
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N04AB02 Orphenadrine Risk of anticholinergic and CNS side 
effects including orthostatic 
hypotension, falls, sedation, weakness, 
confusion, amnesia 
N04BC01 Bromocriptine Risk of CNS side effects 
N05AC01 Propericiazine Anticholinergic and extrapyramidal 
side effects (tardive dyskinesia); 
parkinsonism; hypotonia; sedation; 
risk of falling; increased mortality in 
persons with dementia 
N06AA02 Imipramine Peripheral anticholinergic side effects 
(e.g. constipation, dry mouth, 
orthostatic hypotension, cardiac 
arrhythmia); central anticholinergic 
side effects (drowsiness, inner unrest, 
confusion, other types of delirium); 
cognitive deficit; increased risk of 
falling 
N06AA04 Clomipramine Peripheral anticholinergic side effects 
(e.g. constipation, dry mouth, 
orthostatic hypotension, cardiac 
arrhythmia); central anticholinergic 
side effects (drowsiness, inner unrest, 
confusion, other types of delirium); 
cognitive deficit; increased risk of 
falling 
N06AA06 Trimipramine Peripheral anticholinergic side effects 
(e.g. constipation, dry mouth, 
orthostatic hypotension, cardiac 
arrhythmia); central anticholinergic 
side effects (drowsiness, inner unrest, 
confusion, other types of delirium); 
cognitive deficit; increased risk of 
falling 
N06AA09 Amitriptyline Peripheral anticholinergic side effects 
(e.g. constipation, dry mouth, 
orthostatic hypotension, cardiac 
arrhythmia); central anticholinergic 
side effects (drowsiness, inner unrest, 
confusion, other types of delirium); 
cognitive deficit; increased risk of 
falling 
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N06AA10 Nortriptyline Peripheral anticholinergic side effects 
(e.g. constipation, dry mouth, 
orthostatic hypotension, cardiac 
arrhythmia); central anticholinergic 
side effects (drowsiness, inner unrest, 
confusion, other types of delirium); 
cognitive deficit; increased risk of 
falling 
N06AB03 Fluoxetine CNS side effects (nausea, insomnia, 
dizziness, confusion); hyponatremia 
N06AB05 Paroxetine Higher risk of all-cause mortality, 
higher risk of seizures, falls and 
fractures. Anticholinergic adverse 
effects 
N06AB08 Fluvoxamine Higher risk of all-cause mortality, self-
harm, falls, fractures and 
hyponatraemia 
N06BA04 Methylphenidat May cause or worsen insomnia; 
concern due to CNS-altering effects; 
concern due to appetite-supressing 
effects 
R06AD02 Promethazine Anticholinergic side effects (e.g. 
confusion, sedation) 
 
CNS: central nervous system; GI: gastrointestinal; INR: international normalized ratio; 
PPI: proton pump inhibitors. 
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Table 4.5 - List of drugs for ACB score 
ATC code Drug Name Score 
A02BA01 Cimetidine 1 
A02BA02 Ranitidine 1 
A03AA07 Dicyclomine (Dicycloverine) 3 
A03AX08 Alverine 1 
A03BA01 Atropine 3 
A03BA03 Hyoscyamine 3 
A03BA04 Belladonna 2 
A03CA02 Clidinium 1 
A03CA34 Propantheline 3 
A04AB02 Dimenhydrinate 3 
A04AD01 Scopolamine 3 
A07DA03 Loperamide 1 
B01AA03 Warfarin 1 
B01AC07 Dipyridamole 1 
B01AC30 Dipyridamole 1 
C01AA05 Digoxin 1 
C01BA01 Quinidine 1 
C01BA03 Disopyramide 1 
C01DA14 Isosorbide 1 
C02DB02 Hydralazine 1 
C03BA04 Chlorthalidone 1 
C03CA01 Furosemide 1 
C03EB01 Furosemide/Triamterene 2 
C03DB02 Triamterene 1 
C07AB02 Metoprolol 1 
C07AB03 Atenolol 1 
C07CA02 Chlorthalidone 1 
C07CB02 Chlorthalidone/Metoprolol 2 
C07CB03 Chlorthalidone/Atenolol 2 
C08CA05 Nifedipine 1 
C09AA01 Captopril 1 
C09BA01 Captopril 1 
D07AB02 Hydrocortisone 1 
G04BD02 Flavoxate 3 
G04BD04 Oxybutynin 3 
G04BD06 Propiverine 3 
G04BD07 Tolterodine 3 
G04BD08 Solifenacin 3 
G04BD09 Trospium 3 
G04BD10 Darifenacin 3 
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ATC code Drug Name Score 
G04BD11 Fesoterodine 3 
H02AB07 Prednisone 1 
M03BA03 Methocarbamol 3 
M03BC01 Orphenadrine 3 
N04AB02 Orphenadrine 3 
M03BX07 Colchicine 1 
M04AC01 Colchicine 1 
M03BX08 Cyclobenzaprine 2 
N02AA01 Morphine 1 
N02AB02 Meperidine 2 
N02AB03 Fentanyl 1 
N02AG01 Atropine/Morphine 3 
N02AJ06 Codeine 1 
N02BG06 Nefopam 2 
N03AF01 Carbamazepine 2 
N03AF02 Oxcarbazepine 2 
N04AA01 Trihexyphenidyl 3 
N04AC01 Benztropine 3 
N04BB01 Amantadine 2 
N05AA01 Chlorpromazine 3 
N05AA02 Methotrimeprazine (Levomepromazine) 2 
N05AB03 Perphenazine 3 
N05AB06 Trifluoperazine 3 
N05AC02 Thioridazine 3 
N05AD01 Haloperidol 1 
N05AE02 Molindone 2 
N05AG02 Pimozide 2 
N05AH01 Loxapine 2 
N05AH02 Clozapine 3 
N05AH03 Olanzapine 3 
N05AH04 Quetiapine 3 
N05AH05 Asenapine 1 
N05AX08 Risperidone 1 
N05AX12 Aripiprazole 1 
N05AX13 Paliperidone 1 
N05AX14 Iloperidone 1 
N05BA01 Diazepam 1 
N05BA05 Clorazepate 1 
N05BA12 Alprazolam 1 
N05BB01 Hydroxyzine 3 
N06AA01 Desipramine 3 
N06AA02 Imipramine 3 
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ATC code Drug Name Score 
N06AA04 Clomipramine 3 
N06AA06 Trimipramine 3 
N06AA09 Amitriptyline 3 
N06AA10 Nortriptyline 3 
N06AA12 Doxepin 3 
N06AA17 Amoxapine 3 
N06AB05 Paroxetine 3 
N06AB08 Fluvoxamine 1 
N06AX05 Trazodone 1 
N06AX12 Bupropion 1 
N06AX16 Venlafaxine 1 
R03DA04 Theophylline 1 
R05DA04 Codeine 1 
R05DA20 Codeine 1 
R06AA02 Diphenhydramine 3 
R06AA04 Clemastine 3 
R06AA08 Carbinoxamine 3 
R06AA09 Doxylamine 3 
R06AB01 Brompheniramine 3 
R06AB04 Chlorpheniramine 3 
R06AD01 Alimemazine 1 
R06AD02 Promethazine 3 
R06AE05 Meclizine 3 
R06AE07 Cetirizine 1 
R06AE09 Levocetirizine 1 
R06AX02 Cyproheptadine 2 
R06AX13 Loratadine 1 
R06AX27 Desloratadine 1 
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Table 4.6 - List of drugs for SL score 
ATC code Drug Name Score 
A03CA02 Chlordiazepoxide with klidin 1 
A03CA05 Diazepam with glycopyrronium 1 
A03CA07 Oxazepam with ambutonium 1 
A03FA01 Metoclopramide 1 
A04AD01 Scopolamine 1 
G04BE30 Meprobamate with testosterone and yohimbine 1 
M01AB51 Indometacin with ethylmorphine 1 
M01AE51 Ibuprofen with codeine 1 
N02AA01 Morphine 1 
N02AA05 Oxycodone 1 
N02AA55 Oxycodone 1 
N02AB03 Fentanyl 1 
N02AE01 Buprenorphine 1 
N02AG01 Morphine 1 
N02AJ17 Oxycodone 1 
N02AJ06 Codeine 1 
N02AX02 Tramadol 1 
N02BA51 Metoclopramide with ASA 1 
N02CC Triptans 1 
N03AB Hydantoin derivatives 1 
N03AF Carbamazepine and derivatives 1 
N03AG01 Valproic acid 1 
N03AX12 Gabapentin biperiden 1 
N05A Traditional antipsycotics 2 
N05AD Butyrophenones 2 
N05AF Thioxanthenes 2 
N05AH02 Clozapine 1 
N05AH03 Olanzapine 1 
N05AH04 Quetiapine 1 
N05AL01 Sulpiride 2 
N05AN01 Lithium 2 
N05AX08 Risperidone 1 
N05B Anxiolytics 2 
N05BA01 Diazepam with kinin, orphenadrine, baclofen, tizanidine 1 
N05BB01 Hydroxyzine 2 
N05BC51 Meprobamate with kinin, orphenadrine, baclofen, tizanidine 1 
N05CX01 Meprobamate with kinin, orphenadrine, baclofen, tizanidine 1 
N05C Hypnotics and sedatives 2 
N05CF01 Zopiclone 2 
N05CF02 Zolpidem 2 
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ATC code Drug Name Score 
N05CF03 Zaleplon 2 
N05CM02 Clometiazole 2 
N05CM09 Valerian 2 
N05CX01 Meprobamate with ergot alcaloid 1 
N06AA04 Clomipramine 2 
N06AA06 Trimipramine 2 
N06AA09 Amitriptyline 2 
N06AA10 Nortriptyline 2 
N06AA12 Doxepin 2 
N06AB03 Fluoxetine 1 
N06AB04 Citalopram 1 
N06AB05 Paroxetine 1 
N06AB06 Sertraline 1 
N06AB08 Fluvoxamine 1 
N06AX03 Mianserin 2 
N06AX05 Trazodone 1 
N06AX06 Nefazodone 1 
N06AX11 Mirtazapine 1 
N06AX16 Venlafaxine 1 
N06AX17 Milnacipran 1 
N06CA01 Amitriptyline + chlordiazepoxide 2 
N06CA01 Amitriptyline + perphenazine 2 
R03DA74 Theophylline 1 
R03DA04 Theophylline, combinations 1 
R05CB02 Bromhexine 1 
R05DA01 Ethylmorphine 1 
R05DA04 Codeine 1 
R05DA20 Codeine 1 
R06AE05 Meclozine 1 
R06AE53 Cyclizine (with diazepam) 1 
S01FA02 Scopolamine 1 
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4.2.3 Selection of Appropriate Drug Use Indicators 
 
Among indicators of appropriate drug use, adherence to chronic treatments 
is one of the most utilized, because it is a primary determinant of the 
effectiveness of therapy. 
Prescription and dispensing administrative data can be used to assess 
adherence to treatment, defined as the extent to which a patient’s behavior 
(e.g. taking medications with respect to timing, dosage, and frequency) 
corresponds with agreed recommendations from a health-care provider.  
In administrative claims data, adherence is most often assessed through 
measures such as the proportion of days covered (PDC) or medication 
possession ratio (MPR), which are the most common measures of 
medication adherence using refill records. Briefly, PDC is defined as the 
number of days covered by medication divided by the total number of days 
in follow-up, while MPR is the sum of the days' supply (daily doses) for all 
fills of a given drug during follow-up divided by the number of days of 
follow-up (Box 4.4) [Steiner et al, 1997; Clancy, 2013]. 
For each prescription, the coverage is calculated as total amount of drug 
divided by the specific DDD.  
Despite the fact that both MPR and PDC are sufficient at measuring 
medication adherence, the PDC ratio provides a more accurate 
representation of medication adherence because it eliminates the 
possibility of being unreasonably elevated. In fact, the MPR can be difficult 
to be interpreted since this index can assume values greater than one.  
Basically, the difference between the two methods lies in the days count 
for overlapping prescriptions: the overlapping days are count once for PDC 
while are equal to the number of overlapping drug doses for MPR. 
Furthermore, PDC is recommended for assessing the medication adherence 
of patients on multiple therapies at the same time, and in addition, it is the 
preferred method for assessing adherence by the Pharmacy Quality 
Alliance (PQA) for use in Medicare Star Ratings and also by the US Centers 
for Medicare and Medicaid Services. 
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Box 4.4 – Adherence Measurements 
 
 
On this basis, within the EDU.RE.DRUG project, adherence was measured 
through the PDC calculation. 
For each year considered (2014, 2015, and 2016), we assessed medication 
adherence rate for the following chronic therapies [ATC]: 
• antidiabetics [A10B] 
• anti‐hypertensive drugs [C02, C03, C07, C08, C09] 
• lipid-lowering drugs [C10A] 
• anti‐osteoporosis drug [M05B] 
Two measures of medication adherence are currently utilized in the 
widely available research assessing the adherence to prescriptions. The 
primary measures of medication adherence, PDC (proportion of days 
covered) and MPR (medication possession ratio), can easily be 
calculated with the extraction of retail pharmacy data. 
 
MPR is the sum of the days' supply for all fills of a given drug in a 
particular time period, divided by the number of days in the time period: 
 
MPR = (
∑ 𝑑𝑎𝑦𝑠′𝑠𝑢𝑝𝑝𝑙𝑦 𝑓𝑜𝑟 𝑎𝑙𝑙 𝑓𝑖𝑙𝑙𝑠 𝑖𝑛 𝑝𝑒𝑟𝑖𝑜𝑑
∑ 𝑑𝑎𝑦𝑠 𝑖𝑛 𝑝𝑒𝑟𝑖𝑜𝑑
) ∗ 100% 
 
For the PDC the formula is similar to MPR, but instead of simply adding 
the days' supplied in a given period, the PDC considers the days that 
are “covered”: 
 
PDC = (
∑ 𝑑𝑎𝑦𝑠 𝑖𝑛 𝑝𝑒𝑟𝑖𝑜𝑑 "𝑐𝑜𝑣𝑒𝑟𝑒𝑑"
∑ 𝑑𝑎𝑦𝑠 𝑖𝑛 𝑝𝑒𝑟𝑖𝑜𝑑
) ∗ 100% 
 
An example of medication adherence calculation with MPR and PDC is 
depicted below. 
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PDC ranges from 0 to 1, with 1 corresponding to 100% medication 
adherence. 
For each LHUs involved, adherence to the specific medication was assessed 
following two approaches: 
• for each year, all patients with at least one prescription of the drug 
of interest during the year were selected and adherence was 
calculated as the number of days covered by medication divided by 
365. This approach does not take into account the possibility that 
the beginning of the therapy for a patient may have occurred during 
the year of observation, nor include drug available from 
prescriptions dispensed at the end of the previous year. However, 
this approach provides a crude estimate for each year that allows to 
evaluate adherence trend over time and to make a comparison 
between LHUs. 
• adherence was calculated by selecting all patients with a first 
prescription for the medication of interest between January 1, 2015 
and December 31, 2015. Patients were required not to have prior 
prescription of that drug in the year before the index date (defined 
as the date of the first prescription fill in the period for the selected 
therapy), to select only incident users. Patients were also required 
to have 1 year of enrolment after the index date to allow complete 
adherence evaluation at 1-year of follow-up. Adherence was 
calculated as mentioned above for the first approach. Notably, we 
limited this second phase of analysis to incident users in an attempt 
to limit the influence of confounding factors, as the inclusion of 
prevalent users, more tolerant to the medication, may bias the 
result. This approach also allowed to select a sample of patients with 
comparable treatment timing and to avoid the heterogeneity due to 
the fact that prevalent users may be characterized by a progressive 
reduction of medication adherence over time. 
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4.3 THE INTERVENTION 
 
The EDU.RE.DRUG project has a parallel‐arm design. 
According to LHUs, the GPs and their patients were assigned to one of the 
following four intervention arms (Figure 4.3): 
• A: intervention on GPs and patients (LHUs of Napoli 2 Nord and 
Brianza-Lecco area); 
• B: intervention on GPs (LHUs of Napoli 1 Centro and Bergamo); 
• C: intervention on patients (LHUs of Avellino and Val Padana-
Mantova area); 
• D: control group (LHUs of Caserta and Brianza-Monza Brianza area). 
 
 
Figure 4.3 – Flow chart of the EDU.RE.DRUG project 
 
The intervention designed for GPs consisted in: 
• feedback reports regarding inappropriate prescription status for 
their patients in comparison to median levels of LHU. Specifically, 
the report contained the prevalence of each pre-defined indicator of 
drug consumption and of inappropriate prescribing, evaluated in 
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2016 (the report front page can be found in Figure 4.4; a full 
example can be found in the Appendix I section). Once arranged, 
the reports were transferred to the LHUs. After translating 
anonymous codes, the LHUs sent to each GP the relative report; 
• free on‐line Continuous Medical Education (CME) course about 
pharmacotherapy, evidence‐based medicine, rational prescribing 
and indicators of appropriateness, polypathology management, 
doctor‐patient concordance and communication skills, and 
healthcare continuity from hospital to territory. CME lessons were 
registered in Italian language and provided by specialists with 
clinical experience. A full list of the lessons is reported in the 
Appendix II section. The course, which is recognised by the Italian 
National Agency for Regional Healthcare Services (AGENAS), was 
worth 18 CME credits. It was structured into two modules (9 CME 
credits for each module) and uploaded on the FAD platform of the 
SiTeCS society, as CME provider; according to the protocol, it was 
available for GPs belonging to LHUs of Napoli 2 Nord, Napoli 1 
Centro, Bergamo and Brianza-Lecco area, from November 15, 2017 
and June 30, 2018 (Figure 4.5). In details, the first part was 
focused on the presentation of the project and on theoretical aspects 
concerning the inappropriate prescribing in general practice and the 
categories of the most vulnerable patients, such as the elderly or 
poly-treated patients, with the presentation of clinical cases of 
possible inappropriate prescriptions. The second one concerned the 
measurement of indicators of appropriateness of prescribing, the 
guided reading of reports, and recommendations for prescribing to 
the complex patient and for medication review. 
 
Notably, participation to CME courses was not mandatory, as well as both 
the course and the reports received at baseline may not necessarily lead 
to changes in GPs’ prescriptive behaviour. 
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The intervention administered to patients consisted in flyers and posters, 
focusing on correct drug use, including efficacy/safety of drugs, adherence 
to GP indications, self‐medication. Posters (Figure 4.6) and leaflets 
(Figure 4.7) were distributed in GPs' ambulatories and community 
pharmacies, through Federfarma network, in the LHUs of Napoli 2 Nord, 
Avellino, Val Padana-Mantova area and Brianza-Lecco area, according to 
the protocol. The preparation of these materials involved professionals in 
the topic, in order to communicate educational messages in a language 
appropriate to the subjects' needs and level of understanding. 
 
At the beginning of the study, the GPs belonging to the LHUs involved in 
the A and B intervention arms received a presentation letter from their own 
LHU, with the general description of the project and a formal invitation to 
sign up for the FAD platform and attend the proposed CME course. 
Similarly, local pharmacies and general practices in the LHUs involved in 
the A and C intervention arms received a presentation letter from their own 
LHU with the general description of the project, including a formal 
invitation to publicly exhibit and to promote educational material for 
citizens. Therefore, citizens have not directly received project information 
from the LHUs or the local coordinator operative units. 
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Figure 4.4 – Front page of the feedback report sent to each GP 
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Figure 4.5 – On-line CME course for GPs 
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Figure 4.6 – Poster (50x70cm) for patients 
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Figure 4.7 – Front and back side of the flyer for patients 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
RESULTS
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5.1 DESCRIPTIVE ANALYSES 
 
5.1.1 GPs’ cohorts 
 
The number of GPs included in the study is reported in Figure 5.1. It 
slightly increased in Avellino, Caserta, Napoli1 and Napoli2 LHUs, from 
2014 to 2016, while there has been a small reduction in GP number for 
LHUs in Lombardy region (Bergamo LHU, Lecco, Monza Brianza and 
Mantova areas). 
 
 
Figure 5.1 – Number of GPs for each LHU 
First, second, and third bar represent 2014, 2015, and 2016, respectively, for each LHUs 
 
The majority of physicians were males in all the LHUs, even if the portion 
of females increased in time (Table 5.1). In details, Monza Brianza and 
Bergamo were the LHUs with the highest percentage of women among GPs 
(over 30%); by contrast the lowest percentages, between 17.5 and 21.2%, 
were found in Napoli1 and Napoli2 LHUs. 
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Table 5.1 – Percentage of female GPs in 2014-2016 
Region LHU 2014 2015 2016 
Lombardy 
Bergamo 31.4 32.1 40.9 
Lecco  27.9 28.0 28.8 
Monza Brianza 35.1 35.8 38.1 
Mantova  26.8 27.1 28.2 
Campania 
Avellino 23.0 24.0 25.6 
Caserta 22.3 22.7 25.5 
Napoli 1 20.9 21.2 21.0 
Napoli 2 17.5 17.9 18.2 
 
The overall mean age ranged between 57 and 62 years. The GP age trend 
was growing in time for all the LHUs, except for Monza Brianza and Lecco 
areas; in the 3-year period analysed, Napoli1 LHU held the oldest GPs 
cohort, Bergamo LHU the youngest one (Table 5.2). 
 
Table 5.2 – Mean age (SD) of GPs in 2014-2016 
Region LHU 2014 2015 2016 
Lombardy 
Bergamo 56.7 (6.4) 57.2 (6.6) 57.7 (6.9) 
Lecco  58.4 (6.8) 59.1 (7.0) 58.3 (7.0) 
Monza Brianza 58.7 (6.0) 59.3 (6.3) 58.2 (6.5) 
Mantova  59.0 (5.9) 59.4 (6.0) 59.9 (6.2) 
Campania 
Avellino 59.1 (5.4) 60.1 (5.5) 60.8 (4.9) 
Caserta 59.2 (4.8) 59.8 (5.1) 60.2 (5.6) 
Napoli 1 Centro 58.9 (4.4) 60.7 (4.5) 61.7 (4.5) 
Napoli 2 Nord 58.0 (4.9) 59.0 (4.9) 60.0 (5.0) 
 
Several differences in the median number of assisted individuals per GP 
were observed. In particular, GPs of LHUs of Bergamo, Lecco, and Monza-
Brianza had a median value of about 1,500 registered citizens. The median 
number for Mantova area was around 1,400, while it ranged between 1,000 
and 1,200 for LHUs in Campania (Table 5.3). 
Several differences in the median number of patients per GP were also 
observed between LHUs (Table 5.4 and Table 5.5). In each LHU, the 
median number of patients aged 40-64 years per GP (range 375-423 in 
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Lombardy and 344-409 in Campania) was higher than the median number 
of patients aged ≥65 years (range 275-335 in Lombardy and 179-284 in 
Campania). 
 
Table 5.3 – Median number of citizens per GP in 2014-2016  
Region LHU 2014 2015 2016 
Lombardy 
Bergamo 1,516 1,516 1,519 
Lecco  1,527 1,532 1,553 
Monza Brianza 1,552 1,557 1,588 
Mantova  1,365 1,366 1,458 
Campania 
Avellino 1,109 1,186 1,136 
Caserta 1,168 1,236 1,251 
Napoli 1  1,091 1,158 1,243 
Napoli 2  1,107 1,169 1,298 
 
Table 5.4 – Median number of patients per GP aged 40-64 years in 2014-2016  
Region LHU 2014 2015 2016 
Lombardy 
Bergamo 403 407 405 
Lecco  375 379 397 
Monza Brianza 399 408 423 
Mantova  378 386 394 
Campania 
Avellino 344 361 357 
Caserta 360 392 401 
Napoli 1  357 365 387 
Napoli 2  396 399 409 
 
Table 5.5 – Median number of patients per GP aged ≥65 years in 2014-2016  
Region LHU 2014 2015 2016 
Lombardy 
Bergamo 291 301 307 
Lecco  275 305 332 
Monza Brianza 282 303 335 
Mantova  319 318 329 
Campania 
Avellino 262 280 277 
Caserta 230 243 229 
Napoli 1  218 237 284 
Napoli 2  202 179 203 
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5.1.2 Assisted citizens’ cohorts 
 
The term “LHU population” is used to denote all citizens (of every age and 
sex) resident in the same LHU and covered by NHS. In other words, it 
includes all citizens registered with one of the GPs belonging to that LHU. 
Number of assisted citizens aged 40-64 years increased over time for all 
the LHUs, except for Bergamo area, where a decrease from 400,716 to 
398,836 was observed (Table 5.6). The proportion of this age class on the 
total population did not show a relevant variation over time, nor between 
Lombardy and Campania region (Figure 5.3). 
On the other hand, the number of citizens aged ≥65 years rose in all the 
LHUs, with a marked increase in the Campania areas (Table 5.7). The 
proportion of this age class was higher for Lombardy LHUs than Campania 
LHUs, and showed a slight increase in time in Bergamo LHU and Mantova 
area (Figure 5.4). 
 
Table 5.6 – Number of assisted citizens aged 40-64 years in 2014-2016  
Region LHU 2014 2015 2016 
Lombardy 
Bergamo 400,716 402,602 398,836 
Lecco  121,336 121,935 128,998 
Monza Brianza 313,144 316,329 337,126 
Mantova  151,503 152,589 153,833 
Campania 
Avellino 133,147 140,425 145,909 
Caserta 272,304 290,617 314,205 
Napoli 1  294,243 315,321 341,684 
Napoli 2  302,833 324,218 359,897 
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Table 5.7 – Number of assisted citizens aged ≥65 years in 2014-2016  
Region LHU 2014 2015 2016 
Lombardy 
Bergamo 210,102 213,831 213,996 
Lecco  75,475 77,052 78,498 
Monza Brianza 186,162 189,702 189,806 
Mantova  95,193 95,901 96,865 
Campania 
Avellino 79,719 84,242 87,586 
Caserta 134,065 143,400 155,243 
Napoli 1  163,058 174,780 189,938 
Napoli 2  124,585 134,962 155,476 
 
 
 
Figure 5.2 – Proportion of citizens aged <40 years 
First, second, and third bar represent 2014, 2015, and 2016, respectively, for each LHUs 
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Figure 5.3 – Proportion of citizens aged 40-64 years 
First, second, and third bar represent 2014, 2015, and 2016, respectively, for each LHUs 
 
 
 
Figure 5.4 – Proportion of citizens aged ≥65 years 
First, second, and third bar represent 2014, 2015, and 2016, respectively, for each LHUs 
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5.1.3 Patients’ cohorts 
 
The total number of adult patients included in the study, which corresponds 
to the number of patients aged 40-64 years with at least one prescription 
in the years considered, is reported in Table 5.8. For Bergamo and 
Mantova LHU there were a slightly decrease in number from 2015 to 2016, 
whereas an increase in patient number was found in all the other LHUs. 
The same time trend was observed for older patients (Table 5.9). 
 
Table 5.8 – Number of patients aged 40-64 years included in the study 
Region LHU 2014 2015 2016 
Lombardy 
Bergamo 261,430 262,401 256,470 
Lecco  75,532 76,490 78,040 
Monza Brianza 195,283 199,257 199,963 
Mantova  101,352 101,699 99,278 
Campania 
Avellino 110,208 111,672 113,325 
Caserta 224,016 241,822 248,054 
Napoli 1  245,283 252,102 266,667 
Napoli 2  275,909 276,365 289,321 
 
Table 5.9 - Number of patients over 65 years of age included in the study 
Region LHU 2014 2015 2016 
Lombardy 
Bergamo 193,483 196,806 196,633 
Lecco  57,831 61,874 66,577 
Monza Brianza 142,681 152,065 161,641 
Mantova  85,857 86,515 85,229 
Campania 
Avellino 83,246 87,079 90,754 
Caserta 146,285 153,084 160,737 
Napoli 1  156,793 169,940 200,768 
Napoli 2  152,447 134,970 154,256 
 
The prevalence of patients on assisted citizens aged 40-64 years (Figure 
5.5) showed a decrease from 2014 to 2016, though remaining always 10-
percentage point higher for Campania LHUs. As expected, the prevalence 
of patients on assisted citizens aged ≥65 was very high in all LHUs. 
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Notably, these values were around 100% in the Campania areas (Figure 
5.6). 
 
 
Figure 5.5 – Prevalence of patients on assisted citizens aged 40-64 years 
First, second, and third bar represent 2014, 2015, and 2016, respectively, for each LHUs 
 
 
Figure 5.6 – Prevalence of patients on assisted citizens aged ≥65 years 
First, second, and third bar represent 2014, 2015, and 2016, respectively, for each LHUs 
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The percentage of female patients was higher than men in all LHUs and 
was mostly unchanged during the study period, both for patients aged 40-
64 and ≥65 years, and even higher in the latter age class than in the 
former one (Table 5.10 and Table 5.11). 
 
Table 5.10 – Proportion of females in patients of 40-64 years of age 
Region LHU 2014 2015 2016 
Lombardy 
Bergamo 53.1 53.1 53.2 
Lecco  53.8 53.6 53.4 
Monza Brianza 54.5 54.3 54.1 
Mantova  53.3 53.3 51.8 
Campania 
Avellino 53.1 53.3 53.1 
Caserta 54.0 54.0 53.7 
Napoli 1  55.8 55.1 55.4 
Napoli 2  54.1 54.1 53.9 
 
Table 5.11 – Proportion of females in patients over 65 years of age 
Region LHU 2014 2015 2016 
Lombardy 
Bergamo 56.3 56.1 56.4 
Lecco  57.3 56.8 56.5 
Monza Brianza 57.2 57.0 56.6 
Mantova  57.9 57.6 56.4 
Campania 
Avellino 56.7 56.6 56.4 
Caserta 57.0 56.8 56.5 
Napoli 1  59.4 58.7 58.3 
Napoli 2  55.6 55.7 55.3 
 
 
 
5.2 DRUG CONSUPTION ANALYSES 
 
The mean number of drugs prescribed per patient was higher in patients 
aged ≥65 years, independently by the LHUs. Moreover, for both age 
classes, the average number of drugs prescribed per patient for Campania 
LHUs was higher than Lombardy areas: it was about 4-5 and 9 in Campania 
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compared to about 3 and 6 in Lombardy, respectively for patients aged 40-
64 and ≥65 years (Figure 5.7 and Figure 5.8). 
 
 
 
Figure 5.7 – Average number of drugs prescribed per patient aged 40-64 years 
First, second, and third bar represent 2014, 2015, and 2016, respectively, for each LHUs 
 
 
 
Figure 5.8 – Average number of drugs prescribed per patient aged ≥65 years 
First, second, and third bar represent 2014, 2015, and 2016, respectively, for each LHUs
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We estimated also the percentages of patients (over assisted citizens) 
prescribed polypharmacy (5-9 drugs) or hyperpolypharmacy (≥10 drugs). 
For the age class between 40 and 64 years (Table 5.12), about 8-9% of 
patients received 5-9 drugs in Lombardy; in Campania this percentage was 
two times higher (16-20%) along all the period. In addition, in Lombardy, 
less than 1% of patients belonging to this age class received at least 10 
drugs, while the percentage ranged between 2 and 4.5% in Campania. 
For the elderly (Table 5.13), there were great differences between the 
two regions: for Campania LHUs, about half of older patients received 5 to 
9 drugs compared to one third in Lombardy LHUs. The prevalence of older 
patients with more than 10 drugs in Campania LHUs turned out to be 
considerably higher than Lombardy, ranging from 18 to 25% and from 5 
to 9%, respectively. 
 
Table 5.12 – Prevalence (%) of patients aged 40-64 years with polytherapy 
 LHU 2014 2015 2016 
5-9 drugs 
Bergamo 8.20 8.13 7.95 
Lecco  7.33 7.46 7.15 
Monza Brianza 7.56 7.63 7.29 
Mantova  9.09 9.66 9.09 
Avellino 16.09 17.71 16.09 
Caserta 19.01 20.41 19.01 
Napoli 1  21.08 20.94 19.99 
Napoli 2  21.53 23.27 21.06 
≥10 drugs 
Bergamo 0.84 0.79 0.80 
Lecco  0.64 0.63 0.63 
Monza Brianza 0.45 0.74 0.70 
Mantova  1.02 0.95 0.96 
Avellino 2.99 2.88 2.39 
Caserta 4.27 3.88 3.52 
Napoli 1  4.17 4.25 4.25 
Napoli 2  3.60 4.53 4.06 
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Table 5.13 – Prevalence (%) of patients over 65 years of age with polytherapy 
 LHU 2014 2015 2016 
5-9 drugs 
Bergamo 36.61 36.52 36.90 
Lecco  32.98 30.58 32.98 
Monza Brianza 33.93 31.34 33.93 
Mantova  38.44 38.57 37.60 
Avellino 48.12 47.69 47.01 
Caserta 50.46 49.09 47.10 
Napoli 1  43.91 44.92 46.53 
Napoli 2  52.39 46.50 45.35 
≥10 drugs 
Bergamo 8.90 8.83 8.68 
Lecco  4.91 5.58 6.23 
Monza Brianza 5.65 6.38 7.15 
Mantova  9.20 9.46 9.20 
Avellino 18.94 19.92 18.04 
Caserta 25.55 25.07 24.06 
Napoli 1  20.34 21.85 24.51 
Napoli 2  23.62 25.25 25.32 
 
In addition, Table 5.14 and Table 5.15 show the percentages of patients 
in each age class prescribed by first level of ATC classification. For older 
people, the highest values were reported in C (Cardiovascular system) 
group in all LHUs, ranging from 77.6 to 85.3% in 2014, from 77.7 to 84.9% 
in 2015, and from 78.0 to 84.0% in 2016. The following group was the A 
(Alimentary tract and metabolism) which had some differences between 
LHUs in Lombardy and in Campania. In details, in Lombardy the 
percentages ranged between 61 and 69% over the 3-year period, while in 
Campania they rose up to 72-80%. About 50-52% of patients aged 40-64 
years in Lombardy LHUs were prescribed anti-infectives medications (J 
group); in Campania the percentage was higher for all the years, ranging 
between 63.7 and 70.1% in 2014, between 67.3 and 71.0% in 2015, and 
between 65.6 and 69.3% in 2016. The second group for highest values 
was the A (Alimentary tract and metabolism) also for this age class, 
including about 40% of patients in Lombardy and approximately 50% of 
patients in Campania, followed by the C (Cardiovascular system) class. 
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Table 5.14 – Prevalence (%) of patients aged 40-64 years treated with drugs by 
ATC class at first level 
ATC LHU 2014 2015 2016 
A-alimentary 
tract and 
metabolism 
Bergamo 40.40 41.15 42.16 
Lecco  36.63 38.01 39.73 
Monza Brianza 36.47 37.03 38.52 
Mantova  40.25 40.66 41.10 
Avellino 46.13 46.11 42.62 
Caserta 50.99 49.85 50.28 
Napoli 1  54.30 56.17 56.16 
Napoli 2  51.08 54.94 54.14 
B-blood and 
blood forming 
organs 
Bergamo 14.35 14.22 14.52 
Lecco  14.52 14.83 14.94 
Monza Brianza 14.57 14.45 14.69 
Mantova  14.81 14.53 14.98 
Avellino 16.81 17.04 16.24 
Caserta 18.66 17.69 17.58 
Napoli 1  17.47 17.89 18.57 
Napoli 2  16.90 18.66 18.91 
C-
cardiovascular 
system 
Bergamo 35.14 34.87 35.57 
Lecco  36.39 36.10 36.42 
Monza Brianza 36.41 36.13 36.85 
Mantova  40.47 39.74 40.23 
Avellino 46.13 46.36 46.68 
Caserta 47.38 44.65 44.68 
Napoli 1  44.57 44.28 44.11 
Napoli 2  44.94 44.54 44.69 
D-dermatolo-
gicals 
Bergamo 1.74 1.60 1.52 
Lecco  1.51 1.39 1.29 
Monza Brianza 1.85 1.63 1.51 
Mantova  1.84 1.64 1.57 
Avellino 2.75 2.38 2.17 
Caserta 2.99 2.56 2.43 
Napoli 1  3.85 3.36 3.15 
Napoli 2  3.27 3.06 2.84 
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G-genito urinary 
system and sex 
hormones 
Bergamo 6.94 6.70 6.36 
Lecco  6.92 6.69 6.51 
Monza Brianza 7.23 6.87 6.63 
Mantova  5.90 5.64 5.62 
Avellino 7.00 6.80 6.41 
Caserta 7.58 6.89 6.59 
Napoli 1  7.56 7.47 7.15 
Napoli 2  6.84 7.28 7.03 
H-systemic 
hormonal 
preparations. 
excluding sex 
hormones 
Bergamo 15.10 15.29 15.48 
Lecco  15.20 15.11 15.67 
Monza Brianza 13.92 13.95 14.31 
Mantova  16.33 16.44 17.16 
Avellino 23.25 23.20 22.26 
Caserta 26.89 26.13 25.32 
Napoli 1  24.24 25.08 24.65 
Napoli 2  25.51 29.66 28.42 
J-general 
antiinfectives 
for systemic use 
Bergamo 51.90 52.20 50.58 
Lecco  50.94 52.15 49.76 
Monza Brianza 51.50 52.79 50.40 
Mantova  51.29 52.06 50.25 
Avellino 68.11 68.28 66.49 
Caserta 70.07 69.50 68.00 
Napoli 1  66.23 67.33 65.60 
Napoli 2  63.69 71.04 69.28 
L-antineoplastic 
and 
immunomodu-
lating agents 
Bergamo 2.17 2.12 2.11 
Lecco  2.02 2.04 2.13 
Monza Brianza 2.06 2.12 2.20 
Mantova  2.09 2.09 2.09 
Avellino 1.95 1.88 1.91 
Caserta 2.08 1.87 1.90 
Napoli 1  1.98 2.01 2.10 
Napoli 2  1.47 1.71 1.79 
M-musculo-
skeletal system
Bergamo 18.28 17.42 17.18 
Lecco  16.13 15.43 15.49 
Monza Brianza 18.08 17.58 17.64 
Mantova  20.54 20.10 19.44 
Avellino 35.80 33.80 30.37 
Caserta 40.93 37.95 36.18 
Napoli 1  46.34 45.90 43.93 
Napoli 2  44.99 48.24 45.43 
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N-nervous 
system 
Bergamo 17.60 17.49 17.91 
Lecco  15.78 15.54 16.04 
Monza Brianza 14.79 14.88 15.43 
Mantova  16.80 16.70 17.39 
Avellino 15.95 15.44 15.33 
Caserta 18.39 16.95 16.99 
Napoli 1  16.04 16.09 16.46 
Napoli 2  14.98 15.79 16.06 
P-antiparasitic 
products 
Bergamo 1.50 1.52 1.60 
Lecco  1.53 1.52 1.52 
Monza Brianza 1.16 1.12 1.07 
Mantova  1.19 1.15 1.12 
Avellino 0.86 0.84 0.83 
Caserta 0.94 0.82 0.89 
Napoli 1  0.81 0.86 0.85 
Napoli 2  0.83 0.97 1.02 
R-respiratory 
system 
Bergamo 18.55 18.45 16.31 
Lecco  18.86 18.77 17.06 
Monza Brianza 20.74 21.03 19.03 
Mantova  20.88 20.87 18.64 
Avellino 22.10 22.13 20.73 
Caserta 27.10 26.67 25.93 
Napoli 1  29.45 30.52 29.64 
Napoli 2  27.42 31.61 30.04 
S-sensory 
organs 
Bergamo 1.38 1.35 1.40 
Lecco  1.57 1.55 1.60 
Monza Brianza 1.53 1.50 1.51 
Mantova  1.51 1.46 1.51 
Avellino 1.72 1.67 1.71 
Caserta 2.08 1.89 1.87 
Napoli 1  2.63 2.54 2.46 
Napoli 2  2.03 1.95 1.97 
V-various 
Bergamo 0.11 0.25 0.12 
Lecco  0.07 0.07 0.06 
Monza Brianza 0.08 0.10 0.10 
Mantova  0.08 0.19 0.07 
Avellino 0.13 0.15 0.13 
Caserta 0.12 0.12 0.13 
Napoli 1  0.14 0.15 0.16 
Napoli 2  0.07 0.12 0.15 
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Table 5.15 – Prevalence (%) of patients aged ≥65 years treated with drugs by 
ATC class at first level 
ATC LHU 2014 2015 2016 
A-alimentary 
tract and 
metabolism 
Bergamo 66.86 68.10 68.85 
Lecco  60.80 62.84 64.81 
Monza Brianza 62.26 64.00 65.55 
Mantova  67.12 68.24 69.07 
Avellino 73.93 74.97 72.21 
Caserta 76.68 77.68 77.67 
Napoli 1  78.13 79.95 79.04 
Napoli 2  73.97 80.36 80.30 
B-blood and 
blood forming 
organs 
Bergamo 37.84 38.05 38.27 
Lecco  35.59 36.49 37.32 
Monza Brianza 36.86 38.04 38.78 
Mantova  41.28 41.45 41.78 
Avellino 47.86 49.88 48.29 
Caserta 51.61 51.85 51.16 
Napoli 1  46.96 48.00 49.53 
Napoli 2  46.48 52.18 53.62 
C-
cardiovascular 
system 
Bergamo 77.82 77.73 78.01 
Lecco  77.57 77.98 78.45 
Monza Brianza 77.72 78.23 78.82 
Mantova  83.24 83.09 83.12 
Avellino 83.81 84.10 82.82 
Caserta 85.26 84.62 83.58 
Napoli 1  83.78 83.99 81.76 
Napoli 2  81.20 84.94 83.99 
D-dermatolo-
gicals 
Bergamo 1.77 1.62 1.56 
Lecco  1.60 1.49 1.29 
Monza Brianza 2.10 1.92 1.72 
Mantova  1.99 1.82 1.71 
Avellino 3.39 2.98 2.58 
Caserta 3.90 3.43 3.27 
Napoli 1  5.69 5.07 4.46 
Napoli 2  4.78 4.99 4.31 
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G-genito urinary 
system and sex 
hormones 
Bergamo 12.71 12.85 12.94 
Lecco  12.59 12.70 13.17 
Monza Brianza 14.13 14.34 14.62 
Mantova  11.56 11.52 11.73 
Avellino 14.69 14.87 14.47 
Caserta 15.96 15.92 15.77 
Napoli 1  15.87 16.17 15.64 
Napoli 2  15.10 16.99 16.88 
H-systemic 
hormonal 
preparations, 
excluding sex 
hormones 
Bergamo 15.95 16.28 16.25 
Lecco  15.24 15.50 15.89 
Monza Brianza 15.21 15.64 15.62 
Mantova  18.64 18.75 18.98 
Avellino 25.81 26.75 25.96 
Caserta 28.37 28.34 27.76 
Napoli 1  26.85 27.94 27.77 
Napoli 2  25.93 31.42 30.97 
J-general 
antiinfectives 
for systemic use 
Bergamo 47.97 48.10 46.85 
Lecco  44.30 45.32 44.01 
Monza Brianza 46.30 47.66 45.87 
Mantova  44.76 44.78 44.25 
Avellino 67.32 68.51 66.87 
Caserta 70.91 70.36 69.67 
Napoli 1  68.10 69.65 67.29 
Napoli 2  62.92 73.46 72.28 
L-antineoplastic 
and 
immunomodu-
lating agents 
Bergamo 3.64 3.61 3.59 
Lecco  3.14 3.24 3.38 
Monza Brianza 3.24 3.40 3.47 
Mantova  3.08 3.19 3.16 
Avellino 3.41 3.53 3.44 
Caserta 3.42 3.39 3.28 
Napoli 1  3.05 3.21 3.48 
Napoli 2  1.98 2.80 3.10 
M-musculo-
skeletal system
Bergamo 36.22 35.13 34.10 
Lecco  31.57 30.58 30.30 
Monza Brianza 32.75 31.99 31.68 
Mantova  34.17 33.49 32.70 
Avellino 55.05 54.08 49.72 
Caserta 57.71 55.55 53.33 
Napoli 1  56.99 56.57 52.50 
Napoli 2  53.39 60.65 57.56 
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N-nervous 
system 
Bergamo 28.58 28.70 29.05 
Lecco  22.21 22.79 23.74 
Monza Brianza 21.85 22.72 23.76 
Mantova  26.05 25.86 26.33 
Avellino 26.65 26.75 26.35 
Caserta 30.27 29.68 29.64 
Napoli 1  26.42 26.87 28.54 
Napoli 2  25.47 27.67 29.35 
P-antiparasitic 
products 
Bergamo 1.23 1.26 1.26 
Lecco  0.95 0.94 0.98 
Monza Brianza 1.04 1.02 0.95 
Mantova  0.99 1.02 0.98 
Avellino 0.79 0.77 0.83 
Caserta 0.75 0.76 0.81 
Napoli 1  0.82 0.87 0.81 
Napoli 2  0.87 1.08 1.10 
R-respiratory 
system 
Bergamo 18.96 19.07 17.17 
Lecco  17.63 18.04 16.57 
Monza Brianza 19.81 20.67 19.09 
Mantova  21.99 22.11 20.23 
Avellino 27.33 27.82 26.46 
Caserta 33.21 33.23 32.73 
Napoli 1  33.92 35.40 34.49 
Napoli 2  31.17 37.35 36.53 
S-sensory 
organs 
Bergamo 5.26 5.29 5.45 
Lecco  5.54 5.60 5.74 
Monza Brianza 5.30 5.38 5.59 
Mantova  6.14 6.10 6.27 
Avellino 4.96 4.81 4.74 
Caserta 5.94 5.85 5.86 
Napoli 1  8.96 8.91 8.49 
Napoli 2  6.61 7.29 7.17 
V-various 
Bergamo 0.24 0.64 0.25 
Lecco  0.12 0.13 0.14 
Monza Brianza 0.20 0.29 0.33 
Mantova  0.13 0.37 0.14 
Avellino 0.38 0.42 0.38 
Caserta 0.52 0.55 0.53 
Napoli 1  0.42 0.49 0.62 
Napoli 2  0.39 0.49 0.59 
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In Table 5.16 and Table 5.17 the consumptions (expressed as DDD per 
1,000 inhabitants die) of selected drug classes are reported. As expected, 
consumption of all considered drug classes was higher in patients aged 
≥65 years compared to patients aged 40-64 years. Time trends were 
extremely heterogeneous not only among drug classes but also among 
LHUs. In particular, we observed an increased consumption of angiotensin 
receptor blockers (p-trend<0.05 for all LHUs except for Bergamo and 
Mantova), statins (all p-trends<0.05), selective serotonin reuptake 
inhibitors (p-trend<0.05 for all LHUs except for Bergamo and Mantova), 
and serotonin-norepinephrine reuptake inhibitors (p-trend<0.05 for all 
LHUs except for Mantova) for patients aged ≥65 years over time. The only 
decreasing trend that was consistent among LHUs was the consumption of 
angiotensin receptor blockers in patients aged 40-64 years, although the 
p-trends were significative only for Campania’s LHUs. The consumption of 
antibiotics was about two times higher in Campania areas compared to 
Lombardy areas, independently by age classes. 
 
Table 5.16 – Consumption (in terms of DDD per 1,000 inhabitants die) of some 
of the most commonly used drug classes in patients aged 40-64 years  
ATC LHU 2014 2015 2016 p-trend 
Proton pump 
inhibitors 
Bergamo 47.7 46.2 46.0 0.823 
Lecco  40.6 45.2 36.7 <0.001 
Monza Brianza 43.3 44.9 36.2 <0.001 
Mantova  51.9 52.1 51.8 0.901 
Avellino 74.5 74.1 55.8 <0.001 
Caserta 76.0 76.9 41.3 <0.001 
Napoli 1  79.4 87.1 83.9 <0.001 
Napoli 2  66.0 81.6 73.5 <0.001 
ACE-inhibitors 
Bergamo 89.9 88.8 92.3 0.585 
Lecco  119.6 120.6 116.3 0.222 
Monza Brianza 119.7 120.4 115.1 0.013 
Mantova  114.8 112.7 114.0 0.622 
Avellino 127.1 131.2 146.9 0.365 
Caserta 164.1 159.1 99.4 <0.001 
Napoli 1  137.5 142.0 144.6 <0.001 
Napoli 2  123.0 149.4 156.1 <0.001 
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Angiotensin 
receptor 
blockers 
Bergamo 91.3 88.7 86.3 0.066 
Lecco  86.9 86.1 84.0 0.614 
Monza Brianza 81.5 82.3 79.5 0.145 
Mantova  117.4 111.5 111.9 0.577 
Avellino 165.6 155.7 150.7 <0.001 
Caserta 158.1 152.0 91.4 <0.001 
Napoli 1  132.9 139.4 131.7 <0.001 
Napoli 2  122.1 142.7 136.2 <0.001 
Statins 
Bergamo 51.9 50.8 53.2 0.100 
Lecco  43.8 44.5 42.8 0.018 
Monza Brianza 47.5 47.4 47.6 0.191 
Mantova  59.0 56.7 57.9 0.871 
Avellino 72.1 74.5 75.4 0.135 
Caserta 76.1 73.1 49.6 <0.001 
Napoli 1  60.1 64.1 63.5 <0.001 
Napoli 2  57.1 71.0 71.0 <0.001 
Antibiotics 
Bergamo 12.9 12.9 12.4 <0.001 
Lecco  11.6 11.7 10.9 0.029 
Monza Brianza 12.1 12.7 11.5 <0.001 
Mantova  11.6 11.9 10.9 0.002 
Avellino 24.0 23.3 21.2 <0.001 
Caserta 24.9 23.8 18.7 <0.001 
Napoli 1  22.3 22.3 21.1 <0.001 
Napoli 2  21.9 25.8 23.2 <0.001 
Selective 
Serotonin 
Reuptake 
Inhibitors 
Bergamo 25.7 26.0 26.0 0.108 
Lecco  24.1 25.0 24.7 0.182 
Monza Brianza 24.2 24.6 23.0 <0.001 
Mantova  28.7 29.4 29.6 0.227 
Avellino 25.4 25.7 25.2 0.004 
Caserta 30.7 30.2 19.4 <0.001 
Napoli 1  23.2 24.7 23.7 <0.001 
Napoli 2  20.9 25.0 24.0 <0.001 
Serotonin-
Norepinephrine 
Reuptake 
Inhibitor 
Bergamo 7.9 8.1 8.3 0.191 
Lecco  7.2 7.6 7.2 0.575 
Monza Brianza 6.3 6.6 6.3 0.604 
Mantova  9.0 8.9 9.3 0.869 
Avellino 6.0 6.2 6.9 0.660 
Caserta 7.9 7.6 5.2 <0.001 
Napoli 1  5.0 5.2 5.2 <0.001 
Napoli 2  4.5 5.6 5.4 <0.001 
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Anti-asthmatics
Bergamo 23.3 22.7 22.7 0.360 
Lecco  20.5 19.9 20.7 0.903 
Monza Brianza 22.6 22.2 21.9 0.347 
Mantova  27.4 25.8 25.5 0.287 
Avellino 28.8 28.3 26.4 <0.001 
Caserta 32.9 31.90 26.0 <0.001 
Napoli 1  36.6 38.7 35.4 <0.001 
Napoli 2  30.9 35.8 33.1 <0.001 
 
 
Table 5.17 – Consumption (in terms of DDD per 1,000 inhabitants die) of some 
of the most commonly used drug classes in patients aged ≥65 years  
ATC LHU 2014 2015 2016 p-trend 
Proton pump 
inhibitors 
Bergamo 192.8 198.6 201.9 0.156 
Lecco  117.2 134.8 131.2 <0.001 
Monza Brianza 142.5 161.1 153.3 <0.001 
Mantova  207.3 219.2 223.6 0.023 
Avellino 264.3 287.6 258.8 <0.001
Caserta 281.5 291.8 157.9 <0.001 
Napoli 1  240.2 282.1 309.1 <0.001 
Napoli 2  236.0 281.6 326.3 <0.001 
ACE-inhibitors 
Bergamo 375.8 364.2 365.2 0.022 
Lecco  394.0 407.7 439.1 <0.001 
Monza Brianza 389.2 407.4 435.0 <0.001 
Mantova  399.5 395.1 398.3 0.659 
Avellino 383.2 401.4 429.9 0.002 
Caserta 504.1 491.9 299.7 <0.001 
Napoli 1  399.9 432.2 461.3 <0.001 
Napoli 2  393.4 446.7 525.9 <0.001 
Angiotensin 
receptor 
blockers 
Bergamo 345.5 345.3 351.6 0.336 
Lecco  303.2 316.5 348.8 <0.001 
Monza Brianza 282.8 293.6 325.6 <0.001 
Mantova  396.4 398.4 402.0 0.985 
Avellino 489.1 491.2 479.6 0.001 
Caserta 545.2 532.8 349.5 <0.001 
Napoli 1  429.5 475.3 477.7 <0.001 
Napoli 2  412.5 484.0 533.6 <0.001 
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Statins 
Bergamo 216.9 222.6 234.0 <0.001
Lecco  163.7 178.2 199.2 <0.001 
Monza Brianza 173.4 192.4 212.1 <0.001 
Mantova  244.6 254.2 266.9 0.020 
Avellino 228.4 248.5 253.1 0.001 
Caserta 270.0 280.5 196.8 <0.001 
Napoli 1  199.6 226.6 240.4 <0.001 
Napoli 2  204.7 255.1 297.5 <0.001 
Antibiotics 
Bergamo 19.4 19.4 18.7 0.026 
Lecco  13.3 14.2 15.5 <0.001 
Monza Brianza 14.6 16.0 16.7 <0.001 
Mantova  16.0 15.4 15.1 0.237 
Avellino 36.1 37.8 35.1 0.001
Caserta 42.1 39.9 30.6 <0.001 
Napoli 1  31.8 34.6 37.1 <0.001 
Napoli 2  36.4 39.9 44.7 <0.001 
Selective 
Serotonin 
Reuptake 
Inhibitors 
Bergamo 55.4 55.8 58.5 0.211 
Lecco  33.9 38.0 44.2 <0.001 
Monza Brianza 36.8 40.3 44.7 <0.001 
Mantova  62.1 62.4 61.7 0.953 
Avellino 41.1 42.9 43.9 0.022 
Caserta 55.9 56.2 39.6 <0.001 
Napoli 1  39.7 46.3 49.2 <0.001 
Napoli 2  42.6 48.7 55.4 <0.001 
Serotonin-
Norepinephrine 
Reuptake 
Inhibitor 
Bergamo 19.1 19.9 20.6 0.001 
Lecco  12.1 14.0 14.9 0.001 
Monza Brianza 11.5 12.5 14.1 <0.001 
Mantova  18.0 18.6 19.6 0.141 
Avellino 9.3 10.8 11.1 0.048 
Caserta 15.9 15.5 11.1 <0.001 
Napoli 1  8.4 9.5 11.5 <0.001 
Napoli 2  9.7 10.9 13.7 <0.001 
Anti-asthmatics
Bergamo 72.0 69.4 66.2 <0.001
Lecco  45.7 49.9 56.2 <0.001 
Monza Brianza 52.3 58.2 64.7 <0.001 
Mantova  79.8 75.7 70.8 0.004 
Avellino 108.1 114.5 105.2 <0.001
Caserta 119.1 116.0 97.2. <0.001 
Napoli 1  97.5 110.6 117.3 <0.001 
Napoli 2  104.6 109.8 127.9 <0.001 
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5.3 APPROPRIATE PRESCRIBING ANALYSES 
 
Results from appropriate prescribing analyses are described as trend in 
annual prevalence rates of each indicator investigated. The annual 
prevalence of interested patients for each LHU is calculated as the median 
value between GPs with at least 100 older patients, in order to exclude GP 
at the beginning or at the end of their work activity period, who could 
overestimate the prevalence rates. 
The prevalence rate of each indicator, as reported below, have been 
estimates at LHU level. In the Appendix III section, the GP distribution 
for every indicator in 2014, 2015 and 2016, separately by LHU, is reported. 
 
 
5.3.1 Potential drug-drug interactions (pDDI) 
 
Potential DDI occurred in 10-14% of adult patients in LHUs in Lombardy 
region; the prevalence in Campania is almost 10 percent points higher, 
reaching 20-24%. There is no defined time trend for this indicator: for 
Bergamo LHU, Lecco and Monza Brianza areas the prevalence has been 
consistent during time; for Avellino LHU, Caserta LHU and Mantova area it 
has remained stable in 2015 and then decreased by 2% in 2016; for Napoli 
1 and Napoli 2 LHUs it has increased through the first year by 2 percent 
points and remained similar in the third year (Figure 5.9). However, 
overall, this indicator significantly changes over time for all the LHUs (p-
trends <0.01). 
The most frequent pDDI were ‘hydrochlorothiazide-ibuprofen’ and 
‘pantoprazole-levothyroxine’ in Lombardy, and ‘hydrochlorothiazide-
diclofenac’ in Campania for the three years (Table 5.18, Table 5.19, and 
Table 5.20). 
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Figure 5.9 – Annual prevalence rates of pDDI in the population aged ≥40 years 
 
Table 5.18 – Most frequently occurred pDDI, in 2014 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y 
Bergamo 
Hydrochlorothiazid
e-Ibuprofen 
(3.35%) 
Hydrochlorothiazid
e-Diclofenac 
(2.12%) 
Ibuprofen-
Acetylsalicylic 
acid, low dose 
(2.02%) 
Lecco  
Hydrochlorothiazid
e-Ibuprofen 
(2.97%) 
Hydrochlorothiazid
e-Diclofenac 
(2.54%) 
Pantoprazole-
Levothyroxine 
(1.99%) 
Monza Brianza 
Pantoprazole-
Levothyroxine 
(2.99%) 
Hydrochlorothiazid
e-Diclofenac 
(2.71%) 
Hydrochlorothiazid
e-Ibuprofen 
(2.12%) 
Mantova  
Pantoprazole-
Levothyroxine 
(2.19%) 
Hydrochlorothiazid
e-Ibuprofen 
(2.16%) 
Hydrochlorothiazid
e-Diclofenac 
(2.03%) 
C
am
p
an
ia
 
Avellino 
Hydrochlorothiazid
e-Diclofenac 
(4.65%)
Hydrochlorothiazid
e-Ibuprofen 
(2.57%)
Allopurinol-
Amoxicillin 
(1.90%) 
Caserta 
Hydrochlorothiazid
e-Diclofenac 
(4.06%) 
Pantoprazole-
Levothyroxine 
(2.25%) 
Ketoprofen-
Betamethasone 
(1.86%) 
Napoli 1  
Hydrochlorothiazid
e-Diclofenac 
(4.64%) 
Omeprazole-
Levothyroxine 
(2.69%) 
Ketoprofen-
Betamethasone 
(2.21%) 
Napoli 2  
Hydrochlorothiazid
e-Diclofenac 
(4.42%) 
Omeprazole-
Levothyroxine 
(2.61%) 
Ketoprofen-
Betamethasone 
(2.59%) 
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Table 5.19 – Most frequently occurred pDDI, in 2015 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y 
Bergamo 
Hydrochlorothiazid
e-Ibuprofen 
(3.12%) 
Ibuprofen-
Acetylsalicylic 
acid, low dose 
(2.02%)
Hydrochlorothiazid
e-Diclofenac 
(2.00%) 
Lecco  
Hydrochlorothiazid
e-Ibuprofen 
(2.69%) 
Hydrochlorothiazid
e-Diclofenac 
(2.37%) 
Pantoprazole-
Levothyroxine 
(2.35%) 
Monza Brianza 
Pantoprazole-
Levothyroxine 
(3.40%) 
Hydrochlorothiazid
e-Diclofenac 
(2.54%) 
Hydrochlorothiazid
e-Ibuprofen 
(1.92%) 
Mantova  
Pantoprazole-
Levothyroxine 
(2.52%) 
Hydrochlorothiazid
e-Ibuprofen 
(1.91%) 
Hydrochlorothiazid
e-Diclofenac 
(1.89%) 
C
am
p
an
ia
 
Avellino 
Hydrochlorothiazid
e-Diclofenac 
(4.18%)
Hydrochlorothiazid
e-Ibuprofen 
(2.32%)
Pantoprazole-
Levothyroxine 
(1.98%) 
Caserta 
Hydrochlorothiazid
e-Diclofenac 
(3.85%) 
Pantoprazole-
Levothyroxine 
(2.52%) 
Ketoprofen-
Betamethasone 
(1.91%) 
Napoli 1  
Hydrochlorothiazid
e-Diclofenac 
(4.15%) 
Omeprazole-
Levothyroxine 
(2.41%) 
Ketoprofen-
Betamethasone 
(2.27%) 
Napoli 2  
Hydrochlorothiazid
e-Diclofenac 
(4.11%) 
Ketoprofen-
Betamethasone 
(2.93%) 
Betamethasone-
Diclofenac 
(2.43%) 
 
Table 5.20 – Most frequently occurred pDDI, in 2016 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y 
Bergamo 
Hydrochlorothiazid
e-Ibuprofen 
(2.83%)
Calcium-
Levothyroxine 
(2.00%)
Hydrochlorothiazid
e-Diclofenac 
(1.98%) 
Lecco  
Pantoprazole-
Levothyroxine 
(2.68%) 
Hydrochlorothiazid
e-Ibuprofen 
(2.55%) 
Hydrochlorothiazid
e-Diclofenac 
(2.23%) 
Monza Brianza 
Pantoprazole-
Levothyroxine 
(3.64%) 
Hydrochlorothiazid
e-Diclofenac 
(2.59%) 
Hydrochlorothiazid
e-Ibuprofen 
(1.85%) 
Mantova  
Pantoprazole-
Levothyroxine 
(2.80%) 
Hydrochlorothiazid
e-Ibuprofen 
(1.83%) 
Hydrochlorothiazid
e-Diclofenac 
(1.79%) 
C
am
p
an
ia
 
Avellino 
Hydrochlorothiazid
e-Diclofenac 
(4.18%)
Hydrochlorothiazid
e-Ibuprofen 
(2.41%)
Allopurinol-
Amoxicillin 
(2.06%) 
Caserta 
Hydrochlorothiazid
e-Diclofenac 
(3.87%) 
Pantoprazole-
Levothyroxine 
(2.71%) 
Ketoprofen-
Betamethasone 
(1.86%) 
Napoli 1  
Hydrochlorothiazid
e-Diclofenac 
(4.12%) 
Omeprazole-
Levothyroxine 
(2.38%) 
Pantoprazole-
Levothyroxine 
(2.23%) 
Napoli 2  
Hydrochlorothiazid
e-Diclofenac 
(4.23%) 
Ketoprofen-
Betamethasone 
(2.44%) 
Omeprazole-
Levothyroxine 
(2.26%) 
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5.3.2 Therapeutic Duplicates (TD) 
 
Therapeutic duplicates interested a range between 2.26 and 3.26% of adult 
patients for Lombardy LHUs, while for Campania LHUs TD rates were two 
times higher, from 4.67 to 6.73%, during the entire period analysed. 
In addition, in Lombardy, the annual prevalence rates did not change 
during time (with only a slight decrease for Bergamo and Mantova, p-
trends <0.05), while a more dynamic situation was seen in Campania (p-
trends <0.05, except for Caserta), as shown in Figure 5.10. 
 
 
Figure 5.10 – Annual prevalence rates of TD in the population aged ≥40 years 
 
The class of drugs that was the most frequently involved with TD was the 
‘platelet aggregation inhibitors excl. heparin’ class (ATC code: B01AC), in 
all the LHUs over time (Table 5.21, Table 5.22, and Table 5.23). 
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Table 5.21 – Most frequently prescribed drug classes affected by TD, in 2014 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y 
Bergamo 
Platelet 
aggregation 
inhibitors excl. 
Heparin 
(24.20%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(10.91%) 
Calcium 
(5.33%) 
Lecco 
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(23.42%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(8.09%) 
Calcium 
(5.29%) 
Monza Brianza 
Platelet 
aggregation 
inhibitors excl. 
Heparin 
(22.09%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(12.55%) 
Calcium 
(5.44%) 
Mantova 
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(23.56%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(9.54%) 
Calcium 
(6.25%) 
C
am
p
an
ia
 
Avellino 
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(26.20%) 
Proton Pump 
Inhibitors 
(6.17%) 
Acetic acid 
derivatives and 
related substances 
(5.10%) 
Caserta 
Platelet 
aggregation 
inhibitors excl. 
Heparin 
(23.61%) 
Combinations of 
penicillins, incl. 
beta-lactamase 
inhibitors  
(5.78%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(5.34%) 
Napoli 1  
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(23.65%) 
Proton Pump 
Inhibitors  
(6.83%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(6.31%) 
Napoli 2  
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(12.60%) 
Proton Pump 
Inhibitors  
(6.88%) 
Glucocorticoids 
(6.40%) 
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Table 5.22 – Most frequently prescribed drug classes affected by TD, in 2015 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y 
Bergamo 
Platelet 
aggregation 
inhibitors excl. 
Heparin 
(24.93%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(10.72%) 
Calcium 
(5.54%) 
Lecco 
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(24.98%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(8.87%) 
Calcium 
(5.34%) 
Monza Brianza 
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(22.45%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(11.18%) 
Calcium 
(5.40%) 
Mantova 
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(24.82%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(8.25%) 
Calcium 
(6.56%) 
C
am
p
an
ia
 
Avellino 
Platelet 
aggregation 
inhibitors excl. 
Heparin 
(28.14%) 
Proton Pump 
Inhibitors  
(4.84%) 
Angiotensin ii 
receptor blockers 
(ARBs) and 
diuretics 
(4.60%) 
Caserta 
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(26.49%) 
Combinations of 
penicillins, incl. 
beta-lactamase 
inhibitors  
(5.45%) 
Glucocorticoids 
(4.84%) 
Napoli 1 
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(24.52%) 
Proton Pump 
Inhibitors  
(6.10%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(5.92%) 
Napoli 2 
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(27.27%) 
Glucocorticoids 
(5.47%) 
Proton Pump 
Inhibitors  
(5.05%) 
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Table 5.23 – Most frequently prescribed drug classes affected by TD, in 2016 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y 
Bergamo 
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(25.64%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(9.14%) 
Vitamin D and 
analogues 
(5.90%) 
Lecco  
Platelet 
aggregation 
inhibitors excl. 
Heparin (25.84%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(7.21%) 
Calcium 
(5.49%) 
Monza Brianza 
Platelet 
aggregation 
inhibitors excl. 
Heparin (22.84%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(10.20%) 
Calcium 
(5.85%) 
Mantova  
Platelet 
aggregation 
inhibitors excl. 
Heparin 
(26.33%) 
Adrenergics in 
combination with 
corticosteroids or 
other drugs, excl. 
Anticholinergics 
(7.44%) 
Calcium 
(6.05%) 
C
am
p
an
ia
 
Avellino 
Platelet 
aggregation 
inhibitors excl. 
Heparin 
(32.20%) 
Glucocorticoids 
(4.82%) 
Acetic acid 
derivatives and 
related substances 
(3.82%) 
Caserta 
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(29.50%) 
Glucocorticoids 
(4.64%) 
Combinations of 
penicillins, incl. 
beta-lactamase 
inhibitors  
(4.57%) 
Napoli 1  
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(26.70%) 
Proton Pump 
Inhibitors  
(6.09%) 
Glucocorticoids 
(4.89%) 
Napoli 2  
Platelet 
aggregation 
inhibitors excl. 
Heparin  
(30.10%) 
Glucocorticoids 
(5.56%) 
Proton Pump 
Inhibitors  
(4.59%) 
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5.3.3 Inappropriate prescriptions in the elderly: the ERD-list  
 
At least one drug/drug class included in the ERD-list has been found in 
about 25-27% of older patients in Lecco and Monza Brianza areas and in 
32-35% in Bergamo LHU and Mantova area. Also in this case, Campania 
LHUs achieved higher values for prevalence rates: in 2016, 49% of Avellino 
elderly received at least one inappropriate drug belonging to ERD-list, 50% 
in Caserta, 56% in Napoli 1 and 65% in Napoli 2. 
 
The time trend in prevalence was slight increasing in Napoli2 (p-trend 
<0.001), while decreased in Bergamo, Mantova, Avellino, and Caserta 
LHUs (all p-trends <0.001). No time trend was observed for Lecco (p-
trend=0.79) (Figure 5.11). 
 
 
Figure 5.11 – Annual prevalence rates of ERD indicator in the population aged 
≥65 years 
 
Proton pump inhibitors represented the most frequently occurred ERD-list 
criterion in Lombardy for the entire period considered. In Campania, two 
NSAIDs, ketoprofen and diclofenac, were the most frequently prescribed 
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medications included in the ERD-list in 2014 and 2016, while PPIs and 
ketoprofen in 2015 (Table 5.24, Table 5.25, and Table 5.26). 
 
Table 5.24 – Most frequently prescribed drug in the ERD-list in 2014 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y 
Bergamo Proton Pump Inhibitors Diclofenac Ketoprofen 
Lecco  Proton Pump Inhibitors Diclofenac Ketoprofen 
Monza Brianza Proton Pump Inhibitors Diclofenac Ketoprofen 
Mantova  Proton Pump Inhibitors Ticlopidine Diclofenac 
C
am
p
an
ia
 
Avellino Diclofenac Proton Pump Inhibitors Ketoprofen 
Caserta Ketoprofen Diclofenac Proton Pump Inhibitors 
Napoli 1  Ketoprofen Diclofenac Proton Pump Inhibitors 
Napoli 2  Ketoprofen Diclofenac Proton Pump Inhibitors 
 
 
Table 5.25 – Most frequently prescribed drug in the ERD-list in 2015 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y 
Bergamo Proton Pump Inhibitors Diclofenac Ketoprofen 
Lecco  Proton Pump Inhibitors Diclofenac Nifedipine 
Monza Brianza Proton Pump Inhibitors Diclofenac Ketoprofen 
Mantova  Proton Pump Inhibitors Ticlopidine Diclofenac 
C
am
p
an
ia
 
Avellino Proton Pump Inhibitors Diclofenac Ketoprofen 
Caserta Ketoprofen Proton Pump Inhibitors Diclofenac 
Napoli 1  Proton Pump Inhibitors Ketoprofen Diclofenac 
Napoli 2  Proton Pump Inhibitors Ketoprofen Diclofenac 
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Table 5.26 – Most frequently prescribed drug in the ERD-list in 2016 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y 
Bergamo Proton Pump Inhibitors Diclofenac Paroxetine 
Lecco  Proton Pump Inhibitors Diclofenac Nifedipine 
Monza Brianza Proton Pump Inhibitors Diclofenac Ketoprofen 
Mantova  Proton Pump Inhibitors Ticlopidine Diclofenac 
C
am
p
an
ia
 
Avellino Diclofenac Proton Pump Inhibitors Ketoprofen 
Caserta Ketoprofen Diclofenac Ticlopidine 
Napoli 1  Ketoprofen Diclofenac Proton Pump Inhibitors 
Napoli 2  Ketoprofen Diclofenac Proton Pump Inhibitors 
 
 
5.3.4 Anticholinergic Cognitive Burden (ACB) Score  
 
The annual prevalence rates of ACB score ≥3 in the elderly ranged between 
4.50 and 9.50% in all LHUs (Figure 5.12). Monza Brianza and Lecco areas 
showed the lowest percentages, even if they augmented over time (from 
4.63 to 5.86% for Monza Brianza, p-trend <0.001; from 5.17 to 6.25% for 
Lecco, p-trend <0.001). Similarly, Napoli 1 and Napoli 2 LHUs had an 
increase during time, starting from 6.52% and 7.64% and reaching 8.11% 
and 9.27%, respectively (all p-trends <0.001). The growth registered by 
Avellino was smaller, from 7.28% in 2014 to 7.84% in 2016, although 
significant. Conversely, Mantova area and Bergamo LHU displayed a small 
reduction of ACB rates in time, from 6.98 to 6.67% and from 8.67 to 
8.53%, respectively (p-trends <0.05). Finally, Caserta LHU had a more 
remarkable decrease over time, from 8.53 to 7.09% (p-trend <0.001). 
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Figure 5.12 – Annual prevalence rates of ACB score in the population aged ≥65 
years 
 
The most commonly prescribed drug involved in the ACB Score was 
paroxetine, an antidepressant of the selective serotonin reuptake inhibitor 
(SSRI) class, for Bergamo and Napoli 1 LHUs and for Lecco and Monza 
Brianza areas. In Mantova area and in Avellino, Caserta and Napoli 2 LHUs, 
instead, the diuretic furosemide was the first in terms of prescription 
frequency (Table 5.27, Table 5.28, and Table 5.29). 
 
Table 5.27 – Most frequently prescribed drug with ACB score ≥3, in 2014 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y Bergamo Paroxetine  Furosemide  Quetiapine  
Lecco  Paroxetine  Furosemide  Warfarin  
Monza Brianza Paroxetine  Furosemide  Warfarin  
Mantova  Furosemide  Paroxetine  Warfarin  
C
am
p
an
ia
 Avellino Furosemide  Paroxetine  Warfarin  
Caserta Furosemide  Paroxetine  Digoxin 
Napoli 1  Paroxetine  Furosemide  Warfarin  
Napoli 2  Furosemide  Paroxetine  Digoxin 
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Table 5.28 – Most frequently prescribed drug in the with ACB score ≥3, in 2015 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y Bergamo Paroxetine  Furosemide  Quetiapine  
Lecco  Paroxetine  Furosemide  Warfarin  
Monza Brianza Paroxetine  Furosemide  Quetiapine  
Mantova  Furosemide  Paroxetine  Warfarin  
C
am
p
an
ia
 Avellino Furosemide  Paroxetine  Quetiapine  
Caserta Furosemide  Paroxetine  Quetiapine  
Napoli 1  Paroxetine  Furosemide  Ranitidine  
Napoli 2  Furosemide  Paroxetine  Ranitidine  
 
Table 5.29 – Most frequently prescribed drug with ACB score ≥3, in 2016 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y Bergamo Paroxetine  Furosemide  Quetiapine  
Lecco  Paroxetine  Furosemide  Warfarin  
Monza Brianza Paroxetine  Furosemide  Quetiapine  
Mantova  Furosemide  Paroxetine  Warfarin  
C
am
p
an
ia
 Avellino Furosemide  Paroxetine  Quetiapine  
Caserta Paroxetine  Furosemide  Quetiapine  
Napoli 1  Paroxetine  Furosemide  Quetiapine  
Napoli 2  Furosemide  Paroxetine  Quetiapine  
 
 
5.3.5 Sedative Load (SL) Score 
 
A SL Score ≥3 occurred in a small percentage of older patients. All the 
annual prevalence rates ranged between 0.75 and 1.50%, apart from 
Bergamo LHU, that showed percentages of 1.78, 1.89 and 1.93 in 2014, 
2015 and 2016, respectively. For Napoli 1, and Napoli 2 LHUs, and for 
Monza Brianza areas, the SL rates’ trend significantly increased over time 
(p-trends <0.001). On the contrary, for Caserta and Avellino LHU, it 
increased from 2014 to 2015 and then decreased in 2016, with p-trends 
<0.05 (Figure 5.13). 
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Figure 5.13 – Annual prevalence rates of SL score in the population aged ≥65 
years 
 
All the drugs reported in Table 5.30, Table 5.31, and Table 5.32 
belonged to the ATC code group “N” (Nervous system) and includes 
antidepressants, antiepileptics, psycholeptics, psychoanaleptics, etc. 
Among them, the most frequently prescribed drugs present in the SL list 
were traditional antipsychotics (ATC code: N05A). 
 
  
0.00
0.50
1.00
1.50
2.00
2.50
2014 2015 2016
% p
ati
en
ts
SL Score ≥3 
Bergamo
Lecco
Monza
Mantova
Avellino
Caserta
Napoli1
Napoli2
‐ 122 ‐ 
Table 5.30 – Most frequently prescribed drug or drug classes with SL score ≥3, 
in 2014 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y 
Bergamo Traditional antipsychotics Trazodone Amitriptyline 
Lecco  Traditional antipsychotics Sertraline  Trazodone 
Monza Brianza Traditional antipsychotics Sertraline  Trazodone 
Mantova  Traditional antipsychotics Trazodone Sertraline  
C
am
p
an
ia
 
Avellino Traditional antipsychotics Trazodone Valproic acid  
Caserta Traditional antipsychotics Valproic acid  Trazodone 
Napoli 1  Traditional antipsychotics Paroxetine  Trazodone 
Napoli 2  Traditional antipsychotics Trazodone Sertraline  
 
 
Table 5.31 – Most frequently prescribed drug or drug classes with SL score ≥3, 
in 2015 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y 
Bergamo Traditional antipsychotics Trazodone Sertraline  
Lecco  Traditional antipsychotics Trazodone Sertraline  
Monza Brianza Traditional antipsychotics Sertraline  Trazodone 
Mantova  Traditional antipsychotics Trazodone Citalopram 
C
am
p
an
ia
 
Avellino Traditional antipsychotics Trazodone Paroxetine  
Caserta Traditional antipsychotics Trazodone Valproic acid  
Napoli 1  Traditional antipsychotics Trazodone Paroxetine  
Napoli 2  Traditional antipsychotics Trazodone Sertraline  
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Table 5.32 – Most frequently prescribed drug or drug classes with SL score ≥3, 
in 2016 
 LHU 1° 2° 3° 
Lo
m
b
ar
d
y 
Bergamo Traditional antipsychotics Trazodone Sertraline  
Lecco  Traditional antipsychotics Trazodone Sertraline  
Monza Brianza Traditional antipsychotics Trazodone Sertraline  
Mantova  Traditional antipsychotics Trazodone Sertraline  
C
am
p
an
ia
 
Avellino Traditional antipsychotics Trazodone Valproic acid  
Caserta Traditional antipsychotics Trazodone Valproic acid  
Napoli 1  Traditional antipsychotics Trazodone Paroxetine  
Napoli 2  Traditional antipsychotics Trazodone Sertraline  
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5.4 APPROPRIATE DRUG USE ANALYSES 
 
As describes in Methods section, adherence was assessed applying two 
different approaches; results for the annual adherence evaluation on 
prevalent users are reported in the Appendix IV section. 
Overall, mean proportion of days covered (PDC) for the four selected drug 
classes was less than 60% in all the LHUs (Table 5.33). 
New users of antidiabetic drugs had less than half of their first treatment 
year covered by the therapy, with the exception of Bergamo and Napoli 1, 
which showed the highest values (52.52% and 57.00%, respectively). 
Regarding antihypertensive drugs, four out of eight LHUs (Bergamo and 
Mantova in Lombardy and Napoli 1 and Napoli 2 in Campania) had a mean 
PDC greater than 50%. Mean adherence to bisphosphonates was highest 
for Napoli 2 (56.05%), while for statin none of Campania LHUs showed a 
PDC higher than 50%. This value was reached only for two LHUs in 
Lombardy (50.34% for Bergamo LHU and 50.74% for Mantova area). 
 
Table 5.33 – Mean levels of adherence (as proportion of days covered) to selected 
drug classes in incident users aged ≥40 years 
 LHU Antidiabetic drugs 
Antihyper-
tensive drugs
Bisphospho-
nates Statins 
Lo
m
b
ar
d
y 
Bergamo 52.52% 54.39% 46.89% 50.34% 
Lecco  38.00% 36.90% 33.10% 35.56% 
Monza Brianza 38.68% 36.22% 33.64% 34.56% 
Mantova  49.34% 52.33% 43.48% 50.74% 
C
am
p
an
ia
 Avellino 46.95% 46.55% 39.46% 41.83% 
Caserta 43.75% 42.39% 34.31% 36.98% 
Napoli 1  54.67% 50.27% 44.21% 44.89% 
Napoli 2  57.00% 52.94% 56.05% 46.75% 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
DISCUSSION  
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Over the last decade, national health systems have faced growing common 
challenges: increasing cost of healthcare, population ageing associated 
with a rise of chronic diseases and multi-morbidity leading to greater 
demand for healthcare, shortages, and uneven distribution of health 
professionals, health inequalities and inequities in access to healthcare. 
All these factors have contributed to rise even serious medication-related 
problems, including mis-, under- and over-utilization and consumption of 
drugs, prescription of unnecessary drugs and multi-prescription drugs in 
elderly patients [Spinewine, 2008]. Although there is evidence of a growing 
awareness of the issue [Mannucci et al, 2014; Franchi et al, 2016], in Italy 
there is a lack of official policy statements or regulatory guidelines on 
management of inappropriate prescribing and not-rational use of 
medicines. 
 
 
 
6.1 HOW TO MEASURE APPROPRIATENESS 
 
Medication prescription is one of the most powerful tools for GPs in the 
prevention and treatment of disease and the alleviation of symptoms. 
However, medication-related adverse events are an important source of 
patient morbidity, many cases of which could be prevented by the highest-
quality prescribing and medicines management [Howard et al, 2003; 
Howard et al, 2007; Howard et al, 2008; Pirmohamed et al, 2004]. 
Good indicators are needed for a valid and reliable measurement of the 
quality of prescribing. This implies the need of measurable elements in the 
care provided for which there has to be consensus and which can be used 
to estimate and improve the quality of care provided [Lawrence et al, 
1997]. Evaluation of prescribing practice should be single, integrated 
process that allows to demonstrate that doctors meet current professional 
standards, are up-to-date, and fit to practise. 
There have been many attempts over recent years to develop prescribing 
indicators, such as those based on the interrogation of prescriptions issued 
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by GPs (for example, using prescribing analysis and cost tabulation data). 
Other indicators required very detailed analysis and assessment of clinical 
records (for example, the medication appropriateness index), which would 
not be feasible for the large-scale assessment of all GPs [Bregnhøj et al, 
2005]. 
The evidence base for developing quality indicators for appropriate 
prescribing is limited; however, systematically combining available 
evidence with expert professional opinion using a consensus methodology 
can create quality indicators in areas where it would not otherwise be 
possible [Campbell et al, 2002]. Moreover, with developments in methods 
for interrogating electronic medical records, there is now the opportunity 
to develop and use sophisticated indicators that can give an assessment of 
the quality and safety of prescribing by individual GPs [Batty et al, 2003]. 
The indicators currently described in the literature with respect to the 
prescription of drugs are mainly formulated on the basis of general 
recommendations; they are rarely derived from existing, general practice 
guidelines that are more specific for GPs. Such evidence-based guidelines 
are now available in several countries. 
Quality indicators are increasingly used to facilitate regulation, ensure 
accountability, and improve quality. In recent years there has been 
considerable interest in using high level indicators to compare the 
performance of different health systems. However, developing lower level 
clinical quality indicators is an expensive and time consuming process, and 
there is currently little evidence to suggest that the process can be 
facilitated by transferring indicators developed for the health system in one 
country to another country [Marshall et al, 2003]. Notably, indicators 
cannot simply be transferred directly between countries without an 
intermediate process to allow for variation in professional culture or clinical 
practice. 
 
In Italy, AIFA (Agenzia Italiana del Farmaco), the main authority for drugs 
in Italy, has adopted four tools for the appropriateness of drug 
prescriptions, that are outlined in Box 6.1, and defined a set of indicators 
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focused on prescription behaviours, consumption of medicines, and 
compliance to prescribed therapies [OsMed Report 2014]. Despite this, 
there still is a paucity of studies investigating this phenomenon in the 
Italian population [Allegri et al, 2017]. 
 
Box 6.1 – Tools adopted by AIFA [Garattini et al, 2017] 
 
 
In this research project, we defined a set of explicit indicators for potential 
inappropriate prescription and drug use and we adapted them to the Italian 
drug formulary, providing tools specifically tailored to the Italian context. 
Secondly, using administrative health-care databases from two Italian 
regions, Campania and Lombardy (4.8 million and 4.7 million of adult 
subjects included, respectively), we retrospectively assessed the rates of 
the selected indicators of inappropriate prescribing and drug use among 
community dwelling adults, during the period 2014-2016. 
The set of indicators proposed in the present thesis was developed to 
provide an explicit and meaningful measure of the quality of prescribing in 
a real-world setting. Particularly, the set assessed three main domains, 
including drug consumption (polypharmacy, DID calculation for selected 
drug classes), appropriateness of prescription (potential drug-drug 
interactions, therapeutic duplication, drug to be avoided in the elderly, 
anticholinergic and sedative load in the elderly), and adherence to chronic 
treatments, identifying the occurrence of risky or erroneous prescriptions 
(1) the so called ‘AIFA notes’, which define the reimbursement regimens 
for many drugs and encourage physicians to limit prescriptions to the 
indications with proven efficacy 
(2) price caps for single drugs or therapeutic classes within managed 
entry agreements contracted with pharmaceutical industry 
(3) ‘therapeutic plans’, which state the clinical conditions for 
reimbursement and limit it only to labelled therapeutic indications 
(4) ‘monitoring registries’, which track the eligibility of patients and the 
complete flow of treatments according to approved indications 
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and suboptimal prescribing practice and drug use. An important area of 
application for these prescribing indicators is their use as an instrument to 
estimate and improve the quality of pharmacotherapeutic care. Another 
use of the prescription indicators can be found in research into clarifying 
variables for differences in prescribing behaviour. In a multivariate 
analysis, the prescription indicators, or reliable sum scores of these, can 
be used as independent variables alongside patient and practice 
characteristics and other clarifying variables which are thought to be 
correlated with prescribing, such as degree of urbanisation, type of 
practice, work pressure experienced, etc. 
The definition of these indicators specific for the Italian context allows us 
to estimate the appropriateness of therapies that are actually available and 
traceable in our country. In addition, as shown in this thesis, it allows to 
make temporal comparisons and between different geographical areas. 
However, as the prescribing indicators were calculated using pharmacy 
databases, the link with individual prescription decisions is lacking for 
prescribers, and the indicators are limited to what is measurable in the 
pharmacy databases. Moreover, it should be noted that pharmacy 
databases do not register the drugs prescribed but the drugs supplied to 
the patient. The supply may be influenced by the pharmacist; he could 
advise patients and prescribers and intervene in the case of drug-related 
problems and in partnerships with GPs. 
A source of bias in the calculation of the indicators from pharmacy 
databases is the effect of the patient who, depending on the type of 
prescription, does not always submit all drug prescriptions to the 
pharmacist. As a consequence, an indicator might give an incorrect 
estimate of the degree to which prescribing is in accordance with the 
guideline; however, this effect is probably limited [Beardon et al, 1993]. 
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6.2 EVALUATION OF DRUG CONSUMPTION 
 
6.2.1 Polypharmacy 
 
Polypharmacy, commonly defined as taking five or more medications, 
resulted to be extremely common in the EDU.RE.DRUG population. In 
Campania LHUs, about 45-50% and 20-25% of older people (≥65 years) 
received 5-9 drugs and at least 10 drugs, respectively. These percentages 
were lower for Lombardy LHUs: less than 40% and less than 10%, 
respectively. In comparison with other studies on older adults, Campania 
LHUs showed higher prevalence of polypharmacy, while Lombardy LHUs 
were characterized by lower prevalence rate. For example, in the study of 
Onder and colleagues, around 49% and 11% of Italian people aged 65 
years or over reported a concomitant dispensing of 5-9 drugs and ≥10 
drugs, respectively [Onder at al, 2014]. These data are in accordance with 
findings from a registered-based study performed in a large population of 
older adults in Sweden (44% of subjects with 5-9 drugs and 11.7% with 
≥10 drugs) [Morin et al, 2018]. Another study on Irish primary care 
showed a polypharmacy (5-9 drugs) rate of 30% in adult aged 45-64 years 
and 60% in the elderly, while about 8% on those aged 45-64 years and 
21% of over 65’s patients received a simultaneous prescription of 10 drugs 
or more [Moriarty et al, 2015]. This expected evidence was observed also 
in our study, where younger adults (40-64 years) reported a lower 
prevalence for both the categories of polypharmacy. Two Italian studies 
conducted in community-dwelling elderly people reported that 46% [Nobili 
et al, 2011] and 31% [ARNO Project Report, 2001] were exposed to 5 or 
more drugs. 
All these data are particularly alarming, because polypharmacy increases 
the likelihood of adverse drug events (ADEs). It was estimated that the 
risk of ADEs increases from 13% in a person taking two medicines to 58% 
when taking five and 82% when taking seven or more [Prybys et al, 2002]. 
In another study, the number of regular prescribed medications correlated 
with risk of ADEs: subjects taking 5 to 6 medicines, taking 7 to 8 medicines, 
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and 9 or more medicines showed 2 times, 2.8 times, and 3.3 times higher 
risk, respectively [Field et al, 2001]. This is particularly true in older adults, 
often characterized by the coexistence of many chronic diseases and 
multiple therapies [Field et al, 2004; Wauters et al, 2016]. First, because 
a higher number of drugs comes with a higher risk of harmful drug–drug 
interactions [Johnell et al, 2007]. Second, because the aging process is 
associated with physiological, pharmacokinetics, and pharmacodynamics 
changes that make older adults more prone to adverse drug reactions 
[Sera et al, 2012; Hubbard et al, 2013]. Third, because the high prevalence 
of chronic multimorbidity in old age leads to an enhanced risk of drug–
disease interactions [Mallet et al, 2007; Fortin et al, 2012]. 
Moreover, polypharmacy contributes to non-adherence [Stoehr et al, 
2008], to drug-related hospitalizations [Marcum et al, 2012], and 
consequently, to higher health care costs. According to the Geriatrics 
Working Group of AIFA, 1.3 million elderly Italians take more than 10 daily 
drugs, with the age group between 75 and 84 years recording the highest 
intake: 55% take between 5 and 9 drugs per day, 14% take 10 or more. 
In terms of expenditures, the older citizens absorb 60% (15.7 billion Euros) 
of the total cost of drugs (26.3 billion) [OsMed Report 2014]. 
Beyond the prevalence of multiple concomitant disease, the reason why 
polypharmacy is so widespread can be partially found in the application of 
published guidelines that hardly take into account the presence of 
multimorbidity, especially in older patients [Hilmer et al, 2009]. Physicians 
tend to follow the guidelines available for each of the multiple diseases that 
affect the elderly, and hence prescribe all the drugs recommended for each 
disease [Manucci et al, 2014]. The management of comorbid conditions 
with multiple medications is indeed one of the greatest prescribing 
challenges in geriatrics [Bernabei et al, 2011] that can be summarized by 
the observations of two eminent geriatricians: Dr Jerry Avorn observed 
that “medications are probably the single most important healthcare 
technology in preventing injury, disability, and death in the geriatric 
population” [Avorn et al, 1995]. On the other hand, the risk associated 
with use of medications in the elderly is expressed in the warning by 
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Gurwitz et al. that “any symptom in an elderly patient should be considered 
a drug side effect until proved otherwise” [Gurwitz et al, 1995]. Another 
reason stems from the fact that patients, especially the elderly, are 
followed at the same time by different specialists, in addition to their 
general practitioner. The poor information flow, the lack of habit of a 
medication review, and the reluctance to implement deprescribing, all 
contribute to increasing the prevalence of polypharmacy. Deprescribing 
has been defined as ‘the process of withdrawal of an inappropriate 
medication, supervised by a health care professional with the goal of 
managing polypharmacy and improving outcomes’. This is particularly 
relevant to patients with polypharmacy, because the risk of harm caused 
by medication increases with the number of medications a patient is 
prescribed. Stopping or reducing the dose of medications requires careful 
clinical consideration, with a need to balance issues such as potential loss 
of clinical benefit and increased patient anxiety, against reductions in 
medication errors, adverse reactions and drug burden [Reeve et al, 2015]. 
Factors that influenced decisions of whether or not to deprescribe include 
a sort of clinician inertia, whereby the clinician is aware of the potential 
harmful effects of medications but chooses not to act on this knowledge 
neither to stop the medication. Reasons for this included not wanting to 
generate more work (e.g. having to monitor the effects of stopping 
medications or overcoming logistical issues such as making changes to 
dosette boxes), and avoiding conflict with other healthcare professionals 
who may have started the medication [Anderson et al, 2014]. 
Polypharmacy, therefore, constitutes an important and well-known issue 
in all care settings, but still remains not widely addressed in Italy, as well 
as in some European countries, as reported by recently published data 
from the SIMPATHY Project and showed in Figure 6.1 [McIntosh et al, 
2018]. However, some efforts have been made to implement 
polypharmacy management initiatives in primary care, including guidelines 
to perform medication reconciliation and review or alert system pointing 
out complex chronic patients in electronic medical record. Certainly, a 
multidisciplinary approach implemented in multiple settings, such as 
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primary care, community pharmacies and hospitals, and involving not only 
GP and pharmacists, but also authorities of health‑care systems and 
patients’ families, is the key point to manage polypharmacy issue 
successfully [Hosseini et al, 2018; McIntosh et al, 2018]. 
 
 
Figure 6.1 – SIMPATHY Project: a case study of polypharmacy management in 
nine European countries [McIntosh et al, 2018] 
 
 
6.2.2 Consumption of selected drug classes 
 
Proton pump inhibitors (PPIs) are among the most commonly prescribed 
and used drugs globally: the favourable benefit/risk ratio traditionally 
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attributed to PPIs, combined to their high cost-effectiveness, has increased 
their use, up to fall into the problem of over-utilization. In fact, in one study 
looking at elderly patients discharged from hospital in Italy, 30% were 
receiving a PPI with no clear indication [Schepisi et al, 2016]. Also in our 
study, for older people, time trend in PPI consumption (in terms of DID) 
increased from 2014 to 2016 in all LHUs, apart from Avellino and Caserta 
LHUs. Notably, the amount of PPI DID consumed by elderly in Lombardy 
LHUs was far lower than in Campania LHUs. A smaller difference between 
the two regions was found for patients aged 40-64 years (again, higher 
levels for Campania with respect to Lombardy), for whom a definite time 
trend cannot be described. It is important to keep in mind that, in Italy, 
PPIs are dispensed also without prescription. Thus, our data may 
underestimate real amount of PPI consumption or confound the real trend 
over time. Despite this, the problem of PPI over-prescription and use 
remained. Yet studies consistently show that PPIs are being overprescribed 
worldwide in both primary and secondary care [Naunton et al, 2000; 
Walker et al, 2001; Bjornsson et al, 2006; Grant et al, 2006; Batuwitage 
et al, 2007]. Furthermore, overprescribing is more common in patients 
with comorbidities and polypharmacy, likely due in part to a belief that PPIs 
have greater benefits and safety profiles than have actually been 
demonstrated [Walker et al, 2001]. 
It is clear that actions are needed to curb and reduce PPI over use. Reeve 
and colleague outlined the steps to achieve the purpose: recognition of the 
problem; use of alternative approaches to manage conditions currently 
treated “by default” with PPIs; education regarding appropriate indications 
and durations for their use; and enhanced drug stewardship akin to that 
employed widely for antimicrobials, mandating better documentation 
around PPI prescriptions and regular review. Patient involvement and 
shared decision-making are also essential [Reeve et al, 2014]. In addition, 
Farrell and colleagues, developed an evidence-based guideline to help 
clinicians make decisions about when and how reduce the dose of or stop 
PPIs (Figure 6.2) [Farrell et al, 2017]. To note, an Italian version of this 
algorithm by Maio and colleagues is available [bal.lazio.it website]. 
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Figure 6.2 - Proton pump inhibitor deprescribing algorithm [Farrell et al, 2017] 
 
- 136 - 
Another drug class that has raised concerns for over-prescription is 
antibiotics. A 2016 report by Centers for Disease Control and Prevention 
(CDC) estimates that at least 30% of antibiotics prescribed in US 
outpatient settings are unnecessary [Harris et al, 2016]. Several studies 
show that the Italian consumption of systemic antibiotics is higher than the 
European average, both in hospitals and in the outpatient population 
[Adriaenssens et al, 2011; Morgan et al, 2011]. Reasons cited by doctors 
for overprescribing antibiotics include diagnostic uncertainty, time 
pressure on physicians, and patient demand. Physicians are pressured by 
patients to prescribe antibiotics. It may be easier for the physician pressed 
for time to write a prescription for an antibiotic than it is to explain why it 
might be better not to use one [Schwartz et al, 1997]. These aspects, 
together with socio-demographic (eg, urbanization), socio-economic (eg, 
financial and well-being) and cultural (eg, education level) factors [Russo 
et al, 2018], can explained the great variability in antibiotic consumption 
in our study. 
Indeed, there was a wide difference in amount of DID consumed between 
Lombardy and Campania, where it was about two times higher in both age 
classes (younger and older adults). Moreover, for the elderly, in some LHUs 
(such as Avellino, Bergamo, Caserta and Mantova), antibiotic consumption 
decreased over time. On the contrary, Lecco and Monza Brianza show a 
small increase that was more marked for Napoli 1 and, even more, for 
Napoli 2. 
Although universal agreement that antibiotic overprescribing is a problem, 
more changes in clinical practice are warranted [Fiore et al, 2017]. Besides 
this, there is also strong evidence that when physicians decrease antibiotic 
prescribing, antimicrobial resistance (which has reached alarming levels 
worldwide) follows suit [Seppälä et al, 1997; Guillemot et al, 2005; Butler 
et al, 2007; Baur et al, 2017]. However, some early intervention programs 
(Box 6.2) directed at reducing antibiotic prescribing demonstrated success 
[Gonzales et al, 1999; Perz et al, 2002; Meeker et al, 2016]. 
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Box 6.2 – Examples of practice- and system-level interventions that can decrease 
antibiotic prescribing 
 
 
 
 
 
6.3 APPROPRIATENESS OF PRESCRIPTION 
 
Data on appropriateness of prescribing are not exhaustive in the general 
population; however, there is relevant literature regarding the 
inappropriateness in certain categories of patients, such as the elderly, who 
are certainly the most exposed individuals to potentially inappropriate 
prescriptions (PIP). As already mentioned, the age-related physiological 
changes, the higher incidence of multiple chronic diseases and the greater 
number of prescriptions they receive, make this population more prone to 
medication-related problems [Morin et al, 2018]. In order to give a 
quantitative estimate of this phenomenon in Italy, in the present study we 
measured the prevalence of some indicators among over 65 patients, 
including rate of drugs to be avoided in the elderly, anticholinergic burden 
and sedative load. Notably, in our study we also estimated the prevalence 
of potential drug-drug interactions (pDDI) and therapeutic duplicates (TD) 
in the whole cohort of adult patients, aged 40 years and over. 
 
 
6.3.1 Appropriateness of prescription in adult patients 
 
A range between 10 and 15% of residents in Lombardy LHUs were exposed 
to severe pDDI; in Campania the percentage was about two times higher 
1) Monthly e-mails to physicians that compare their antibiotic prescribing to set 
goals or “top performers” within the organization. 
2) Electronic medical record “prompts” that require physicians to provide an 
“antibiotic justification note” when a potentially inappropriate antibiotic is 
prescribed for a particular diagnosis. 
3) Distribution of patient information that explains the limitations and potential 
harms of overprescribing antibiotics to patients. 
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(between 21 and 25%). Evidence obtained for Lombardy LHUs are in 
accordance with a previous study conducted using the administrative 
prescription database of the LHU of Lecco, where 16% of elderly patients 
had at least one severe pDDI in 2003 [Nobili et al, 2009]. This percentage 
is slightly higher comparing to results for Lecco LHU in our study (nearly 
11%), probably due to the different age of patients included, or to the time 
elapsed between theirs and our evaluation. In fact, the elderly constitutes 
a population at high risk of serious pDDIs because of the high rate of drug 
prescription. Accordingly, in another Italian study among patients aged 65 
years or older recruited at hospital admission 18.9% were exposed to at 
least one severe pDDI [Pasina et al, 2013]. Another study on registered-
based population in Sweden reported even higher percentages (31%) for 
people aged ≥75 years [Johnell et al, 2007]. Moreover, in a recently 
published study, among elderly patients in primary care, nearly 55% were 
found to have pDDIs [Gören et al, 2017]. By contrast, in Swedish people 
aged 15–95 years, the prevalence of potential DDIs has been estimated to 
be about 14% [Merlo et al, 2001], more in accordance with Lombardy data, 
while lower in comparison with Campania results.  
There is a great variability of pDDI prevalence between studies, that is 
strongly influenced by the type of population (patients’ age and the 
severity of the diseases) and care setting examined and by the type of 
interactions investigated. In some studies, in fact, not all the possible drug 
interactions were examined, but only some of the most clinically relevant 
pairs [Malone et al, 2004; Gagne et al, 2008; Tragni et al, 2013]. In a 
study conducted in Italy the most commonly observed pDDI was warfarin-
NSAID combination [Gagne et al, 2008]. By contrast, in our study, the 
most frequent pDDI were hydrochlorothiazide-ibuprofen and pantoprazole-
levothyroxine in Lombardy LHUs, and hydrochlorothiazide-diclofenac in 
Campania LHUs. The anti-inflammatory properties of NSAID therapy 
appear to result from their common ability to inhibit the biosynthesis of 
prostaglandins, which are involved in the modulation of blood pressure. 
The administration of ibuprofen or diclofenac has been shown to produce 
small increases in systolic and mean arterial blood pressure in older 
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subjects with hypertension controlled with hydrochlorothiazide. More than 
five days of treatment with both drugs are normally required for the 
interaction to manifest. Although the changes in blood pressure resulting 
from this interaction are typically small, some patients can experience 
substantial elevations in both systolic and diastolic blood pressure. Patients 
subjected to antihypertensive treatment should undergo closer blood 
pressure monitoring at the start of analgesic treatment [Koopmans et al, 
1987; Gurwitz et al, 1996]. Concerning pantoprazole-levothyroxine 
interaction, studies have shown that gastric acidity enhances the 
dissolution of levothyroxine tablets. Thus, PPIs, which suppress gastric acid 
secretion, might be expected to inhibit absorption of levothyroxine 
delivered as a tablet [Vita et al, 2014]. 
Although the estimation of the prevalence of pDDIs varies greatly from 
study to study, it is understandable that pDDIs represent an important 
issue in clinical practice. Several studies demonstrated that the exposure 
to pDDIs can lead to serious problems, such as adverse events, and 
increase the risk of hospitalizations and length of stay in the intensive care 
unit [Hamilton et al, 1998; Juurlink et al 2003; Rodrigues et al 2017]. 
However, pDDIs are not the same as actual DDIs [Seymour et al, 2011]. 
Even if we only included potentially clinically relevant type C DDIs (which 
may require at least dose adjustment) and potentially serious type D DDIs 
(which should be avoided), we have no way of verifying whether the 
concomitant prescription of two potentially interacting drugs resulted in 
their actual concomitant intake, nor whether it is hesitated in relevant 
clinical consequences. In addition, we could not know if GP who has 
prescribed two interacting drugs at the same time, has also explained to 
the patient to postpone or to suspend one of the them. 
 
Our study indicates a relatively low prevalence of patients with at least one 
TD, defined as overlapping prescription of two drugs with same ATC code 
at the fourth level but different ATC code at the fifth level. In particular, it 
counts for 2-3% and 5-7% of adult residents in Lombardy LHUs and in 
Campania, respectively. Also in the study by Azoulay and colleagues 
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involving patients aged ≥65 years in Iran, prescribing medications having 
the same ATC fourth level was regarded as TD. Out of this study’s 
population, 25% had prescriptions with medication duplications [Azoulay 
et al, 2005]. The large discrepancy between the latter and our results is 
mainly due to the source of data used in our study. It should be 
remembered that the evaluation of therapeutic duplicates, as well as of the 
other indicators, was limited to the drugs prescribed under the 
reimbursement regime. Of note, the most prevalent drug-class duplication 
was NSAIDs (32.8%), a class of drugs particularly prone to duplicate. 
Indeed, in Italy, medications containing NSAIDs could be prescribed by 
physicians but also freely purchased by the citizen (over the counter 
drugs), who often does not know their composition. In addition, it may be 
partially due to the different characteristics of patients included. With 
regard to therapeutic duplicates, it is difficult to make comparison with 
previous studies, because of the variety of TD definition, besides the 
heterogeneity of settings and populations studied. In a national-based 
study in Austria, for about 13-15% of subjects treated with 
antihypertensives, hypoglycemic, or lipid-lowering medication at least one 
occurrence of TD was reported [Heinze et al, 2016]. In this study, TD was 
defined as the overlapping prescription of the same substance with the 
same route of administration by two different prescribers to the same 
patient. Our findings appear to be in accordance with those reported in a 
study conducted among home healthcare patients in US [Meredith et al, 
2001], as well as in another study performed in Belgium’s Flemish County 
pharmacies in 2001 that showed that 5.4% of patients had TD [Leemans 
et al, 2003], even if, in the latter study, TD was defined as “two or more 
medicines containing the same medicinal compound”. In the same year, in 
a study conducted in 112 European community pharmacies (across 
Austria, Denmark, Germany, The Netherlands, Portugal and Spain) drug 
duplication was found in 2.2 % of patients [Paulino et al, 2004]. 
 
 
 
- 141 - 
6.3.2 Appropriateness of prescription in elderly patients 
 
Over the past two decades, several lines of evidence demonstrated an 
increasing prevalence in prescribing potentially inappropriate medications 
in the elderly, determined by a variety of different screening tools across 
a number of different jurisdictions and health care settings. In this regard, 
we developed a list of inappropriate drugs in the elderly, called 
EDU.RE.DRUG list or ERD-list, specifically adapted to Italian drug 
formulary. 
Also in this case, findings from our study showed differences in prevalence 
and time trend between the two geographical areas in Italy: out of the 
elderly population (1.7 million in Lombardy; 1.6 million in Campania), 
around 25-35% in Northern LHUs and between 50 and 65% in the South 
received prescriptions of at least one inappropriate drug/drug class 
included in the ERD-list. The results for Lombardy region are consistent 
with a cohort study conducted in elderly outpatients of Parma LHU (Emilia-
Romagna region, Italy), using pharmacy database [Maio et al, 2010]. In 
the mentioned study, about 26% of elderly people received a prescription 
for at least one drug included in the list the authors developed by adapting 
the Beers 2003 criteria to Italian context. Of note, a previous study by the 
same author showed a lower percentage (18%) of elderly outpatients, in 
Emilia-Romagna region, affected by PIP [Maio et al, 2006]. However, in 
the latter study the update Beers 2003 criteria, originally developed in the 
US, were used. The same criteria list was utilized in two other studies 
conducted in Italy [Landi et al, 2007; Ruggiero et al, 2010]: in the first one 
nearly 26% of elderly population (≥80 years), while in the second one 48% 
of older people (≥65 years) living in 31 nursing home across Italy, were 
exposed to PIP. In addition, the prevalences reported in our study for 
Lombardy region, unlike Campania region, are in accordance with several 
Italian studies conducted among in-hospital older adults [Onder et al, 
2003; Onder et al, 2005; Pasina et al 2014; Di Giorgio et al, 2016]. Results 
found in Campania region are even more alarming if we look at other 
European countries. In a study published in JAMA, the prevalence of 
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inappropriate drugs was studied in a sample of patients aged ≥80 years 
receiving home care services in 11 European countries, including Italy 
[Fialová et al, 2005]. The authors observed that, overall, about 20% of 
patients received the prescription of at least one inappropriate drug, with 
wide differences between the various countries. Italy (26.5%) was second 
only to the Czech Republic (41.1%). Similarly, a systematic review, that 
included fifty-two manuscripts evaluating the prevalence of PIP in 
community-dwelling older adults across Europe, reported un overall 
prevalence of 22.6% [Tommelein et al, 2015]. 
Among the most prevalent ERD criteria, there were the PPI therapy for 
more than 8 weeks. PPIs are a class of medications used to treat acid-
related disorders and, as already described (see paragraph 6.2.2), their 
use has significantly increased over the last few decades. Since they have 
been on the market, a number of post-marketing studies have been 
published demonstrating associations between longer duration of PPI 
therapy and a number of adverse effects that are a concern in older adults. 
PPIs have been associated with an increased risk of a number of adverse 
effects including osteoporotic-related fractures, Clostridium difficile 
infection, community-acquired pneumonia, vitamin B12 deficiency, kidney 
disease, and dementia, demonstrated by a number of case-control, cohort 
studies, and meta-analyses. Older adults should be periodically evaluated 
for the need for continued use of PPI therapy [Maes et al, 2017]. In addition 
to PPIs, prescriptions of diclofenac and ketoprofen were found in elderly. 
It can put you at risk for falls and other dangerous events. In general, 
NSAIDs can cause extreme sleepiness, confusion, dizziness, loss of 
balance, and severe stomach problems in the elderly [Hughes, 1991]. 
 
In our study we found a relatively low prevalence of anticholinergic burden, 
estimated as defined by Anticholinergic Cognitive Burden (ACB scale) 
[Boustani et al, 2008; Campbell et al, 2013], which is the most frequently 
validated expert based anticholinergic scale on adverse outcomes 
[Salahudeen et al, 2015]; the proportion of older study population with an 
ACB score of 3 or higher ranged between 4.6% and 9.3% in all the LHUs. 
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Indeed, in a study among a cohort of older adults attending primary care 
clinics, Boustani and colleagues stated that the percentage with at least 
one medication with ACB score of 3 was 20% [Boustani et al, 2008]. 
Moreover, in a population of community-dwelling adults 65 years or older 
in the US, an ACB score of 3 or greater was identified in 47.8% of patients 
[West at al, 2013]. This discrepancy may be due to the fact that we 
evaluated only drugs reimbursed by Italian NHS, which do not comprise 
some medications with anticholinergic properties, such as antihistamines, 
or antiemetics. However, a more recent study, involving community 
dwelling Australian men aged 70 years and over, showed that 8% of 
subjects was exposed to high (≥3) anticholinergic exposure according to 
the ACB [Pont et al, 2015], being comparable with our results. In another 
English community-based study a high burden of anticholinergic drug use 
was reported in 4% of older people included [Fox et al, 2011]. 
Unfortunately, making comparison with other countries is quite chancy, 
because of multiple local-related variables. Yet, there is not great 
availability of Italian literature in this regard. Only one study was 
conducted in primary care, but the author used another classification for 
the ACB scale by Cai et al. [Cai et al, 2013], defining a high score as ACB 
≥2; 13.6% of adult patients (≥45 years) with first cognitive impair 
reported a high ACB score [Grande et al, 2017]. In a multicentre study 
conducted in Italy in adults over 40 years with intellectual disabilities, 
11.3% of the total population showed an ACB score ≥3; of these only 10% 
were over 65 years old [De Vreese et al, 2018]. Finally, Pasina and 
colleagues, determined the ACB score in a cohort of hospitalized elderly 
patients; of these, nearly 8.5% had an ACB score of 3 or greater. Moreover, 
they found a dose-response relationship between total ACB score and 
cognitive impairment, thus suggesting that the ACB scale can be a useful 
tool for a rapid identification of drugs potentially inappropriate in the 
elderly. In line with other similar studies, among participants with ACB 
scores ≥3, paroxetine (score 3), furosemide (score 2), and warfarin (score 
1) were the most frequently used medications on the ACB scale [Green et 
al, 2016]. 
- 144 - 
We also found extremely low prevalence of sedative load, assessed as 
defined by the Sedative Load (SL) Model [Linjakumpu et al, 2003]. In the 
elderly population of the EDU.RE.DRUG study less than 2% showed a high 
SL score (≥3), with no remarkable variation depending on the geographical 
area. The epidemiology of sedative load as SL score has been studied only 
in another Italian study conducted in primary care setting: about 21% of 
older people had elevated SL score [Allegri et al, 2017]. Such a difference 
might be explained, again, to the limited drug formulary included in our 
analysis. In fact, numerous drugs with sedative effects, first of all 
benzodiazepines, are not currently reimbursed by Italian NHS. Lower 
percentage of subjects with high SL score with respect to the previous 
discussed study (8%, still higher than our results) was found in a cohort of 
community-dwelling patients aged 75 years and older in Finland [Taipale 
et al, 2012]. Another Finnish study among community-dwelling elderly (64 
years or over) reported that 12% had a sedative load ≥3 [Linjakumpu et 
al, 2004]. The same study investigated the factors associated with sedative 
load, reporting that older age (≥80 years) and female sex were associated 
with sedative load ≥3. Despite the different setting, a very similar 
percentage of people having high SL (12.2%) was found among residents 
with dementia living in residential aged care facilities in Ireland [Parsons 
et al, 2011]. Accordingly, a study comparing sedative load between those 
with and without dementia in the same study population found that 
residents with and without dementia had a similar sedative load (SL mean 
3.0 versus 2.7) [Bell et al. 2010]. All in all, these data suggest that the use 
of drugs with sedative properties is widespread also among patients 
without established cognitive impairment, thus confirming that our results 
may be affected by an underestimation of this indicator. 
 
Unlike the prevalence of the other indicators of appropriateness, which are 
quite stable over time, the percentage of elderly patients with of high ACB 
score and SL score showed some increase over time. As regards the 
prevalence of high ACB score, a slight increase can be observed over time 
(with the exception of Bergamo and Caserta), up to around +11-12% for 
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Lecco, Monza, and Napoli 1. For high SL score, with the sole exception of 
Caserta area, which showed a slight decrease, in all LHUs the percentages 
increased from 2014 to 2016, with increments of 40% for Lecco and Monza 
and even higher for Napoli 1 and Naples 2 (+65% and +54%, 
respectively). These trends could be secondary to an increased prescription 
of selected serotonin reuptake inhibitors (as we observed in the 
consumption analysis by DID) and of antipsychotics among elderly. 
Indeed, based on AIFA data, Lombardy and Campania regions recorded an 
increase of antipsychotics consumption from 2014 to 2016 [OsMed Report 
2017]. 
 
 
6.3.3 Factors associated with prescribing practice 
 
Our study found differences between the two regions involved in the study. 
In general, compared to Lombardy LHUs (in the North of Italy), Campania 
LHUs (in the South of Italy), reported higher prevalence for most of the 
indicators of quality prescribing evaluated in this study. Previous studies 
have showed that geographical location and other sociodemographic and 
socioeconomic factors, such as urbanization, low wages, education level 
and social deprivation, have been associated to an increased risk of 
potentially inappropriate prescribing [Zhang et al, 2012, Holmes et al, 
2013; Lund et al, 2013; Beuscart et al, 2017]. In a study conducted in 
Italy, patient living in rural areas (hill and mountain locations) were found 
to be more likely to be prescribed potentially inappropriate medications 
[Maio et al, 2006]. Moreover, for some indicators we found differences 
between LHUs within the same region. This is consistent with another study 
conducted in Lombardy region [Nobili et al 2011]. However, Lombardy 
region is quite homogeneous in terms of clinic-epidemiological factors, and 
there are no significant differences in relation to the age distribution of 
patients. For this reason, and in light of the fact that a strong correlation 
was found between the overall prescription prevalence rate and exposure 
to chronic drugs and chronic polypharmacy, the authors concluded that the 
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quantitative and qualitative differences between LHUs might therefore be 
due not to differences in the epidemiology of disease, but to different 
prescribing habits between physicians.  
In fact, there have been several factors that influence the prescribing 
behavior of GPs (Figure 6.3), that can be summarized in five different 
classes [Prosser et al, 2003; Muijrers et al, 2005; Mason, 2008; Spurling, 
2010]: 
• GP factors – education, clinical knowledge, experience, confidence, 
risk aversion, evidence-based medicine skills; 
• patient factors – compliance, ability to pay, specific request; 
• clinical factors – need, previous adverse events, comorbidities; 
• medication factors – safety, cost, efficacy; 
• systems factors – marketing, pharmaceutical representative visits, 
clinical information sources. 
All these variables may further complicate the process of properly choosing 
a drug. All of this must then be adequately contextualized in the daily work 
of the GP, which is not always able to fit into an optimal diagnostic-
therapeutic process. 
 
 
6.3.4 Interventions aimed at improving prescribing practice 
 
Ameliorated decision-making about drug prescribing by clinicians could 
lead to significant improvements in patient outcomes and effective use of 
healthcare expenditure. There is a significant body of literature about 
interventions designed to change the behaviours of health professionals in 
order to decrease inappropriate prescribing. Of these, interventions that 
rely solely on passive information transfer appear to be ineffective; 
conversely, active knowledge translation strategies (such as audit and 
feedback involving comparison with peers, educational outreach, and “real-
time” reminders) are usually effective [Ostini et al, 2009]. Finally, 
multifaceted interventions, that incorporate two or more strategies, are 
more likely to work than single ones [Sumit et al, 2003]. 
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Figure 6.3– Factors affecting prescribing in clinical practice [Sketris et al, 2007] 
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Besides GP-related strategies, also patient education to improve 
medication compliance turned out to be effective in reducing inappropriate 
prescribing and adverse events [Kaur et al, 2009]. Additionally, particular 
emphasis should be placed on the emerging role that pharmacists play in 
moderating medication appropriateness in primary care. Indeed, 
pharmacist-led interventions involving access to medical notes and 
medication reviews conducted in physician practices with feedback to 
physicians may improve prescribing appropriateness in community-
dwelling older adults [Riordan et al, 2016].  
A systematic review by Garcia specified five ways to reduce inappropriate 
prescribing in the elderly: (i) obtain pharmacist recommendations; (ii) use 
computerized alerts; (iii) review patient medications; (iv) consider using 
Beers’ criteria; and (v) educate patients to improve compliance [Garcia et 
al, 2006]. In a recent publication also, the authors outlined a list of 
strategies to prevent inappropriateness of prescribing that is reported in 
Box 6.3 [Varghese et al, 2019]. 
 
Box 6.3 – Strategies to prevent inappropriate drug prescribing 
 
• Maintain an accurate medication list and medical history and update 
whenever possible. 
• Encourage patients to bring all medications including prescription, OTC 
drugs, supplements, and herbal preparations. 
• Review any changes with patient and caregiver and if possible, provide all 
the changes in writing. 
• Use the fewest possible number of medications and the simplest possible 
dosing regimen. 
• Try to link each prescribed medication with its diagnosis. 
• Discontinue all unnecessary medications. 
• Screen for drug-drug and drug-disease interactions. 
• Use a team approach if possible, involving the caregiver or family and 
pharmacist (community pharmacist). 
• Avoid starting potentially harmful medications; use Beer’s criteria. 
• Try to start a new medication at the lowest dose and then titrate slowly. 
• Avoid starting medications to combat the potential side effects of other 
medications. 
• Careful medication reconciliation during transitions of care including proper 
communication handoffs to accepting providers. Ensuring a close post 
discharge follow up for updating medical history and medications can help 
in preventing medication errors, treatment failures, and rehospitalizations. 
• Consider goals of care and life-expectancy of patients when assessing 
medication appropriateness. 
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6.4 ADHERENCE TO CHRONIC TREATMENTS 
 
Adherence was defined as the extent at which a person’s behaviour –taking 
medication, following a diet, and/or executing lifestyle changes- 
corresponds with agreed recommendations from a health care provider 
[WHO, 2003]. Measurement of adherence to chronic treatment provides 
useful information regarding the patient’s actual behaviour towards drug 
therapies. This is extremely important because chronic therapies are 
widespread: in Italy, 50% of older patients (about 6.8 million of subjects) 
had at least one chronic therapy, such as diabetes, osteoporosis, and 
hypertension. Unfortunately, it was estimated that adherence averages 
only 50% among patients suffering long-term diseases [WHO, 2003]. Poor 
medication adherence is exactly the first cause for unsuccessful 
pharmacological treatment [Haynes et al, 2002], being consequently 
associated with higher risk of hospitalization, increased morbidity and 
mortality [Vermiere et al, 2001; Sokol et al, 2005]. On the other hand, 
high rates of adherence not only have a positive impact on patient’s health 
status, but it is also related with economic benefits. In fact, the PGEU 
(Pharmaceutical Group of the European Union) report showed that, in 
Europe, low medication adherence and inappropriate drug use cause 
194,500 deaths and cost 125 billion Euros for related hospitalizations every 
year [PGEU annual report, 2012]. In Italy, it was estimated that up to 11.4 
billion Euros per year would be spared with higher adherence to chronic 
therapy, and, therefore, fewer adverse events, lower admission to first aid 
and hospitalizations and lower pharmaceutical expenditure [Centro Studi 
SIC-Sanità in Cifre- website]. 
In the light of these data, having an estimation of adherence to chronic 
therapies is extremely important to understand the magnitude of this 
problem and to manage it. 
In our study, we evaluated the adherence level, as proportion of days 
covered (PDC), among new users of four different chronic therapies 
(antidiabetic and antihypertensive drugs, bisphosphonates and statins). 
For antidiabetic drugs, mean PDC ranged between 38 and 57%, with great 
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differences between all LHUs. Mean adherence to antihypertensives and 
bisphosphonates was between 36 and 54% and between 33 and 56%, 
respectively. New statin users had less than half of their first treatment 
year covered by the therapy in all the LHUs (range: 34.5-50.7). Overall, 
for all the long-term therapies analysed, a suboptimal adherence level was 
observed (standard PDC threshold is 80% -the level above which the 
medication has a reasonable likelihood of achieving the most clinical 
benefit). 
Our data describe a critical situation, which is not too far from that referred 
to the entire Italian population. In 2016 in Italy, only 57.7% of patients 
adhered to antihypertensive treatments, 63.4% to hypoglycemic drugs for 
the treatment of diabetes, 46.9% to statins and 52.1% to treatments for 
osteoporosis [OsMed Report 2016]. The percentage reported in a study 
conducted in Southern Italy was even lower: only 39% were adherent to 
therapies, according to the MMAS-4 (Morisky Medication Adherence 4-item 
Scale), that is used as self-reported adherence measure [Napolitano et al, 
2016]. Another study conducted in Southern Italian primary care, showed 
that 43% of new statin users had an optimal medication adherence 
(defined as MPR ≥80%) after 6 months, while 26% after 4-years of follow-
up [Ferrajolo et al, 2014]. In the study by Mazzaglia and colleagues, 
involving about 400 GPs across Italy and their patients aged 35 years and 
over, only 8% of newly diagnosed hypertensive subjects were classified as 
having high adherence levels (PDC ≥80%) after 6 months from the first 
prescription. The percentage of patients with low adherence levels (PDC 
≤40%) was about 51%. 
Although it is difficult to make a comparison with our results, because of 
the difference in the methodologies used for adherence estimation in the 
discussed studies, poor medication adherence to long-term therapies 
represents a common problem. It is also a complex problem, as it is 
simultaneously influenced by several factors, including social and economic 
aspects, the health care team/system, the characteristics of the disease, 
disease therapies and patient-related factors. For this reason, a 
multidisciplinary approach is needed in order to make progress in this area, 
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requiring coordinated action by health professionals, researchers, health 
planners and policy-makers [WHO, 2003]. Recently, some efforts have 
been made to address this issue and to improve the ability of patients to 
follow treatment plans in an optimal manner. Figure 6.4 depicts the level 
of involvement of institutions in promoting medication adherence in chronic 
disease care in Italy, in 2018. According to the data, 38% of local 
healthcare centres and pharmaceutical companies encouraged the 
implementation of activities aimed at improving therapeutic adherence 
among patients suffering from chronic diseases [Federfarma Report 2018]. 
 
 
Figure 6.4 – Level of involvement of institutions in promoting long-term 
medication adherence 
 
 
 
6.5 STRENGTHS AND LIMITATIONS 
 
This project has contributed to explore inappropriate drug prescription and 
use, thus addressing a critical concern of great epidemiological, clinical and 
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socio-economic impact. The investigation was not only at qualitative level, 
but also quantitative. In fact, we define and develop prescribing 
appropriateness indicators, specifically adapted to Italian setting, that 
could be used both by the physician in the daily prescription activity and 
by the LHU for the activities of evaluation and monitoring of the 
prescriptive performance. This provides benefits both for GPs’ activity and 
for health policy. On one hand, healthcare providers can target patients, 
evaluate patient’s medication list and make appropriate changes to 
decrease polypharmacy and adverse events; and considering that the 
majority of drug-related adverse events can be preventable, a set of 
indicators for detecting prescribing inappropriateness, especially in the 
elderly, is crucial to improve the patient's quality of healthcare and to 
enhance safe prescribing practices. On the other hand, a useful tool is 
available for the evaluation of prescription appropriateness by LHU. These 
procedures could be applied to other specific sub-populations and to other 
regions or at national level, thus reducing the costs associated with 
inappropriate/unnecessary prescribing. Unfortunately, they cannot be 
applied to other countries, because there may be differences in national 
drug formularies or local policies. We have also to acknowledge that all our 
analyses were conducted through the automatic application of explicit 
criteria, that can yield false-positive. As already mentioned, the rationale 
for prescribing or starting medications was not known and patients might 
be wrongfully classified as being prescribed an inappropriate drug, because 
their medication history was not known. Despite the potential of 
prescription database analysis, the appraisal of the appropriateness in 
prescription cannot rely on the use of explicit criteria only. It must be 
embedded within a patient’s global assessment of his/her clinical status, 
the complete pharmacological history and his/her preferences and needs. 
In this study we used secondary data, as they are routinely gathered at 
individual level for administrative purposes and as a part of the healthcare 
system in Italy. The use of existing data represents a powerful and relative 
low-cost research tool; however, drugs traced in these databases are 
limited to those that are reimbursed by Italian NHS, probably leading to 
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underestimation of PIP prevalence. Furthermore, our analyses did not 
assess important areas of suboptimal prescribing, such as benzodiazepines 
with long half-life or some drugs with anticholinergic properties, which are 
not reimbursed by the Italian NHS. 
In addition, these administrative databases do not contain information on 
the patient clinical history (together with other lifestyle and 
sociodemographic factors that could drive the choose of drug 
prescriptions), on GP instructions, on dose and times of administration, nor 
on indication for treatment. To note, the only source for diagnoses is the 
hospital discharge database. 
Finally, another great limitation is represented by the lack of information 
on patient real adherence to prescribed/dispensed drugs: a dispensed drug 
from pharmacy does not necessarily mean that the patient will take the 
medication, and will actually follow GP’s instructions. In this regard, it must 
keep in mind that the DDD (defined by WHO) is a fixed unit of 
measurement and does not necessarily reflect the recommended or 
prescribed daily dose for a specific patient. Doses for individual patients 
and patient groups are based on patient characteristics (e.g. age and 
weight) and pharmacokinetic considerations, and thus may differ from the 
DDD. As a result, DDDs provide only a rough estimate of drug utilization, 
useful for comparisons between countries, LHUs, etc.. These limitations, 
however, are less relevant if we look at the results from the point of view 
of the appropriateness of the prescription habits of physicians. 
Despite these limitations, large population administrative databases would 
have several advantages, such as the detection of different patterns of 
prescribing in real world setting and the analysis of the complexity of drug 
prescriptions. They are a great source of information on drug utilization 
and GPs’ behaviors in routine clinical practice. Indeed, different types of 
information deriving from different sources (including pharmacy drug 
dispensation data, patients’ and GPs’ registry) can be combined through 
record linkage processes. 
More details about advantages and limitations of administrative databases 
are outlined in Table 6.1.  
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Table 6.1 – Advantages and limitations of administrative databases 
PROs CONs 
Time and cost saving Great variation depending on the context 
Regional/national coverage Uncomplete or missing data 
Free from recall bias 
Information only on outpatient 
prescription drugs reimbursed by NHS or 
only on events leading to hospital 
admission 
Information on dispensed drugs or 
hospital admissions 
No information on lifestyle factors or other 
risk factors 
Standardized coding 
No information on prescribed dose and 
instructions for use 
Possibility of record linkage between 
different sources 
No information on adherence to 
prescriptions 
 
 
 
6.6 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Being able to prescribe appropriately is a complex task that is difficult to 
accomplish in daily clinical practice. The prescriber must take into account 
at least five fundamental elements: therapeutic indication, the real benefit 
that the patient will get from taking the drug (effectiveness), the risk of 
adverse drug reactions, the interactions with other drugs and the cost of 
treatment. 
In our study, using administrative health-care databases from two Italian 
regions, we highlight a high drug consumption rate, a high prevalence of 
inappropriate drug prescriptions, and a suboptimal level of adherence to 
chronic therapies in primary care setting. Despite any possible clinical 
justification, potentially inappropriate prescription has been associated 
with adverse outcomes in many previous studies, thus suggesting that our 
project describes and highlights a real and worrying situation, 
characterized by drug-related issues. For this reason, it would be extremely 
important to implement strategies promoting proper prescription and drug 
use. To the best our knowledge, relatively few trials have focused on 
interventions to improve appropriate prescribing in primary care. In Italy 
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GPs have a key role in prescribing drugs, in summarizing pharmacological 
recommendations from specialists, and in carrying out the therapeutic 
reconciliation after a hospital discharge. Therefore, they are the preferred 
target of an intervention aimed to optimize drug management. The 
intervention implemented during this study and addressed to GPs, could 
thus be extremely important for showing the impact of different 
approaches targeting the quality of prescribing. However, since the 
prescribing practice is entrusted to the GP and is based on GP final 
judgment, any intervention cannot necessarily impose decisions, but only 
educate and inform the doctors, supporting their activity. 
Moreover, the prescribing process relies on the relationship between GP 
and patient. The patient, in fact, is the first actor in his own health care 
and, nowadays, the availability of informatic and social media makes the 
self‑medication, defined as the selection and use of medicines by 
individuals to treat self‑recognized or self-diagnosed conditions or 
symptoms [WHO, 1998], the most common form of medicine use 
worldwide. For this reason, in our study, we also implemented a strategy 
of intervention addressed to patients, believing that multidimensional 
interventions are required for the integration of some improved decision-
making processes into the daily prescribing practice. 
Although we did not observed a unique time trend for the measured 
indicators during 2014-2016, due to the large variability between different 
geographical areas, the prevalence of indicators on inappropriate 
prescribing is noteworthy, and deserves to be targeted by harmonized 
interventions, that addressed not only the general practitioners but also all 
those involved in the prescriptive process, and the patients themselves. 
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Gentile Dr/Dr.ssa 
 
Il presente Report ha l’obiettivo di evidenziare le potenziali aree di inappropriatezza 
prescrittiva attraverso la misurazione di specifici indicatori. 
 
Per quanto riguarda gli indicatori di performance, l’analisi delle prescrizioni è stata ristretta a 
specifiche categorie terapeutiche: inibitori di pompa protonica (abbreviato in PPI) (ATC: 
A02BC); antibiotici (ATC: J01); antiasmatici (ATC: RO3); statine (ATC: C10AA); ACE-inibitori 
(ATC: C09AA); sartani (ATC: C09CA); inibitori selettivi del reuptake della serotonina 
(abbreviato in SSRI) (ATC: N06AB); inibitori della ricaptazione della serotonina-norepinefrina 
(abbreviato in SNRI) (ATC: N06AX). Per ciascuna di queste categorie, nelle fasce d’età 40-64 
anni e ≥65 anni, viene riportato il numero di pazienti trattati e i volumi di prescrizione 
misurati in termini di DDD (Defined Daily Dose o dose definita giornaliera, vedi box) per 1000 
assistiti die. 
 
Sono successivamente descritti alcuni indicatori di inappropriatezza. Nello specifico, su tutti 
gli assistiti over 40 anni sono state valutate le prescrizioni a rischio di interazione 
farmacologica (pDDI, limitatamente alle potenziali interazioni di rilevanza clinica 
controindicata/maggiore) e le prescrizioni concomitanti di farmaci appartenenti alla stessa 
classe chimico-terapeutica, ovvero duplicati terapeutici (livello 4 dell’ATC; ad es. statine 
C10AA). Sugli assistiti over 65 anni sono stati analizzati indicatori di inappropriatezza specifici 
per la popolazione anziana, quali prescrizioni di farmaci non indicati o controindicati negli 
anziani (sulla base di una lista [ERD-list] derivante dall’armonizzazione di tre diversi criteri 
espliciti Beers, STOPP e EU(7)-PIM limitatamente ai farmaci disponibili in Italia e prescritti in 
classe A), prescrizioni concomitanti di farmaci ad elevato carico anticolinergico 
(AntiCholinergic Burden [ACB] score ≥3) e prescrizioni concomitanti di farmaci ad elevato 
carico sedativo (Sedative Load [SL] score ≥3). Per ciascun indicatore, è riportata nei grafici la 
percentuale di pazienti coinvolti e sono elencati dettagliatamente i farmaci o le classi di 
farmaci più frequentemente interessate all’inappropriatezza. 
 
 
 
 
DEFINIZIONI 
 
Dose definita giornaliera (Defined Daily Dose, DDD): rappresenta la dose di 
mantenimento per giorno di terapia, in soggetti adulti, relativamente all’indicazione 
terapeutica principale della sostanza (si tratta di una unità standard e non della dose 
raccomandata in ciascun singolo paziente). Il numero di DDD giornaliere prescritte, 
rapportato a 1000 assistibili, è un indice standardizzato di consumo. 
 
Numero trattati: indica il numero di soggetti che hanno ricevuto almeno una 
prescrizione nel periodo considerato. 
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CARATTERISTICHE GENERALI 
 
MEDICO 
Assistiti 1559 
Numero (%) assistiti con età 40-64 anni 668 (42,8) 
Numero (%) assistiti con età ≥65 anni 371 (23,8) 
DISTRETTO 
Assistiti 105.644 
Numero (%) assistiti con età 40-64 anni 44.896 (42,5) 
Numero (%) assistiti con età ≥65 anni 26.052 (24,7) 
MACROAREA 
Assistiti 300.215 
Numero (%) assistiti con età 40-64 anni 126.847 (42,3) 
Numero (%) assistiti con età ≥65 anni 75.631 (25,2) 
 
 
 
 Distribuzione per classi di politerapia (%) 
1-4 farmaci 5-9 farmaci ≥10 farmaci 
MEDICO 
Tra gli assistiti con età 40-64 anni 54,9 13,9 2,7 
Tra gli assistiti con età ≥65 anni 44,7 30,5 5,4 
DISTRETTO 
Tra gli assistiti con età 40-64 anni 52,8 8,0 0,7 
Tra gli assistiti con età ≥65 anni 42,0 31,1 5,8 
MACROAREA 
Tra gli assistiti con età 40-64 anni 53,3 8,3 0,8 
Tra gli assistiti con età ≥65 anni 41,6 32,1 6,2 
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INDICATORI DI PERFORMANCE PRESCRITTIVA 
 
 Percentuale di trattati sul totale assistiti 
Medico Distretto Macroarea 
Inibitori di pompa protonica (ATC: A02BC) 
Tra gli assistiti con età 40-64 anni 22,6 14,0 14,6 
Tra gli assistiti con età ≥65 anni 32,9 32,4 32,5 
Antibiotici (ATC: J01) 
Tra gli assistiti con età 40-64 anni 40,1 28,1 27,9 
Tra gli assistiti con età ≥65 anni 39,9 33,2 33,3 
Antiasmatici (ATC: RO3) 
Tra gli assistiti con età 40-64 anni 5,5 7,2 7,4 
Tra gli assistiti con età ≥65 anni 8,4 10,1 10,5 
Statine (ATC: C10AA) 
Tra gli assistiti con età 40-64 anni 12,9 7,6 6,8 
Tra gli assistiti con età ≥65 anni 29,6 25,2 24,0 
Ace-inibitori (ATC: C09AA) 
Tra gli assistiti con età 40-64 anni 5,1 6,8 7,0 
Tra gli assistiti con età ≥65 anni 9,2 17,7 19,4 
Sartani (ATC: C09CA) 
Tra gli assistiti con età 40-64 anni 7,2 5,2 4,4 
Tra gli assistiti con età ≥65 anni 17,3 12,8 12,1 
SSRI (ATC: N06AB) 
Tra gli assistiti con età 40-64 anni 4,0 3,6 3,6 
Tra gli assistiti con età ≥65 anni 3,2 5,9 6,1 
SNRI (ATC: N06AX) 
Tra gli assistiti con età 40-64 anni 2,4 1,3 1,3 
Tra gli assistiti con età ≥65 anni 4,0 3,2 3,1 
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DDD/1000 ab die per le principali categorie terapeutiche nelle classi di età 40-64 anni e 65 anni: 
confronto medico vs distretto vs macroarea 
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INDICATORI DI APPROPRIATEZZA PRESCRITTIVA NEI PAZIENTI OVER 40 
 
Percentuale di pazienti con almeno una prescrizione di farmaci a rischio di interazione 
farmacologica (pDDI) o di duplicati terapeutici (TD): confronto medico vs distretto vs macroarea 
 
 
 
 
 
N soggetti con prescrizione di coppie di farmaci potenzialmente interagenti (pDDI) = 223 
 
Prime 3 per frequenza N di assistiti interessati 
PREDNISONE-MELOXICAM 33 
DESAMETASONE-DICLOFENAC 17 
IDROCLOROTIAZIDE-DICLOFENAC 10 
 
 
N soggetti con prescrizione di duplicati terapeutici (TD) = 55 
 
Primi 3 per frequenza N di assistiti interessati 
INIBITORI DELLA POMPA ACIDA (A02BC) 8 
GLICOCORTICOIDI (H02AB) 7 
INIBITORI DELLA HGM COA REDUTTASI (C10AA) 6 
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INDICATORI DI APPROPRIATEZZA PRESCRITTIVA NEI PAZIENTI OVER 65 
 
Percentuale di pazienti con almeno una prescrizione inappropriata per farmaci non indicati o 
controindicati negli anziani (ERD-list), con prescrizioni concomitanti di farmaci ad elevato carico 
anticolinergico (ACB score ≥3) e prescrizioni concomitanti di farmaci ad elevato carico sedativo 
(SL score ≥3): confronto medico vs distretto vs macroarea 
 
 
 
 
 
N soggetti con prescrizione di farmaci presenti nella ERD-list = 149 
 
Primi 3 per frequenza N di assistiti interessati 
ETORICOXIB 20 
MELOXICAM 17 
CELECOXIB 15 
 
 
N soggetti con prescrizione di farmaci con elevato carico anticolinergico (ACB score ≥3) = 20 
 
Primi 3 per frequenza N di assistiti interessati 
PAROXETINA 6 
PREDNISONE 6 
FUROSEMIDE 5 
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N soggetti con prescrizione di farmaci con elevato carico sedativo (SL score ≥3) = 3 
 
Primi 3 per frequenza N di assistiti interessati 
QUETIAPINA 2 
ACIDO VALPROICO 1 
AMITRIPTILINA 1 
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APPENDIX II 
 
CORSO ECM-FAD: Appropriatezza prescrittiva in medicina 
generale: aspetti teorici e pratici. 
 
PRIMO MODULO 
Obiettivi: presentazione del progetto e introduzione generale 
all’appropriatezza prescrittiva, al paziente anziano e a casi tipici di 
prescrizione inappropriata in questa popolazione, con esempi pratici 
1. Presentazione del progetto: aspetti generali – Elena Tragni 
2. L’appropriatezza prescrittiva nella medicina generale: concetti 
generali – Ettore Saffi Giustini 
3. Il paziente anziano: invecchiamento, cronicità, multimorbilità – 
Marco Visconti 
4. Il paziente anziano: modificazioni fisio-patologiche della 
farmacocinetica e della farmacodinamica – Alberto Corsini  
5. Il paziente anziano: politerapia e criticità – Marco Visconti 
6. L’aderenza alla terapia – Alberto Aronica  
7. Inappropriatezza prescrittiva nell’anziano: farmaci inappropriati 
(Criteri di Beers, criteri START, il carico anticolinergico; 
epidemiologia e casi clinici) – Alessandro Nobili (Luca Pasina) 
8. Inappropriatezza prescrittiva nell’anziano: overuse, duplicazione 
terapeutica, interazioni tra farmaci (epidemiologia e casi clinici) – 
Alessandro Nobili (Luca Pasina) 
9. I medication errors – Manuela Casula 
10. La farmacovigilanza: concetti generali – Annalisa Capuano 
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SECONDO MODULO 
Obiettivi: spiegazione degli indicatori e della reportistica; presentazione 
di strumenti per il miglioramento della gestione del paziente anziano 
1. Come misurare l’appropriatezza: gli indicatori di performance – 
Enrica Menditto 
2. Come misurare l’appropriatezza: gli indicatori espliciti – Manuela 
Casula 
3. Come misurare l’uso appropriato dei farmaci: aderenza e 
persistenza alle terapie croniche – Lorenza Scotti 
4. La reportistica del progetto: una lettura critica – Davide Lauri 
5. L’approccio al paziente anziano: valutazione multi-dimensionale e 
diagnosi differenziale – Graziano Onder 
6. La comunicazione medico-paziente: l’importanza, le strategie, gli 
strumenti – Silvia Muggia  
7. Raccomandazioni per la prescrizione al paziente anziano complesso 
– Graziano Onder  
8. Medication review, riconciliazione terapeutica e deprescribing – 
Paolo Longoni  
9. Reazioni avverse ai farmaci nell’anziano: ADR prevenibili e 
migliorabili – Annalisa Capuano 
10. La gestione del paziente anziano complesso: prospettive future – 
Ettore Saffi Giustini 
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APPENDIX III 
 
Potential DDI, GP distribution 2014-2016 
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Therapeutic Duplicates, GP distribution 2014-2016 
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ERD-list, GP distribution 2014-2016 
 
 
 
 
 
- 178 - 
 
 
 
 
 
 
- 179 - 
 
 
 
 
 
 
- 180 - 
 
 
 
 
  
- 181 - 
ACB Score, GP distribution 2014-2016 
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SL Score, GP distribution 2014-2016 
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APPENDIX IV 
 
 
 
 
Annual adherence to antidiabetic drugs in prevalent users aged ≥40 years 
 
 
 
Annual adherence to antihypertensive drugs in prevalent users aged ≥40 years 
30
35
40
45
50
55
60
65
70
75
80
2014 2015 2016
P
D
C
 (
%
)
Antidiabetics drugs 
Bergamo
Lecco
Monza
Mantova
Avellino
Caserta
Napoli1
Napoli2
30
35
40
45
50
55
60
65
70
75
80
2014 2015 2016
P
D
C
 (
%
)
Antihypertensive dugs  
Bergamo
Lecco
Monza
Mantova
Avellino
Caserta
Napoli1
Napoli2
- 190 - 
 
 
 
Annual adherence to bisphosphonates in prevalent users aged ≥40 years 
 
 
 
Annual adherence to statins in prevalent users aged ≥40 years 
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(Effectiveness of informative and/or educational interventions aimed at 
improving the appropriate use of drugs designed for general practitioners 
and their patients), that is the object of the present thesis. The protocol of 
this pragmatic trial, that is still ongoing, has been preparing for publication. 
We also planned a number of manuscripts concerning the baseline 
analyses, the results of which are showed in the present thesis. 
Besides this project, during my PhD course, I have also collaborated with 
the research group of Professor Corrao, at the Department of Statistics and 
Quantitative Methods (University of Milano‐Bicocca). In this context, I 
could gain experience in the design and the conduction of epidemiological 
studies aimed at evaluating the prevalence of risk factors and their 
correlation with cardiovascular diseases in the Italian population, through 
the analysis of healthcare data from regional administrative databases of 
the outpatient drug prescriptions. In particular, we conducted a case-
control study investigating the association between proton pump inhibitors 
use and risk of hospitalization for cardio/cerebrovascular events that has 
been published in Atherosclesosis. We also performed a cohort study 
exploring the effect of the exposure to oral bisphosphonates on 
cardiovascular risk. The manuscript describing the latter study has been 
submitted for publication. 
Furthermore, I spent a period of my PhD program at the Cardiovascular 
Epidemiology Unit, Department of Public Health and Primary Care 
(University of Cambridge, Cambridge, UK), under the supervision of 
Professor Ference, where I could improve my skills in performing 
systematic reviews of scientific literature and meta-analysis of randomized 
controlled trials (RTCs) in the field of cardiovascular diseases. In this 
regard, we conducted a meta-analysis of RTCs investigating the association 
between apolipoprotein B levels and cardiovascular risk, which will be 
published soon (paper in preparation). 
In this context, I have also enhanced my knowledge on genomic and 
pharmacogenomic topic related to the cardiovascular system, and 
experienced the conduction of studies based on the principles of Mendelian 
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randomization, to identify risk factors that have both a causal and a 
cumulative effect of the risk of disease, in an attempt to identify targets 
for early intervention, and to model “naturally randomized trials” that 
attempt to frame and answer clinical questions to fill evidence gaps when 
an actual clinical trial would be impractical or impossible to conduct. 
 
 
 
During my PhD programme, I attended a number of congresses (outlined 
below), at national and international level, in the belief that sharing 
experiences with other research groups working on the same topic of 
interest is a valuable key point to broaden knowledge and develop and 
optimize research practices. 
 
 
List of publications: 
 
Casula M, Scotti L, Galimberti F, Mozzanica F, Tragni E, Corrao G, Catapano AL. 
Use of proton pump inhibitors and risk of ischemic events in the general 
population, Atherosclerosis (2018).doi:10.1016/j.atherosclerosis.2018.08.035. 
 
Casula M, Olmastroni E, Galimberti F, Tragni E, Corrao G, Scotti L, Catapano 
AL. Cardiovascular risk reduction with cumulative exposure to 
bisphosphonates: a population-based cohort study. [IN SUBMISSION] 
 
Casula M, Menditto E, Galimberti F, Russo V, Olmastroni E, Scotti L, Orlando V, 
Corrao G, Catapano AL, Tragni E, on behalf of EDU.RE.DRUG Group. A 
pragmatic controlled trial to improve the appropriate prescription of drugs in 
adult outpatients: design and rationale of the EDU.RE.DRUG study.  
[IN PREPARATION] 
 
Galimberti F, Catapano AL, Cupido AJ, Katzmann JL, Kitch T, Snidermann AD, 
Ference BA. Association between apolipoprotein B lowering and cardiovascular 
risk reduction: a meta-analysis of randomized controlled trials.  
[IN PREPARATION] 
 
Others: 
Galimberti F. Applicazione della randomizzazione Mendeliana allo sviluppo dei 
farmaci. GIFF 2019;11(2):12-18. 
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Date Title of contribution Site 
26-28 May 
2019 
Use of bisphosphonates and risk of 
cardiovascular events: a population-based 
retrospective cohort study. 
Science at a glance e-poster presentation 
87th EAS Congress - 
Maastricht 
5-6 
October 
2018 
Differenze di genere nell’aderenza alla 
terapia con statine. 
Oral communication 
XII Congresso 
Nazionale SITeCS - 
Milan 
20-21 
September 
2018 
Inappropriate medication prescribing 
among adult patients in two Italian 
Regions. 
Oral communication 
XXI SIF SEMINAR ON 
PHARMACOLOGY for 
PhD students, fellows, 
post doc and specialist 
trainees – Bresso 
(Milan) 
22-26 
August 
2018 
Association between PPI use and risk of 
cardiovascular events. 
Poster 
Inappropriate medication prescribing 
among elderly patients in Italy. 
Poster 
Monitoring of Italian pharmaceutical 
administrative databases: an assessment of 
prescriptive performance. 
Poster 
ISPE’s 34th 
International 
Conference on 
Pharmacoepidemiology 
and Therapeutic Risk 
Management - Prague 
3 July 
2018 
Association between PPI use and risk of 
cardiovascular events 
Oral communication 
Next Step 9th ed: La 
giovane ricerca avanza 
- Milan 
6-8 May 
2018 
Use of PPI and risk of ischemic events in 
the general population. 
Science at a glance e-poster presentation 
86th EAS Congress - 
Lisbon 
6-7 April 
2018 
Use of PPI and risk of ischemic events in 
the general population. 
Oral communication 
SPRING meeting 2018. 
Novità nello studio 
dell'aterosclerosi e 
delle sue complicanze. 
Incontro tra giovani 
ricercatori SIIA, SIMI 
e SISA - Rimini 
19-21 
November 
2017 
Use of proton pump inhibitors and risk of 
cardiovascular events in Lombardy. 
Oral communication 
31° Congresso 
Nazionale SISA - 
Palermo 
25-28 
October 
2017 
Adherence to therapy with different 
second-line hypoglycaemic drugs in 
patients with type 2 diabetes mellitus. 
Oral communication 
38° Congresso 
nazionale SIF - Rimini 
20-21 
October 
2017 
Rischio di eventi cardiovascolari associato 
all’uso di inibitori di pompa protonica nella 
popolazione lombarda. 
Oral communication 
XI Congresso 
Nazionale SITeCS – 
Milano 
29 June 
2017 
The LIPIGEN study: Dutch Lipid Clinic 
Network Score in Italian patients with FH. 
Oral communication 
Next Step 8th ed: La 
giovane ricerca avanza 
- Milan 
23-26 
April 2017 
Characterization of Italian patients with 
familial hypercholesterolemia: the LIPIGEN 
study. 
Poster 
LDL-cholesterol reduction with PCSK9 
inhibitors: a meta-analysis of randomized 
controlled trials. 
Poster 
85th EAS Congress - 
Prague 
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Characterization of metabolic syndrome in 
PLIC cohort. 
Poster 
7-8 April 
2017 
Cardio-metabolic profile in a cohort from 
Lombardy region: the PLIC study. 
Poster 
SPRING meeting 2017. 
Novità nello studio 
dell'aterosclerosi e 
delle sue complicanze. 
Incontro tra giovani 
ricercatori SIIA, SIMI 
e SISA - Rome 
 
Moreover, in the last three years, I followed a series of seminars, 
conferences and educational courses (listed below), in order to keep on 
training and updating my knowledge. 
 
List of seminars, conferences and educational courses 
 
2019. BHF Cambridge Cardiovascular Annual Research Symposium. Cambridge. 
 
2019. External seminar: ‘Identifying drug targets at scale using GWAS fine 
mapping and colocalization analyses’. Cambridge. 
 
2018. EAS Advanced Course on Rare Dyslipidaemia and Atherosclerosis - 
Importance of Personalized Medicine and Differential Diagnosis. Cinisello 
Balsamo (Milan). 
 
2018. Convegno Regionale SISA Lombardia, XVII Giornata Studio - Il soggetto 
ad alto rischio cardiovascolare: ricerca clinica e di base nell’ambito 
dell’aterosclerosi. Milan. 
 
2018. International Conference on Pharmacoepidemiology & Therapeutic Risk 
Management Course: Precision Medicine with a Skills-based Focus for the 
Pharmacoepidemiologists. Prague. 
 
2018. International Conference on Pharmacoepidemiology & Therapeutic Risk 
Management Course: Comparative Effectiveness Research: Real-World 
Evidence in Health Technology Assessment. Prague. 
 
2018. International Conference on Pharmacoepidemiology & Therapeutic Risk 
Management Course: Propensity Scores in Pharmacoepidemiology. Prague. 
 
2018. International Conference on Pharmacoepidemiology & Therapeutic Risk 
Management Course: Advanced Drug Utilization Research. Prague. 
 
2018. 1° HOT TOPICS IN NUTRIZIONE – Linee guida nutrizionali e nutrizione 
personalizzata: una sfida per il futuro. Milan. 
 
2017. XXVI Seminario Nazionale, Istituto Superiore di Sanità - La valutazione 
dell’uso e della sicurezza dei farmaci: esperienze in Italia. Rome. 
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2017. Convegno Regionale SISA Lombardia, XVI Giornata Studio- Il soggetto 
ad alto rischio cardiovascolare: ricerca clinica e di base nell’ambito 
dell’aterosclerosi. Milan. 
 
2017. Convegno Istituto Superiore di Sanità – Le analisi sull’uso dei farmaci: 
metodi ed esperienze in Italia. Rome. 
 
2017. Symposium - Lipids & Lipoproteins Atherosclerosis: from genes to 
therapy. Prague. 
 
2017. Corso di formazione speciale e aggiornamento professionale – 
Prevenzione dei rischi chimico e biologico in laboratorio. Segrate (Milan). 
 
2016. XXX Congresso Nazionale SISA. Rome. 
 
2016. Convegno SifMed “Farmaco equivalente, Aderenza e Cronicità: una sfida 
per le Cure primarie”. Milan. 
 
2016. X Congresso Nazionale SITeCS. Milan. 
 
2016. Convegno Regionale SISA Lombardia, XV Giornata Studio - Il soggetto 
ad alto rischio cardiovascolare: ricerca clinica e di base nell’ambito 
dell’aterosclerosi. Milan. 
 
2016. Conferenza SIF-SITOX - Conferenza nazionale sullo Switch 
farmacologico. Milan. 
 
Finally, in the awareness that transferring scientific knowledge within the 
scientific community and, above all, to the public is one of the hardest 
challenges of the “research world” nowadays, I have carried out 
information and dissemination activities. In particular, I am a member of 
SEFAPnews editorial-board, that provides monthly newsletters published 
on SEFAP website (www.sefap.it), on the topic of pharmacovigilance, 
pharmacoepidemiology, pharmacoutilization and health economy. 
Furthermore, I was involving in dissemination activity through RicercaMix 
blog of the Department of Pharmacological and Biomolecular Sciences of 
the University of Milan (www.ricercamix.org). 
